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Shortages of kidneys for transplantation is a universal concern. Countries like the United 
Kingdom have had success improving the number of kidneys available notably through 
expanding their living donation program. However, trends indicate the discrepancy between 
supply and demand will never fully be met with current practise. Bioengineering of donor 
specific organs may provide the ultimate answer, but despite rapidly growing progress it will 
be many more years until complex organs, such as a kidney, are available for transplantation. 
 
Utilising kidneys that traditionally would not be considered suitable for transplantation will 
drastically increase the donor pool of kidneys. To implant these ‘marginal’ kidneys we have 
to minimise the ischaemia reperfusion injury (IRI) they sustain during the transplantation 
process. Cellular therapies offer the greatest potential in ameliorating transplant related IRI 
and allowing these marginal kidneys to recover with acceptable long-term function.  
 
The field of cellular therapies, in particular stem cell therapy, has expanded rapidly in the 
last ten years. Adipose tissue offers one of the most attractive sources of stem cells due to 
its relatively easy accessibility and high abundance of stem cells. The adipose derived 
stromal vascular fraction (ADSVF), which contains the adipose derived stem cells, can 
quickly be extracted from the adipose tissue with minimal technical expertise. Multiple 
animal studies of renal IRI have demonstrated significantly improved kidney function after 
treatment with ADSVF. However, administration of freshly isolated, uncultured ADSVF 
administered via the renal at the time of transplantation has never been attempted in human 
kidneys. Before considering clinical translation, we need to better understand the use of 
ADSVF in such settings.  
 
In chapter one, experiments characterise the ADSVF obtained from inguinal and peri-renal 
adipose tissue of both rats and humans. Chapter two describes the development of a novel 
animal model which closely mimics the transplant recipient in order to accurately investigate 
the ADSVF. Chapter three demonstrates the biodistribution of the ADSVF administered via 
the renal artery and chapter four highlights some of the potential mechanisms of action of 
the ADSVF. 
 
In summary, ADSVF from peri-renal and inguinal adipose tissue consist of a similar 
heterogenous cell population, although they differ in the proportions of each subset. When 
administered via the renal artery, ADSVF likely ameliorate IRI via multiple mechanisms, 
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by reducing the immediate injury, modulating the inflammatory response and reducing the 
progression to fibrosis. Administration via the renal artery is an effective means of reducing 
non-target biodistribution and deliver the majority of the ADSVF to the cortex of the kidney. 
The animal model developed as part of this research better mimics the transplant patient, 
compared to existing models, without increasing the risks to the animal.  
 
The findings of this research combined with recently published data using mesenchymal 
stem cells in human kidney IRI, provides enough support to consider renal artery 
administration of uncultured ADSVF. Initially this translational research could be performed 
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1.1 END STAGE RENAL DISEASE 
 
When the kidneys can no longer adequately perform their vital functions, a state of end-stage 
renal disease (ESRD) is reached. Unlike acute kidney injury, which is often reversible, 
ESRD is of gradual onset and permanent. The most common causes are diabetes and 
hypertension, both of which are increasing worldwide and concernedly the highest rates of 
increase are in low middle-income countries (Mills et al. 2016; Saeedi et al. 2019). 
Autoimmune diseases, polycystic kidney disease and recurrent infection, make up most of 
the other aetiologies.  
 
In 2017 there were 8001 people in the United Kingdom newly diagnosed with ESRD. There 
has been an overall upward trend of incidence since the United Kingdom renal registry was 
established (NHS BT 2019). Improved therapies and early diagnosis of kidney disease has 
not yet been enough to reverse this trend. Currently, there are no therapies that can reverse 
chronic renal damage and recuperate full renal function in the ESRD population. Early 
diagnosis of kidney damage allows making significant lifestyle changes or adding therapies 
that can slow down, halt or sometimes reverse some damage. Although this slows the 
progression and can prevent patients from developing ESRD, there is still a large proportion 
of patients in which therapies are ineffective, and often patients cannot achieve the drastic 
lifestyle changes required. 
 
Kidneys play a significant role in the elimination of waste products, fluid balance, electrolyte 
balance, production of red blood cells, blood pressure control and vitamin D production. 
When any of these processes become disturbed, there is a knock-on detrimental effect on 
other bodily systems such as the cardiovascular, immune, and nervous system. Symptoms 
of decreasing renal function include nausea, lethargy, muscle cramps and shortness of 
breath. Left unchecked and unmanaged patients will ultimately succumb to their ESRD. 
 
Once a patient develops ESRD, they will require some form of renal replacement therapy 
(RRT). This takes the form of kidney dialysis or kidney transplantation. The prevalence of 
patients on RRT in the United Kingdom in 2017 was 64,887. In 2013 there were almost 
10,000 patients less on RRT.  
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Despite kidney dialysis being a lifesaving intervention, it is not without major drawbacks. 
Firstly, any type of dialysis requires a means of accessing the circulation or the peritoneal 
cavity. This involves an intervention that has risks associated with it. Secondly, these forms 
of access are not permanent and will eventually run into complications such as infection or 
decreased efficacy. At this point another procedure will be required to obtain access. In some 
circumstances the patient runs out of common access options and find themselves in a 
precarious situation, often requiring high-risk access procedures, when they are at their 
physiological weakest. In 2017 there were 28,433 adult patients in the United Kingdom on 
renal dialysis (NHS BT 2019). This is up from the previous year and is a trend that is 
increasing.  
 
For patients that are suitable for transplantation, dialysis is a means of survival until such 
time an organ becomes available. Compared to patients that stay on dialysis, transplant 
patients live a longer life and have a significant reduction in cardiovascular events (Tonelli 
et al. 2011; Wolfe et al. 1999; Laupacis et al. 1996; Meier-Kriesche et al. 2001).  Quality of 
life is also substantially better among transplant patients (Tonelli et al. 2011; 
Kontodimopoulos & Niakas 2008; Simmons et al. 1990; Laupacis et al. 1996). 
Transplantation does carry the risks of surgery, the need for lifelong immunosuppression 
and often the need for more than one transplant in their lifetime, however, it is still the 
preferred RRT of choice for patients. As a result, the number of patients on the transplant 
waiting list has always exceeded the supply of kidney grafts available. Unfortunately, time 
spent on dialysis is an independent predictor of poor transplant survival due to ESRD 
associated systemic physiological deterioration (Meier-Kriesche & Kaplan 2002). 
 
As well as the health benefit of transplant over dialysis, there is also a significant cost-
benefit. In the United Kingdom, haemodialysis costs £35,000 per annum per patient and 
peritoneal dialysis £17,500 per annum per patient. With 28,433 adults on dialysis, this is a 
high cost to the NHS, and in 2013 it accounted for 3% of the National Health Service budget. 
In comparison within dialysis, renal transplantation saves the NHS £25,800 annually per 
patient (Pruthi et al. 2013).With kidney transplants reported as lasting on average 8-15 years, 
they are extraordinarily cost-effective in addition to reducing morbidity and mortality of 
ESRD patients. Unsurprisingly, the discrepancy in the demand and supply of kidney grafts 





1.2 TRENDS IN KIDNEY TRANSPLANTATION 
 
Worldwide organ demand for transplantation has overwhelmed supply due to improved 
surgical safety, survival benefit over dialysis, improved immunosuppression regimes, 
increased ESRD patients and older and frailer patients being listed. On the supply side, there 
are reduced numbers of deceased donors due to factors such as improved road safety, 
advances in healthcare (such as interventional radiology to treat intracranial haemorrhage) 
and safer working environments. 
 
Recent data from 2019 shows 4954 patients actively waiting for kidney transplantation in 
the United Kingdom and an additional 3147 patients suspended on the waiting list (Fig. 1.1). 
The number of patients on the waiting list has steadily declined over the last nine years. 
However, this rate of decline is slowing and could plateau especially as the number of 
transplants, for the first time in 2019, failed to be higher than the previous year (Fig. 1.3).  
 
 
Figure 1.1 United Kingdom kidney transplant waiting list 2010 to March 2019.  Taken 
from NHS Blood and Transplant annual report on kidney transplantation 2018/2019 (NHS 
BT 2019) 
 
Delving deeper into the waiting list and transplantation data, it is crucial to understand the 
sources of renal allografts. Donor/donation after brain stem death (DBD), donor/donation 





Formerly known as "heart beating donors", DBD was traditionally the majority of all 
deceased donors. Donors who have suffered from irreversible brain injury and irreversible 
loss of central respiratory drive (ability to perform respiration). Once a donor has been 
pronounced brainstem dead, by two separate senior clinicians on two separate occasions, 
they remain on mechanical ventilation until all necessary pre-retrieval investigations, 
administration and consenting for donation has been completed. The donor remains on 
mechanical ventilation until the retrieval team has arrived and set up. Mechanical ventilation 
and organ perfusion persist as retrieval surgery begins. In contrast, with DCD donor’s 
retrieval is performed after confirmation of death using cardio-respiratory criteria. This may 
be in a controlled environment where there is the withdrawal of life-sustaining treatments or 
in an unexpected cardiac arrest in which the patient cannot or should not be resuscitated. In 
the United Kingdom, there must be at least five minutes of monitored asystole before transfer 
to theatre and retrieval surgery can commence. 
 
Physiological changes after brainstem death (a DBD donor) involve the cardiovascular, 
endocrine, and pulmonary systems. Core temperature changes and coagulopathies also add 
to the challenges of managing DBD donors. Many of these changes can be managed during 
the optimisation period; vasopressors can help maintain tissue perfusion after the loss of 
sympathetic tone, and administration of tri-iodothyronine can support pituitary failure. In 
DCD retrieval, the kidney is exposed to suboptimal perfusion after life-sustaining treatments 
are withdrawn. A kidney can be subjected to this hypotension and hypoxia for up to three 
hours (and potentially longer) in what is called the agonal phase (the time after the 
withdrawal of life support and the onset of cardiac arrest). After cardiac arrest, there is the 
further ‘5-minute mandatory wait’ to ensure no further signs of life. These two periods 
expose the kidney to what is termed warm ischaemia. During the transportation of kidney 
grafts, they are perfused or preserved in cold preservation fluid. This is termed the cold 
ischaemic time (CIT) and lasts until the kidney is re-perfused by the recipient’s blood at the 
time of implantation. The longer the ischaemia the higher the rates of primary non-function 
and delayed graft function (Singh et al. 2011; Renkens et al. 2005). Due to the addition of 
the warm ischaemia period – DCD kidneys often have a longer ischaemic time. 
 
Nevertheless, DCD graft usage has grown every year to increase the donor pool. The 
Netherlands has some of the highest rates of DCD usage, and a study of 3611 DBD and 2711 
DCD transplants reported long-term outcomes of DCD kidneys equivalent to that of DBD 
kidneys in terms of estimated glomerular filtration rate (eGFR) and graft survival 
(Schaapherder et al. 2018). In the short-term, DBD kidneys fared better in terms of graft 
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survival. This builds on similar outcomes from Huynh et al. and Weber et al. as long as cold 
ischaemic times are less than 24 hours (Huynh et al. 2015; Luan 2002). A survival benefit 
can still be demonstrated in recipients accepting a DCD kidney rather than waiting on 
dialysis for a DBD kidney to become available (Snoeijs et al. 2010). 
 
Living donor transplants are either from family and friends or an unrelated altruistic donor 
in a directed or non-directed donation. Unlike deceased donations, retrieval and implant 
surgery are much more controlled with everything set up in advance and both donor and 
recipient optimised for surgery. Also, the donor is healthy with no significant co-morbidities, 
which is often not the case with deceased donors. The medical history of the donor is well 
known and, in most cases, both surgeries take place in the same hospital so cold ischaemic 
time for the kidney is significantly reduced. As would be expected, live donor kidney 
transplants give the best outcomes compared to age-matched deceased donor transplants 
(Meier-Kriesche & Kaplan 2002). Another advantage of living donor transplant is that they 
can be used as part of paired exchanges or a chain of donations making it possible for friends 
and family to donate even if they are not compatible (Fig. 1.2). 
 
In 2013 there was a strategy set out by NHS Blood and Transplant division on how they 
would improve organ utilisation by 2020. Improving the number of grafts available has been 
a multi-strategic approach. Efforts included live donor awareness campaigns, chain 
donations, increased donor referral, ABO incompatibility transplants, opt-in donation, 
thereby improving decline rates of kidneys, improving consent rates for donation. From an 
administration point of view, a United Kingdom transplant HUB has been set up to 
effectively coordinate donations and collect data on transplant activity such as usage, 
declines and organ damage during retrieval. Real-time data sharing of donor parameters and 








Figure 1.2 Live donor kidney donations can be used to trigger further donations. (A) 
Donation across two pairs and (B) open chain donation (Reese et al. 2015) 
 
 
When scrutinising the data in 2019, we can see that most kidney donors remain DBD donors 
followed by DCD then living donors (Fig. 3). This has not always been the trend, and this is 
the first year in at least ten years in which the number of DCD transplanted kidneys is higher 
than living donors (NHS BT 2019). As knowledge, experience, strategies, and therapies have 
grown, so have the boundaries for accepting and implanting DCD kidneys. On the other 
hand, live donor transplant numbers seem to have plateaued (NHS BT 2019). Perhaps those 
who had a live donor have been transplanted, and we are nearing the maximum annual 
utilisation rate of live donors. If live donor transplant numbers continue to remain static, 
there will be further drive to use deceased donor kidneys.  
 
Despite increasing DCD transplants, the number of patients on the kidney transplant waiting 
list remained at over 8000 people on the 31st of March 2019. It is encouraging that the 
number of patients on the waiting list has steadily declined since 2010, and continual 
innovations and strategies have the desired effect. The opt-out system introduced in the UK 
may help to further push deceased donor numbers. To fully utilise this increase in donors, 





Figure 1.3 Type of adult only kidney transplants 2009 to 31st March 2019. Taken from 




From the early 2000s, most of the increase in donor numbers have come from DCD donors. 
An increase in DCD kidneys plus an increase in donor age and comorbidities have resulted 
in a surge in the use of "marginal" kidneys. With the fate of the waiting list relying on DCD 
and marginal kidneys, now more than ever do we require new therapies to improve graft 
function and survival. 
 
 
1.3 STRATEGIES TO TACKLE THE KIDNEY TRANSPLANT WAITING LIST 
 
To increase the number of transplanted kidneys, there are three main areas where 
intervention can be applied: the donor, the retrieval and peri-transplant period, and the 
recipient. Advances in one area which results in a seismic shift in practise and waiting times 
do not come around often. A combination of interventions is where progress has been made 
in the past, and it will likely be the same moving forward.  
 
Donor strategies have aimed at increasing referrals for donation, improving consent rates 
and increasing the number of live donor transplants. Lowering the “minimal kidney criteria” 
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has also increased the number of kidneys available but we have now researched the point of 
diminishing returns. Improved optimisation of the donor before retrieval has extending graft 
survival and reduced the number of patients being relisted for another transplant.  
 
The recipient can also play a role in tackling the waiting list times. If graft survival is 
prolonged, then the chance of requiring another transplant will reduce, and fewer patients 
will be re-listed. An effective method of achieving this is with pre-emptive transplants where 
it is known that both living and deceased transplant grafts last longer when the patient is 
transplanted preemptively or within six months after dialysis. Optimising the recipient 
before transplant by achieving and maintaining a healthy weight, improving cardiovascular 
health, positive lifestyle changes would seem to have obvious benefits. However, for dialysis 
patients, it is notoriously difficult to exercise, eat healthily, all the while battling lethargy 
(due to anaemia, medications, dialysis, poor sleep), having regular dialysis sessions, 
physiologically deteriorating and often under financial strain from not being able to work.  
 
The 'obesity paradox' complicates issues with higher BMI associated with lower mortality 
risk in patients on maintenance haemodialysis (J.-L. Wang et al. 2012; Schmidt & 
Salahudeen 2007; Rhee et al. 2016). On the other hand, obese patients have higher peri-
transplant complications and delayed graft function compared to non-obese patients. 
Considering these increased risks, obese patients receiving transplant still have better 
outcomes than those staying on dialysis (D. W. Johnson et al. 2002; W. M. Bennett et al. 
2011; Gill et al. 2013). Therefore, the outcome for long term recipient and graft survival is 
not as clear with new evidence drawing doubt on the correlation between obesity and long-
term graft and patient survival (Nicoletto et al. 2014). A carefully planned multidisciplinary 
approach to weight loss with minimal lean mass loss and protein-energy wasting will ensure 
optimisation for surgery, better graft survival and less chance of weight gain post-transplant.  
Evidence supporting recipients fasting peri-transplant has not been demonstrated clinically, 
but several animal models have shown the protective benefits against ischemia reperfusion 
injury (IRI) (Mitchell et al. 2010).  
 
Post-transplant follow up, a healthy post-transplant adjusted lifestyle, adherence to 
immunosuppression should all be advocated, and the benefits of each can add up to 
significantly to improve graft function and longevity (Denhaerynck et al. 2005; Adams 
2006). Nonadherence with immunosuppression is a particularly complex issues but is 
essential to address to maximise graft survival. First year after transplantation adherence is 
at its best but electronic monitoring has demonstrated a gradual increase in nonadherence 
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over time. However data on nonadherence is difficult to accurately collect and is often 
underpowered (Nevins et al. 2017).  The strongest risk factor for nonadherence is being an 
adolescent. Tailored intervention, such as changing to a once daily regime in a patient with 
well-matched kidney, can help motivate and improve adherence.  Immunosuppression 
regimes or tolerance inducing therapies could hold the key to the next seismic shift in 
transplantation with regards to the recipient interventions.  
 
Strategies to improve the retrieval process have been successful not only in tackling the 
waiting list but by progressing in a timely manner – unlike other strategies such as live donor 
campaigns that may take years to come to fruition. A transplant hub to coordinate all 
donations with real-time donor data available for surgeons has helped to streamline the 
process of donation, retrieval, allocation, transportation, and implantation. The data 
collected by the hub has been used to audit practises such as refusal rates from different 
transplant centres, organ injury during retrieval and ischaemic times. Other approaches by 
NHS’s Blood and Transplant division include disseminated activity reports, forwarding 
discarded organs for research, collation and analysis of decline data and support to clinicians 
who accept reasonable risk (NHS Blood and Transplant. 2019).  
 
The ‘Fasttrack’ scheme which offer out kidneys which have already been retrieved but 
subsequently declined by the intentional implantation centre has further reduced the number 
of discarded kidneys. However, the risk of mistakes is inherent, such as the death of two 
young recipients who died of meningitis secondary to parasite infection transmitted from 
their transplant. Understandably transplant teams are now hesitant in accepting these higher 
risk organs. This case highlighted the dangers of pushing surgeons and the transplant teams 
to accept kidney offers that would conventionally be declined. Added to the further pressure 
that retrieval is now largely performed during the daytime and implantation at night. There 
is a growing issue of sustainability of delivering a service which involves making complex 
decisions and increased operating during the middle of the night.    
 
Peri-transplant management, in particular induction immunosuppression, offers another vast 
area of research and potential. Tolerance inducing cellular therapies and other therapies 
administered peri-transplant have been widely studied over the last decade. Clinical trials of 
such therapies are taking place and if successful, could reduce the need for daily lifelong 
immunomodulatory drugs which eventually fail and have their associated risks. The field of 
tolerance inducing cellular therapies, although exciting and demonstrating huge potential, is 
out of the scope of this thesis.  
 29 
This leaves us to one of the most widely researched fields of transplantation - ischaemia 
reperfusion injury (IRI). With many methods of intervention being investigated and already 
implemented, significant progress has been made. Ameliorating IRI will improve graft 
outcome, graft survival, and increase the kidney pool (as marginal kidney offers and 
acceptance will increase). A therapy that effectively treats or protects a kidney from IRI 
would drastically reduce waiting times. 
 
 
1.4 KIDNEY ISCHAEMIA REPERFUSION INJURY AFTER TRANSPLANTATION 
 
The degree of IRI a kidney sustains directly correlates to the long-term outcome in terms of 
overall graft function and survival. Over-simplifying it, renal IRI results in reduced nephron 
mass, increased allogenicity, a lower baseline for general decline, a predisposition to chronic 
fibrosis and tubular atrophy (Eltzschig & Eckle 2011; Mueller et al. 2011; Burns et al. 1998; 
Salahudeen et al. 2001). 
 
The pathophysiology of IRI has been well studied, and many of the critical processes are 
well understood. Nevertheless, that should not take away from the complexity that is IRI 
with its array of interlinked cellular and molecular processes. The initial changes from the 
ischaemia trigger a switch to anaerobic metabolism, then the innate response begins to 
activate in response to cellular stress. The second wave of injury at reperfusion is mainly a 
result of the surge of reactive oxygen species. The limited capacity of repair and regeneration 
cannot return the kidneys to normal, but instead, the kidneys have remodelled vasculature 
with compromised flow, reduced nephron numbers and the beginning stages of fibrosis. 
 
The ischaemic injury begins once the blood flow to the kidney does not meet the cellular 
demand for oxygen. When there is not enough oxygenated blood, the highly metabolically 
active renal cells convert to anaerobic metabolism. Following the brain and heart, the kidney 
is the third most susceptible organ to ischaemia. After 30 minutes, irreversible damage starts 
to develop, starting at the cortex, which has the highest oxygen requirements. Some of the 
critical and well-understood processes, of IRI, are described below. 
 
Once the kidney converts to anaerobic respiration, via glycolysis to increase ATP, cellular 
lactate accumulates and is one of the primary reasons for the cellular pH to drop. H+ ions 
are exchanged for Na+ via the Na+/H+ exchanger in an attempt to counteract the drop in pH 
(Baines 2009; Murphy & Steenbergen 2008) The Na+ ions, in turn, are exchanged for 
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calcium by the Na+/Ca+ exchanger and this among other processes (such as impaired Ca+ 
uptake into the ER) causes a massive increase in intracellular calcium (Sanada et al. 2011; 
Szydlowska & Tymianski 2010; Talukder et al. 2009). This intracellular calcium initiates 
cell death through multiple pathways. Mitochondrial uptake of calcium, via the 
mitochondrial Ca+ uniporter, attempts to restore balance but once excessive levels of 
calcium are reached in the mitochondria, mitochondria permeability transition (MPT) ensues 
(Szydlowska & Tymianski 2010). Raised Cytosolic calcium also activates calpains and 
calcium/calmodulin-dependant protein kinases (CAMKs), which contributes to cell 
death(Kalogeris et al. 2012; Croall & Ersfeld 2007). Also, raised intracellular calcium and 
sodium lead to cell swelling and cell cycle arrest (Ponticelli 2015).  
 
With the lack of oxygen, ATP production falls as does the intracellular pH, and the delicate 
balance within the mitochondria become disturbed. The mitochondria swell and allow the 
efflux of cytochrome c into the cytosol where it initiates apoptosis (Dorweiler et al. 2007; 
McCully et al. 2004). The fission and fusion cycles of the mitochondria become unbalanced, 
and excess fission causes fragmentation and damage to the mitochondria, which then leads 
to cell death. A study which inhibited mitochondrial fission demonstrated a reduction in IRI 
-induced mitochondria fragmentation (Ong et al. 2010). The MPT pore (a non-specific 
channel in the mitochondrial membrane) is opened in reaction to the increase of calcium and 
reactive oxygen species (ROS) causing further depletion of ATP as the permeability of the 
membrane dissipates the proton electrochemical gradient. Swelling, rupture and cell death 
is a high risk when the MPT pore remains open. Hence the MPT pore plays a vital role in 
necrosis (Baines 2009; Halestrap 2010; Kroemer et al. 2007).  
 
When reperfusion ensues, essential ATP generation via aerobic respiration restarts; 
however, this critical reperfusion comes with its detrimental effects. The influx of oxygen 
and rapid production of ATP, from oxidative phosphorylation, results in an increased and 
overwhelming generation of the by-product ROS.  ROS (precisely, a term for several 
reactive molecules and free radicals derived from oxygen) under normal circumstances can 
be handled and dealt with by the cell via several defence mechanisms, but when ROS levels 
become excessive the resultant damage is termed “oxidative stress”. Reactive nitrogen 
species (RNS) which are nitrogen-containing oxidants, together with ROS are collectively 
termed RONS. The extent of injury from reperfusion is due to the individual and combined 
effects of ROS and RNS (Kvietys & Granger 2012). RONS affect cell signalling and directly 
damage DNA, protein, and lipids among other cell molecules. The damage can directly 
disrupt cell structure leading to cell death or can activate and propagate the inflammatory 
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cascade resulting in cytokine release, apoptosis, structural cell damage and again cell death 
(Kalogeris et al. 2012). Inflammatory cells such as macrophages and neutrophils also release 
a burst of ROS, typically reserved as a host defence against invading pathogens, but this is 
triggered in the immune response to IRI further adding to the overwhelming volume of ROS. 
(Kvietys & Granger 2012). 
 
Cell death and injury activate the innate immune system with most of the insult from the 
immune system coming during the reperfusion stage in response to the injury caused by the 
RONS. The resultant inflammation is termed a sterile inflammation as there is no pathogen 
present, and its intensity relies on the pro and anti-inflammatory mediators released by 
resident renal cells and recruited inflammatory cells.  
 
Initially thought to play a passive role, the epithelial cells are now considered to play a 
significant, initial role during the reperfusion phase. No reflow phenomenon, which is 
reduced or no blood flow, particularly in the outer medulla, without mechanical obstruction, 
is seen at reperfusion. It is a result of intense endothelial vasoconstriction, swelling of the 
endothelial cells (see above) and reduced production of vasodilators(Sutton et al. 2002; 
Flores et al. 1972). This causes patchy perfusion of the kidney, prolongation of the ischaemic 
insult and production of danger-associated molecular patterns (DAMPs) which in turn 
activate Toll-like receptors (TLR) (Beg 2002). These TLR are involved in the pathways 
associated with apoptosis and the production of many pro-inflammatory cytokines and 
chemokines such as tumour necrosis factor α (TNF- α), IL-1beta, IL-6, C-C motif ligand 2 
(CCL2) which in turn can further cascade the increase of pro-inflammatory mediators (Wolfs 
et al. 2002; Huiling Wu et al. 2007). Animal studies looking at TLR2 and TLR4, in 
particular, found a dampened inflammatory response, better survival and reduced fibrosis 
when inhibited. (Huiling Wu et al. 2007; Leemans et al. 2005; L.-M. Zhang et al. 2016). The 
swollen injured tubular epithelial cells also activate the complement system through the 
alternative pathway as they produce less complement receptor 1-related gene/protein y 
(Crry). Crry is a complement inhibitor post-IRI (Thurman et al. 2006). Activated 
complement system enhances the attraction of immune cells like neutrophils and 
macrophages to the kidney. Macrophages and neutrophils are further attracted to the kidneys 
by many other immune effects after IRI such as the increased expression of intracellular 
adhesion molecule 1 (ICAM-1) and  c-x-c motif chemokine ligand 1(CXCL1) within renal 
cells (Sutton 2009; Oh et al. 2008). 
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Neutrophils attracted to injured tubules have been found to have a negative effect. Studies 
looking at neutrophil depleted mice, and ICAM-1 knockout mice sustained less injury 
secondary to IRI (Kelly et al. 1996). Awad et al. suggested that among other detrimental 
effects, they create more ROS (Awad et al. 2009). After neutrophils, macrophages arrive 
attracted by the release of cytokine and chemokines such as C-X3-C motif chemokine 
receptor 1 (CX3CR1) and c-c motif chemokine receptor 2 (CCR 2). Along with dendritic 
cells, they propagate the immune-inflammatory response with the release of pro-
inflammatory cytokines (X. Dong et al. 2007; Bajwa et al. 2009; L. Li et al. 2008) As the 
inflammatory process continues, dendritic cells make up the majority of the leukocytes in 
the kidney. However, not all leukocytes have a detrimental effect. Resident monocytes 
which are exposed to interleukin 4 (IL-4), IL-13, immune complexes, or IL-10 differentiate 
into resident anti-inflammatory or pro-repair macrophages also known as M2-type 
macrophages (Y. Wang et al. 2007; S. Lee et al. 2011). However, although the M2 phenotype 
may be initially beneficial, the longer-term effects are still uncertain, as they may drive renal 
fibrosis (Meng et al. 2014). 
 
The full innate response is vast, complex, and out of the scope of this chapter; however, due 
to its translation in clinical trials, it is worth mentioning T cells. Natural killer cells (NK) 
and CD4+T cells seem to exacerbate IRI. Natural killer cells can be found in the kidney 30 
minutes after IRI, and three hours later, its pro-inflammatory cytokines such as interferon-
gamma (IFN-y) production is at its peak (X. Dong et al. 2007). Natural killer T cells (NKT) 
can also increase the dendritic cell response in IRI (X. Dong et al. 2007). CD4+T also act 
early in the IRI innate response with infiltration by one hour (Burne et al. 2001). Studies 
looking at blocking endothelial CD80 expression, which attracts CD4+T cells to migrate to 
the kidney, found reduced kidney injury and a reduction in pro-inflammatory cytokines 
(Burne et al. 2001; Z.-X. Zhang et al. 2008). However, not all T cells have a negative impact 
post-IRI on the kidney. T regulatory cells (T regs), which express the cell marker 
transcription factor forkhead box P3 (FoxP3) and CD25 have demonstrated promise in 
reducing the inflammatory response, graft rejection and even improving long term tolerance. 
Phase I clinical trials have shown their safety and feasibility (Romano et al. 2019). T regs 
interact with many other immune cells including CD4+ and CD8+ cells, NKT cells, B 
lymphocytes, dendritic cells (DC), neutrophils and monocytes suppressing their function 
either by direct interaction or indirectly through multiple mechanisms (Vignali et al. 2008). 
Tregs can produce anti-inflammatory cytokines such as (IL-10, IL-35) in addition to 
suppressing T lymphocyte proliferation and activity, both of which can ameliorate 
IRI(Romano et al. 2017). As mentioned earlier, the positive attributes of M2 macrophages 
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can be enhanced through Tregs ability to push monocytes toward the M2 phenotype 
(Tiemessen et al. 2007). 
 
 
1.5 KIDNEY RECOVERY AFTER ISCHAEMIA REPERFUSION INJURY 
 
The aftermath and long-term outcome for the kidney depend on the severity of the IRI and 
the kidney’s capacity to repair itself. Recent studies have suggested that rodent adult kidneys 
can regenerate through unipotent precursor cells, but this has not been demonstrated in adult 
human kidneys. Human kidney regeneration potential and the exact source remains elusive. 
It could be through endogenous tubular epithelial cells, with the aid of bone marrow-derived 
stem cells and paracrine function, that divide and repair locally. Renal progenitor cells seem 
a more likely source of human kidney regeneration after injury (Lombardi et al. 2016; 
Rinkevich et al. 2014; Angelotti et al. 2012). Either way, there is no agreed conclusion. 
Unlike some human organs, the kidney, as far as we are aware, has a limited capacity to 
create new nephrons. The skin and intestine can completely self-renew within a few days, 
but even though limited studies exist, it is generally thought that human kidneys cease to 
create new nephrons after birth, with the majority of nephrons developing in the second half 
of gestation (Blanpain et al. 2007; Blanpain et al. 2004; Ryan et al. 2018). All is not doomed 
as the kidney can recover function after injury though not through regeneration, as described 
above, but through hypertrophy. Even if the patient is elderly or has some underlying 
comorbidities (Taner et al. 2015). The number of nephrons in the healthy human kidney can 
vary between 250,000 to two million, and it can be surmised that humans with high nephron 




1.6 THERAPIES TO MITIGATE TRANSPLANT RELATED KIDNEY ISCHAEMIA 
REPERFUSION INJURY  
 
The degree of IRI, which is proportional to the CIT, harms graft function and survival 
(Quiroga et al. 2006; Sert et al. 2014; Barba et al. 2011). In addition to delaying graft function 
and reducing graft survival IRI triggers immune system activation subjecting the recipient 
to an increased risk of rejection which is associated with increased hospital admissions, 
monitoring and biopsies (Barba et al. 2011; Brennan et al. 2004). Conquering its complexity 
and developing an intervention will not only improve function but will open the door to more 
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DCD and marginal kidneys. Currently, many DCD and marginal kidneys are not accepted 
or offered for transplantation as the evidence tells us they will not have an acceptable 
function or longevity after sustaining an ischaemic reperfusion insult. Hoverer a therapy to 
ameliorate IRI will open the door to the kidneys which are not offered or declined.  
IRI is associated with increased immunogenicity, chronic renal graft dysfunction, loss of 
renal mass, and fibrosis formation (H. Zhao et al. 2018). Multiple approaches are taken to 
address IRI, and the main areas of research and development include perfusion solutions and 
ex vivo perfusion rigs, pre and post graft conditioning, pharmacological interventions, and 
cellular therapies.  
 
 
1.6.1 KIDNEY PERFUSION FLUID AND EX VIVO PERFUSION RIGS 
 
Traditionally retrieved kidneys are preserved in static cold containers during transportation 
and the period spent there is termed the cold ischaemic time. Extreme efforts are made to 
keep this time as low as possible as CIT is directly related to delayed graft function (DGF) 
and graft survival and outcomes. To limit the damage caused during the CIT kidney storage 
solution was invented to perfuse and surround the kidney post retrieval and when being 
prepped for implantation. The most used are University of Wisconsin, Histidine-tryptophan-
ketoglutarate and Celsior solution. These solutions aim to slow down the metabolic 
processes and preserve the grafts as long as possible. Key ingredients include colloids, 
buffers, nutrients and antioxidants (Yimeng Chen et al. 2019). Despite the three solutions 
mentioned above still widely used today, there have been many adaptations to these 
solutions.  
 
Additives to the solutions have been investigated to target specific pathways of IRI such as 
the use of hydrogen sulphide (H2S) to slow O2 requirements and apoptosis, prostaglandin 
E1 to target oxidative stress, and various trophic factors (Lobb et al. 2015; McAnulty et al. 
2002; Polyak et al. 1999). Novel gaseous additives such as xenon, argon, hydrogen sulphide 
and carbon monoxide, in addition, or as a replacement of traditional nitrogen gas saturation, 
have increased in popularity due to their favourable non-toxic characteristics at therapeutic 
doses, cheap cost and growing evidence in animal studies at ameliorating IR.  Again, gasses 
target pathways of IRI such as H2S antiapoptotic and anti-inflammatory effects or the theory 
that CO will prevent a pro-inflammatory increase in haem content by inhibiting the 
degradation of cytochrome P450 (Nakao et al. 2008; Lobb et al. 2014; Hunter et al. 2012). 
Gases may also more easily permeate the cell membrane. 
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To improve on static cold storage, mobile rigs were created to constantly perfuse the kidney 
with cooled perfusion solution in an enclosed system under a specific pressure during 
transportation. This ex vivo hypothermic machine perfusion has significant evidence 
supporting it over cold static storage with a drop in delayed graft function, increase in 1-year 
survival and 3-year survival (Ray et al. 2009; Wszola et al. 2014; Treckmann et al. 2011; 
Tingle et al. 2020). With multiple temperatures, pressure and perfusion time combinations 
possible, there is likely to be further developments in this field with regards to optimal 
conditions (De Deken et al. 2016).  
 
In 2011 the first renal transplant was performed using a kidney that underwent ex vivo 
normothermic perfusion (Hosgood & Nicholson 2011). This has the added advantages of 
limiting some of the effects of anoxic hypothermic preservation as the kidney is perfused 
with warm oxygenated red cell-based solutions. This not only preserves and resuscitates but 
allows observation of kidney perfusion, urine output monitoring and the option to perform 
biochemical or histological analysis. Phase II studies of 400 patients have already started 
recruitment (Hosgood et al. 2017). Again, this is likely only the beginning as there is a vast 
and growing combination of therapy time, pressure, and solutions.  
 
Another significant advantage of ex vivo perfusion rigs is the opportunity to administer 
therapies while being perfused on the rig. Easy access to the kidney and its artery opens the 
door for several routes of administration. Administering therapies on the rig (ex vivo) 
reduces the risk of therapies passing onto patients and having undesirable side effects. 
Higher dosage regimes can then be tested, ethics approval for trials will be simpler, and 
kidneys that would otherwise be discarded can be given a chance to demonstrate if it has any 
acceptable residual function. 
 
 
1.6.2 PRE AND POST ISCHAEMIC CONDITIONING  
 
As with many therapies and techniques to counteract IRI, the renal transplant community 
attempted to adopt a technique which had shown much promise in cardiac surgery. 
Ischaemic preconditioning demonstrated significant amelioration in kidney dysfunction and 
damage in animal models of renal IRI (Jiang et al. 2015; van den Akker et al. 2013; 
Kadkhodaee et al. 2011). Popular regimes of pre-conditioning involve ischaemia and 
reperfusion of a limb for four cycles of 5 minutes either before transplant or post-
implantation. Unfortunately, a multicentre prospective study between Sweden, Denmark and 
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Netherlands of 225 patients who underwent remote ischaemic pre-conditioning peri-
implantation did not find any differences in their primary outcome of kidney function (serum 
Cr) (Krogstrup et al. 2017). Different combination of pre, post and remote ischemia for 
varying lengths of time in both live and deceased donors have been attempted, but none have 
shown significant long-term advantages(Jianyong Wu et al. 2014; Nicholson et al. 2015; 
Yeling Chen et al. 2013; van den Akker et al. 2014). A larger study of 406 live donors 
attempting late and early remote ischaemic preconditioning also found no change on 
glomerular filtration rate (GFR) or the inflammatory response to surgery (MacAllister et al. 
2015).  Clinical studies on remote ischaemic pre-conditioning for renal IRI seems to have 
largely fizzled out. 
 
 
1.6.3 PHARMACOLOGICAL INTERVENTION 
 
Pharmacological intervention has so far been disappointing. There is no widely used drug 
which convincingly ameliorations IRI and has made the transition to successful clinical 
application (despite promising animal studies). Two that made it to clinical studies (for acute 
kidney injury) were statins and erythropoietin. Statins were initially thought to improve 
contrast-induced kidney injury, but a prospective study failed to validate the improvement 
(Attallah et al. 2004; Khanal et al. 2005; S.-H. Jo et al. 2008). Erythropoietin administered 
peri transplantation again showed promising results both in animal models and in some 
clinical studies, but a metanalysis by Vlachopanos et al. found no significant difference when 
administered for deceased donor transplants in either DGF, mortality, rejection, DGF and 4-
week kidney function (Xin et al. 2015; Vlachopanos et al. 2015). More novel 
pharmacological treatment has been promising in animal models such as CD47-blocking 
antibody (alphaCD47Ab). AlphaCD47Ab inhibits nitric oxide and oxidative stress by 
ameliorating thrombospondin mediated IRI signalling (Rogers et al. 2012). Helix B peptide 
surface peptide of erythropoietin reduced apoptosis and inflammation with subsequent 
increase in renal function in a rodent model of renal IRI (Yang et al. 2014). When added to 
reperfusion solution, the kidneys had improved urine output and decreased tissue damage – 
the helix B peptide seems to hold the protective abilities of erythropoietin (Yang et al. 2015). 
Pharmacological agents aimed at inhibiting the matrix metalloproteinases (MMPs) and ROS, 
both of which are heavily involved with the mechanism of injury, in theory could be a 
promising route of study and perfusion rigs could offer a means of administration. The scope 
of this research is enormous due to the thousands of interventions points possible in the 
complex IRI pathophysiology, more of which is described in chapter five. However, 
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currently, there have been no breakthroughs in terms of peri-transplant pharmacological 
intervention to reduce transplant-related IRI injury. Phase two clinical trials in 2009 of 
Diannexin were promising with improved GFR and urine output in recipients who received 
it intravenously post reperfusion of their marginal kidney (M et al. 2010). Diannexin is an 
agent that binds to phosphotidyl serine on the cell surface and inhibits mononuclear cell 
attachment attenuating IRI. No further research has been published regarding Diannexin in 
kidney transplant patients. Finally, the University of Edinburgh is currently recruiting for 
their randomised controlled clinical trial looking at the use of heme arginate to mitigate the 
inflammatory response of IRI. Heme arginate induces expression of the heme-oxygenase 
which is an enzyme that breaks down heme and reduces the inflammatory response. 
Recruitment is due to be completed by the end of 2020. 
 
 
1.6.4 CELLULAR THERAPIES 
 
Of all the interventions so far cellular therapies, in particular stem cell therapy, show the 
most promise. Therapies investigated to date have attempted to harness the protective and 
regenerative therapies not just of stem cell like cells but many cell types such as T cell, 
dendritic cells, and macrophages. The field is expanding rapidly, as is our understanding. It 
is a minefield of definitions, categories, disputes, and that was before the inclusion of stem 
cell-derived/associated mediators like stromal vascular fraction, extracellular vesicles, and 
stem cell-derived microRNA. So far, clinical trials of stem cells in renal transplantation have 
been low (Fig.1.4). However, with the popularisation of perfusion rigs and their unique 
ability to administer cellular therapies ex vivo, trials using cellular therapies in kidney grafts 
is undoubtedly going to surge.  
 
 
1.7 STEM CELLS AND STROMAL CELLS WITH STEM CELL LIKE 
PROPERTIES 
 
Within the scientific community, the first name that often comes to mind when discussing 
discoveries in stem cell research is Dr Yamanaka. In 2006 Dr Yamanaka reprogrammed 
adult (mature) human cells to become pluripotent by inserting four genes (retroviral 
transduction of Oct3/4, Sox2, c-Myc, and Klf4) (Takahashi et al. 2007). He later won the 
Nobel Prize for the work discovering the induced pluripotent stem cells. To the public, the 
most famous of all in the field of stem cell research is Dolly the sheep. A team from the 
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Roslin Institute, Edinburgh, led by Ian Wilmut, were the first to artificially clone an animal, 
by nucleus transfer, from a cultured embryonic cell line (Campbell et al. 1996). Although 
these breakthroughs were ground-breaking, there were many revolutionary discoveries that 
provided the foundations for stem cell research. 1969 saw the use of bone marrow transplants 
to treat immunodeficiency and there have been steady discoveries in animal and humans 
since then.  
 
One of the earliest breakthroughs in terms of human stem cells for mass therapeutics was Dr 
Thomson and his team's achievement in creating the first human embryonic stem cell line 
(Thomson et al. 1998). A human stem cell line that still exists today and is one of the 
discoveries that has facilitated an explosion of research on stem cells as it negated the first 
(of many to come) stumbling block which was the need of repeated embryo retrieval from 
humans (not to mention the ethical issues associated with that). Since then, there has been a 
flow of discoveries such as new categories of stem cells, new sources, new stem cell lines. 
To add to all the discoveries, there are now thousands of ways they can be altered. Growing 
organs ex vivo, making organoids to test therapies and using animals to grow human organs 
are just a few ways in how they are now used but many of which will not see widespread 
clinical translation any time soon. However, the most likely approach that will see them 
widely used in the clinical setting is as an administered therapy for their regenerative, 
reparative, and protective effects. 
 
With over 2000 publications per year and growing it can be overwhelming when trying to 
keep up with the field of stem cell research. Some of the directions of study has raised 
concern and beyond what is ethically acceptable not only to the scientific community but to 
donors, recipients, and society. Source selection, harvesting techniques, induction, the 
introduction of CRISPR gene editing and the crossover of humans and animals need to be 
regulated to safeguard the public but continue to allow research to progress. Laboratories, 
organisations, and governments have their regulations; however, as with many sectors, in 
recent times, the laws cannot keep up with the rate of research. Wading through the research, 
sparks new ideas but is also a rollercoaster of excitement, admiration, dubiety, and concern. 
Analysing the research from the late 90 into the 2000s, there is an impression that we were 
on the verge of changing medicine forever. Two things have since become apparent. Firstly, 
the field is more complex and challenging to implement than first anticipated, and secondly, 




1.7.1 DEFINITION AND CATEGORISATION  
 
Within the scientific community, despite best efforts of organisations such as the 
International Society for Cellular and Gene Therapies (ISCT) and International 
Federation for Adipose Therapeutics and Science, there remains inconsistency in the 
categorising, phenotyping, and even what is considered a stem cell. Understandably, 
without careful reading of articles and understanding the retrieval and preparation 
process, it easy to get mislead if authors are referring to stem cells or stromal cells with 
some stem cell-like characteristics.  The word “stem cells” is often inaccurately used as 
the authors have failed to stringently prove what they are referring to are stem cells and 
not stromal cells with stem cell-like characteristics. Bone marrow-derived mesenchymal 
stem cells and bone marrow-derived mesenchymal stromal cells being a prime example 
of two terms that are often interchanged but do not necessarily represent the same thing. 
Having the same acronym (MSC) does not help! 
 
Mesenchymal stromal cells (MSC), as defined by The International Society for Cellular 
Therapy,  are adherent to plastic, positive for CD105, CD73, and CD90 and negative for 
the expression of CD45, CD34, CD14 or CD11b, CD79 or CD19, and human leukocyte 
antigen class II, and should also be able to differentiate in vitro into osteoblasts, 
adipocytes, and chondroblasts (Horwitz et al. 2005). Cells were initially thought to be 
CD34- but processing and culturing techniques can alter their expression. This is the 
minimum criteria for MSC and all though very similar (and often argued to be the same 
population but just different due to their microenvironment, retrieval, and culturing 
techniques) there are some differences in cell surface markings from MSC of different 
sources. Table 1.1 displays some of the mild differences of surface cell markers from 
adipose-derived mesenchymal stromal cells (ASC) and bone marrow-derived 




















Mesenchymal stem cells refers to a stem 
cell population with demonstrable 
progenitor cell functionality of self-renewal 
and differentiation whereas MSC refers to a 
bulk population with notable secretory, 
immunomodulatory and homing properties 
and that is capable of in vitro 
differentiation into adipocyte, chondrocyte 

















Method of isolation: 
Ficoll density gradient method 











Method of isolation: 
Digestion method 








 Other sources of MSCs include muscle, 
tendons, umbilical cord, synovial 
membrane, skin, nervous system, 
Wharton’s jelly 





Table 1.1 Surface markers of bone marrow derived and adipose derived 
mesenchymal stromal cells. 
 
According to the 2019 ISCT committee position statement the term “stem cell” should 
not be used unless they can be vigorously demonstrated to have more specific stem cell-
like characteristics: 1) adherence to tissue plastic 2) multipotency and the maintenance of 
multipotency on in vitro expansion and 3) self-renewal capacity (Viswanathan et al. 
2019). It can be said that MSC represents a bulk, unfractionated heterogeneous cell 
population that have secretory, immunomodulatory, and homing properties, of which a 
tiny population of the MSC will be true stem cells. As mass cytometry technology 
improves and the use of next-generation single-cell sequencing increases, these 
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population within MSC will likely become more defined (Viswanathan et al. 2019). The 
ISCT Mesenchymal Stromal Cell Committee made the following statement:  
 
“Ultimately, the questions of whether mesenchymal stem versus stromal cells are 
functionally distinct subpopulations and whether the stem and stromal cells have 
overlapping paracrine and immunomodulatory functions are best answered based on 
single-cell sequencing experiments, statistical clustering and analyses of data. From a 
clinical translational perspective, the secretory and immunomodulatory functions 
associated with clinical benefits of MSC-based therapies are thought to reside in the bulk, 
heterogeneous stromal cell fraction.” – 2019 ISCT position statement (Viswanathan et al. 
2019)  
 
BM MSCs, until recently, had been the most widely understood and studied. Friedenstein 
and colleagues first identified bone marrow-derived non-haemopoietic MSC in the 1970s 
(Friedenstein et al. 1970). Nowadays, MSCs have been isolated from almost every bodily 
tissue (Via et al. 2012). Bone marrow derived haemopoietic and MSCs may have had a 
head start in terms of research and clinical translation but in recent times focus and 
understanding of other tissues sources has dramatically increased as they offer different 




Figure 1.4 Clinical trials currently using embryonic and adult stem cells. (A) Pie chart 
showing the relative numbers of clinical trials using different types of stem cells as listed on 
the U.S. NIH website clinicaltrials.gov. (B) Percentage of MSC-based clinical trials 
classified by disease type. (C) MSC-based therapies in different kidney diseases. Rota C, 
Morigi M, Imberti B. Stem Cell Therapies in Kidney Diseases: Progress and Challenges. Int 
J Mol Sci. 2019;20(11):2790. Published 2019 Jun 7. doi:10.3390/ijms20112790 
 
 
1.7.2 STEM CELLS IN ORGAN TRANSPLANTATION 
 
Solid organ transplantation has revolutionized the treatment of organ failure. Immunological 
barriers have progressively reduced, but the challenge of inadequate donor organ supply has 
grown with increasing demand (Levitt 2015). This has led to escalating use of 
older/comorbid donor organs (Saidi et al. 2014). Aside from intrinsic increased cellular 
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senescence (Braun et al. 2012), such organs do not tolerate the injurious processes associated 
with removal, storage, and transplantation as well as traditionally used organs from younger 
donors {Port:2002in}. In particular, kidneys from older and co-morbid donors are more 
vulnerable to the ischemia reperfusion injury (IRI) (H. Zhao et al. 2018). 
 
Regenerative medicine approaches to organ transplantation initially focused on the 
generation of functioning neo- tissue, highlighted widely as the main potential benefit of 
pluripotent stem cells. This approach spans artificial organ construction, the engineering of 
bioactive, organ-like tissue (Bantounas et al. 2018), and the use of infused stem cells (Raven 
et al. 2017). Examples of such tissue successfully generated for clinical use do exist (De 
Filippo et al. 2015) for relatively simpler tubular structures, but translation in solid organ 
transplantation has been slow and frequently remains at the preclinical stage (Taylor et al. 
2018). 
 
This has led to a switch in focus to addressing the regenerative capacity of organs already 
available — including those currently declined for solid organ transplantation because of 
predicted poor function post-transplantation. This approach focuses on protecting organs 
from peri-transplantation injury (principally IRI) and enhancing tissue regeneration after 
transplantation. Stem cells provide a promising source of protective and regenerative 
properties; however, there are many different forms of “stem cells” and accurate 
characterization and functionality can be complex. Pluripotency, multipotency, or 
oligopotency are clearly essential to form functioning neo-tissue but such characteristics 
may be less critical in stem cell’s ability to influence other tissue to survive injury and 
regenerate. The wide variety of stem cell subtypes currently used in organ regeneration is 












1.7.3 UNDERSTANDING ANIMAL MODELS USED TO INVESTIGATE STEM 
CELLS IN RENAL TRANSPLANTATION  
 
Most data which exist on stem cells in transplantation is based on animal models which 
attempt to mimic renal transplant IRI. Therefore, it important to understand the common 
models used and their limitations.  
 
The aim of the animal model of renal IRI is to inflict a reproducible and significant insult 
that will develop into renal fibrosis. There needs to be a measurable and permanent reduction 
in renal function without unacceptable rates of animal mortality. Therefore, establishing a 
degree of renal failure. Animal models that achieve this can be used to test therapies aiming 
to ameliorate renal transplant related IRI along with other forms of renal IRI.  
 
Animal models include bilateral ischaemia and unilateral ischaemia with contralateral 
nephrectomy (Fig. 1.6). Ischaemic times of 30 to 60 minutes have been shown to cause acute 
renal dysfunction. However, this length of ischaemia usually results in normal serum levels 
of urea and creatine within one week (Wei & Z. Dong 2012; Forbes et al. 2000; Ysebaert et 
al. 2000; Jablonski et al. 1983). In these models, more extended periods of ischaemia are 
associated with unacceptable rates of animal death from the acute kidney injury and in the 
majority of these model’s serum creatinine (Cr), and urea (Ur) will return to normal within 
two weeks making it impossible to test the long term efficacy of therapies (Zager 1987; 
Zager 1991; Hörbelt et al. 2007; Basile et al. 2001).  Therefore, to assess therapies more 
accurately, an animal model that causes a severe renal IRI injury that results in long term 
reduction in renal function (like the IRI associated with transplantation) is desired. 
Nevertheless, still adhering to the principles of the 3Rs as high mortality rates from an 
extreme IRI would not be acceptable.  
 
Unilateral ischaemia, without nephrectomy, allows for more prolonged levels of ischaemia 
resulting in permanent renal injury. The untouched contralateral kidney ensures survival. 
Whalen et al. demonstrated that 120 minutes of ischaemia of the left kidney in adult Fischer 
344 rats produced a significant loss of renal function that persisted after six weeks (Whalen 
et al. 2016). Histology at week six looking at hyaline casts and epithelial breaks confirmed 
chronic damage. Kidney function by Whalen et al. was measure by inulin clearance studies 
(Fig. 1.5).  
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Inulin is a fructose polymer that filtered via the glomerulus without being secreted, 
reabsorbed or metabolized in the renal tubules; therefore, an ideal molecule for GFR 
calculations (Aurell 1994). Determining the renal function of the injured kidney using inulin 
clearance is a terminal procedure. The inulin is injected systemically to create a constant 
plasma concentration then the ureters are cannulated, and urine and blood are serially 
collected to measure the inulin concentration. Inulin clearance and therefore, GFR can be 
calculated from the data. Plasma clearance studies such as this are considered the gold 
standard in determining renal function in the form of glomerular filtration rate and is 
significantly more accurate than serum Ur and Cr measurement. Cr and Ur are useful as 
surrogate markers of renal function but cannot be relied on for accurate renal function 
analysis, and they do not become elevated until 50-75% of kidney function is lost (Finco & 
Duncan 1976; Katayama et al. 2010). Even if there has been a severe long-standing injury 
to one kidney the normally functioning untouched contralateral kidney will be able to keep 
Ur and Cr serum levels within normal limits hence the additional need of inulin studies in 







Figure 1.5 Functional and histological analysis performed by Whalen et al. 
demonstrating a significant and permanent reduction in renal function with 
correlating histological findings in kidneys that are exposed to 120 minutes of 
ischaemia and then reperfused. The left kidney of the rat was clamped for 120 minutes 
then reperfused. Kidneys were then retrieved two weeks and six weeks later, after functional 
analysis using inulin clearance studies, for histological analysis. Left kidney renal function 
in Group 1 (sham-operated), Group 2 (120 minutes IRI with two weeks recovery) and Group 
3 (120 minutes IRI with six weeks recovery). (A) Renal histology shows that Group 2 
animals exhibit significantly more epithelial breaks than Group 1 animals (p<0.0001). 
Similarly, more epithelial cell breaks are observed in Group 3 animals than Group 1 
(p<0.0001). Group 2 animals had more epithelial breaks than Group 3 animals (p<0.0001). 
(C) Group 2 animal experience a severe reduction in GFR (~50%) compared to sham 
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5.45 RENAL HISTOLOGY SCORING 
Histological examination of kidney tissues as described above reveals significant 
disruption in renal architecture in those animals subjected to 120 minutes of warm 
ischemia.  (See figure 5.5) 
 
 Figure 5.5: (a) Renal histology shows that Group 2 animals exhibit significantly more epithelial 
breaks than Group 1 animals (p<0.0001). Similarly, more epithelial cell breaks are observed in Group 3 
animals than Group 1 (p<0.0001). Group 2 animals had more epithelial breaks than Group 3 animals 
(p<0.0001).  
(b) More hyaline casts are observed in both Group 2 (p<0.0001) and Group 3 (p=0.0285) when 
compared Group 1.  More hyaline casts are found in Group 2 animals compared to Group 3 animals 
(p=0.0001).  










































































5.44 GLOMERULAR FILTRATION RATE 
120 minutes of renal ischemia was found to produce a permanent, severe and 
reproducible injury that resulted in a long-term GFR deficit.  (See figure 5.4).  
 
 
Figu e 5.4: Left sided renal functio  in Group 1 (sham-operated), Group 2 (120 mi utes IRI with two 
weeks recovery) and Group 3 (120 minutes IRI with six weeks recovery).  Group 2 animals experience 
a severe reduction in GFR (~ 50%) compared to sham operated animals (p=0.0022).  GFR is typically 
~ 65% of sham values after six weeks recovery (p=0.0013). 



































operated animal (p=0.0022). GFR is typically ~65% of sham values after six weeks recovery 
(p=0.0013). Statistical analysis by one-way ANOVA with Turkey multiple comparisons test. 
Permission obtained from Whalen at al. to use figure. Published in Renal Failure 2016 
Nov;38(10):1694-1701. doi: 10.3109/0886022X.2016.1144024. A novel rodent model of 
severe renal ischemia reperfusion injury. Whalen H, Shiels P, Clancy M. 
 
 
Animal survival and well-being as assessed by weight gain in the Whalen et al. model was 
good and followed a similar trend to sham rats that underwent surgery with no IRI. 
Therefore, Whalen et al. produced an acceptable model of renal IRI which resulted in 
longstanding changes in renal function. With these long-term effects and the use of inulin 
clearance to measure renal function, it is a useful model to screen potential therapies before 
progressing on to technically more challenging and higher risk transplant models.  Also, 
Whalen et al. would administer therapies directly into the renal artery at the time of the 
ischaemia by transecting the artery, cannulating it to administer the therapies then suture 
anastomosing the artery back together. With the renal artery easily accessible at the time of 
human transplantation, it could prove to be an efficient route for administration with 
improved retention, reduced extra-renal biodistribution (see chapter 4).  
 
There were, however, some issues with the Whalen et al. model. Firstly, the fully functioning 
right kidney can effectively increase its functional capacity and meet the renal requirements 
of the rat including the “mopping up” of the metabolic disturbance, such as hyperkalaemia, 
uraemia, hypercalcaemia, hyperphosphatemia, that results from the IRI. Therefore, the 
environment in which the injured kidney is recovering is not representative of the transplant 
patient. Secondly, inulin studies in this model are time-consuming (taking up to 6 hours), 
surgically difficult and terminal therefore increasing the numbers or rats required as serial 
measurements are not possible. Thirdly, completely transecting the left renal artery was 
again time-consuming and technically challenging. To this end, an animal model that could 
provide the severe IRI but address some of the shortcomings would be optimal for testing 





Figure 1.6 Commonly used rodent animal models of renal IRI. Animal models of IRI 
can be split into bilateral IRI models or unilateral IRI models. Figure highlights some of the 
limitations of each kind of model. Coloured box highlights the ideal model for testing 













































1.7.4 STEM CELLS AMELIORATE KIDNEY ISCHAEMIA REPERFUSION 
INJURY  
 
The efficacy of infused MSCs, from various origins, in limiting IRI across multiple 
preclinical models is well established. Several such models have demonstrated this effect in 
rodent models of kidney IRI (Tögel et al. 2005; Lange et al. 2005; Asahara et al. 1996). A 
multicellular suspension of adipose-derived stromal vascular fraction cells (ADSVF) with a 
substantial MSC component has also exhibited similar properties (Z. Feng et al. 2010). 
Analogous observations have been described in liver models (X. Wang et al. 2018) and while 
less relevant to transplantation, similar cell types have been widely applied to the inhibition 
of ischemia reperfusion in myocardial infarction (Lim et al. 2018) and stroke (Nagahama et 
al. 2018).  
 
While efficacy against IRI has been known for more than 10 years, the mechanism of stem 
cell action remains poorly understood (Morigi et al. 2008; Giordano et al. 2007). A 
consistent theme in recent studies suggests that stem cells exert a paracrine effect 
transferring cytokines and extracellular vesicles (EVs) to neighbouring cells, and in the 
context of IRI, initiate repair through the limitation of fibrotic progenitors, inhibition of cell 
death, and the reduction of inflammation. Zhu and colleagues show that injected EVs, 
exosomes, extracted from ASC in a renal IRI mouse model improved renal outcome by 
tubular epithelial cell activation of transcription factor, SRY (sex determining region Y)-box 
9 (Sox9) (F. Zhu et al. 2017). Sox9 as a reparative factor is consistent with evidence that 
shows Sox9 promotion of tubular epithelial cell proliferation during embryonic 
development; and supports Zhu et al.’s additional studies which indicated an abrogation of 
tubular epithelial cell proliferation after administration of Sox9 inhibitors in the IRI model. 
ASC exosomal activation of Sox9 may also reduce progression to chronic kidney disease 
through simultaneous upregulation of Sox9 and downregulation of transforming growth 
factor (TGF)-β1 potentially avoiding upregulation of genes involved in building 
extracellular matrix and developing fibrosis (Meng et al. 2016). Sox9 may be a key 
regenerative mechanism in other organs as Sox9-dependant processes are also present during 
liver repair (A. Jo et al. 2014). However, whether the Sox9 gene can be administered as a 
therapeutic remains unclear, as a high Sox9 expression is correlated with glomerulosclerosis 
and liver fibrosis (M. R. Bennett et al. 2007). MSCs were also associated with elevated levels 
of transcription factors, AP-1, STAT3, and NF-kB. These factors may serve a reparative role 
by priming resident cells to enter the cell cycle, promoting proliferation and ultimately 
regeneration of injured tissue (W. Wang et al. 2014). 
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Stem cell extracellular vesicle transfer of specificity protein 1 (SP1) and its downstream 
regulators of necroptosis have been shown to be another paracrine mechanism in IRI 
inhibition. Necroptosis, like apoptosis, is a form of regulated cell death; however, unlike 
apoptosis, necroptosis is initiated by inflammation-related cellular damage that externally 
stimulates TNF receptors in the absence of active caspases (Belizário et al. 2015; Pasparakis 
& Vandenabeele 2015). SP1 is a transcription factor that upregulates sphingosine kinase-1 
(SK1) which enzymatically catalyses the formation of sphingosine-1-phosphate (S1P). S1P 
is a bioactive sphingolipid metabolite that promotes cell growth and survival by acting on 
several G protein-coupled S1P receptors which upregulate anabolic and survival pathways 
(Jin et al. 2008; Maceyka et al. 2012). Delivering SP1-containing extracellular vesicles 
derived from human-induced pluripotent stem cell-derived MSCs (hiPSC- MSCs) to a rat 
IRI model improved renal function, histological features, and reduced kidney necroptosis as 
established by annexin V/PI positivity tests (Xiaodong Yuan et al. 2017). Co-administration 
of SP1 or SK1 inhibitors increased necroptosis and abolished the renoprotective effects in 
the animal model. Analogously, SK and S1P-dependant inhibition of necroptosis is also a 
demonstrated MSC mechanism in liver IRI treatment (Man et al. 2005). 
 
In addition to inhibiting necroptosis, stem cells may also discourage cell death by inhibiting 
apoptosis. Stem cell pro- motion of mitogen-activated protein kinases (MAPK), which 
potentiate downstream signalling leading to apoptosis has been proposed as a potential stem 
cell induced pathway, especially given that bone marrow-derived stem cells have been 
shown to reduce the phosphorylation of ERK and p38, both vital signalling proteins in 
MAPK transduction(Qi & Dongcheng Wu 2013). However, further studies confirming stem 
cell downstream effects in inhibiting cell death, either through apoptosis or necroptosis are 
required. 
 
Reducing regulated cell death may improve residual organ function but being able to 
modulate the immune systems’ response to IRI may provide greater benefits on both 
retaining residual function and on long-term organ survival by disrupting positive feedback 
of sensitizing events. Stem cell immunomodulation has been extensively researched, in 
particular, stem cell-induced expansion of T-regs is proposed as a key therapeutic 
mechanism (Gonzalez-Rey et al. 2010). T-regs are known to suppress inflammatory 
functions of cells such as CD8+ T cells, macrophages, dendritic cells, natural killer cells, 
and B cells. In the context of renal IRI, it is reported that T-regs downregulate IFNγ 
production by local T cells, reducing the overall kidney inflammatory insult (Hu et al. 2016). 
In a recently studied IRI mouse model, endometrial regenerative cell treatment resulted in a 
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significant increase in splenic T-regs which is proposed to have improved the renal IRI 
outcome by potentiating a de- crease in CD4+ T cells, CD8+ T cells, and inflammatory- 
associated M1 macrophages levels while increasing levels of regulatory M2-type 
macrophages (P. Sun et al. 2016). Other potential mechanisms through which T-regs support 
organ preservation in IRI include metabolic interference, cytolysis, and targeting of antigen-
presenting cells (Romano et al. 2017; Vignali et al. 2008). Multiple clinical studies 
modulating T-regs in the context of organ transplantation are on-going and while not the 
principal end-point, evidence of an improved preservation effect may emerge (Romano et 
al. 2017). 
 
Another recent discovery implicating beneficial IRI immunomodulatory effects of stem cells 
was made by Shen et al. This group uncovered that mesenchymal stem cells and their 
exosomes contain particularly high levels of chemokine receptor proteins—CCR1 and 
CCR2 (Shen et al. 2016). These receptors actively bind and reduce the amounts of free 
CCL2. They went on to demonstrate that the decrease in available CCL2 resulted in reduced 
migration and activation of macrophages expressing the CCL2 cognate receptor, CCR2. 
Administration of MSC-derived exosomes rich in CCR2 to a mouse model of IRI conferred 
protection and was reversed by a knockdown of CCR2 on MSC-derived exosomes. This 
study thus provides a potentially novel target for therapeutic studies in IRI and suggests that 
stem cell-derived exosomes not only mediate cellular transfer of transcription factors and 
microRNAs but also of protein receptors. 
 
Another recent study links stem cell IRI modulation of the complement pathway. C5a is a 
major regulator in inflammation and can potentiate NF-κB activation. NF-κB regulates the 
transcription of many inflammatory genes and can serve as an upstream activator of 
macrophages. Bone marrow derived MSCs administered in a mouse model of renal IRI 
significantly suppressed C5a in serum and C5aR in kidney tissue. The suppression of the 
C5a/C5aR-NF-κB pathway resulted in reduced macrophage activation and reduced secretion 
of macrophage pro-inflammatory cytokines, TNF-α and IL-6, with significant improvement 
in renal function (Tang et al. 2018). 
 
Mechanistic data has paved the way for clinical trials in stem cell therapy in organ 
preservation and indicates important roles for reducing fibrosis, cell death, and 
inflammation. However, new discoveries of stem cell-derived regenerative factors and 
newly discovered stem cell targets of modulation still leaves us well short of understanding 
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the full scope of stem cell’s potential beneficial effects including possible synergistic effects 
between multiple cell types. 
 
Stem Cell Homing  
 
Other factors that can affect the biodistribution of stem cells are the pathophysiological 
events taking place in the treated organ. During inflammation, hypoxia, repair and 
unregulated cell divisions, circulating chemokines, cytokines and integrins play a vital role 
in the homing ability of stem/stromal cells. Many factors are linked with the homing ability 
of both endogenous and exogenous stem/stromal cells. One of the most recognised pathways 
involved with stem cell homing is the SDF1/CXCR4 signalling pathway. SDF1 is thought 
to be the critical factor in attracting stem cells to repair damaged tissue (Rennert et al. 2012; 
Ko et al. 2013). Most studies involving this pathway were performed using bone marrow-
derived stem cells, but there is research now supporting its vital role in adipose-derived stem 
cells and cells from other sources. Mi Jung Kim et al. previously demonstrated the efficacy 
of adipose-derived stem cells in the healing of ischaemic limbs. By transfecting stem cells 
with C-X-C motif chemokine receptor 4 (CXCR4), they were able to significantly 
demonstrate a correlation between CXCR4 expression levels and homing and engraftment 
rate of the adipose-derived stem cells. Also, they found the intra-arterial injection of stem 
cells to be just as effective as a direct intramuscular injection when comparing stem cell 
numbers within the ischaemic limb. They hypothesise that intravascular injection may be 
more effective as it protects the stem cells from being delivered directly into the severe 
environment induced by ischaemia.  
 
It should also be noted that MSCs also express CCR1, CCR4, CCR7, CCR9, CCR10, 
CXCR5 and CXCR6 which play a role in migration (Lüttichau et al. 2005; Honczarenko et 
al. 2006). As well as these receptors, MSCs also express adhesion molecules – selectins and 
integrins. ASCs and BM MSCs are very similar when it comes to surface marker expression. 
These surface markers play essential roles in stem cell homing and mobilisation. However, 
it should not be presumed that research and factors on homing of certain types of stem cells 
like BM MSCs can be translated and relevant to other types of stem cells such as adipose-
derived or embryonic. For example, ASCs unlike BM MSCs, express CD49d, CD54, but 
unlike BM MSCs, do not express CD106 (De Ugarte et al. 2003). These small differences 
could have vast effects on homing. CD106 plays a significant role in haemopoietic stem cell 
mobilisation and homing from bone marrow (De Ugarte et al. 2003). Likewise, CD54 
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(ICAM-1) was demonstrated by Kronenwett et al. to mediate the passage of haemopoietic 
stem cell across endothelium (Kronenwett et al. 2000). 
 
Injury in organ systems can also affect biodistribution. Systemic injection of stem cells 
homes to injured heart, kidneys, liver, gut and brain (Yaojiong Wu & R. C. H. Zhao 2012; 
Morigi et al. 2004; S. Zhang et al. 2015; Parekkadan et al. 2011; Jiang Wu et al. 2007). As 
mentioned before the homing effect is often transient. Most of the research looking at stem 
cell chemo-attractants has been in the context of myocardial injury. Such chemo-attractants 
to the injured heart include monocyte chemotactic protein-3 but also the generic attractant 
found in other organs like SDF-1 (Schenk et al. 2007; Ghadge et al. 2011). What has still to 
be determined is if these chemo-attractants released during MI are released during other 
organ injury (not just MI) which again may alter the biodistribution of injected cells.  Once 
the MSCs have reached areas of injury, adhesion molecules (selectins and integrins) seem 
to play a role in allowing the MSCs to migrate between the endothelial cells in a leukocyte 
type fashion by extending podia, rolling, then by manoeuvring between endothelial cells. 
Such adhesion molecules include very late antigen 4 (VLA-4) on the MSCs and vascular 
cell adhesion molecule 1 (VCAM-1) on the endothelial cells (Rüster et al. 2006). Christian 
Reiss et al. demonstrated that human-derived mesenchymal stem cells expressed proteolytic 
enzyme MMP-2 which allowed them to break down basement membranes and migrate 
between endothelial cells (Ries et al. 2007). 
 
 
1.7.5 IMPROVING THE EFFICACY AND SURVIVAL OF STEM CELLS AGAINST 
ISCHAEMIA REPERFUSION INJURY 
 
The lifespan of mesenchymal stem cells is short when administered to models of IRI, 
typically < 4% detectable by day 4 post-administration (Leibacher & Henschler 2016), 
potentially due to the harsh micro- environment created by IRI(Sosa et al. 2016). Improving 
stem cell resilience and survival could improve the efficacy and potency of the administered 
cells, perhaps reducing side effects related to cell dosage. Current techniques to fortify stem 
cells for clinical use include culture preconditioning and stem cell genetic transduction. 
 
A recently devised method to precondition MSCs utilizes heat shock. Qiao et al. heated 
MSCs in a 42 °C water bath 2 h before treating rats suffering from hepatic IRI. They found 
that heat shock pre-treated MSCs experienced less apoptosis than non-treated MSCs and 
further discovered that pre-treated MSCs coped in a high oxidative stress environment of 
 55 
hydrogen peroxide by increasing levels of autophagy. Furthermore, the authors 
demonstrated that an increase in autophagy was via the p38MAPK/mTOR signalling 
pathway, since a p38MAPK inhibitor removed the effect. Finally, it was demonstrated that 
MSCs pre-treated with heat shock before administration to hepatic IRI rats improved liver 
function, histological scores, and increased levels of proliferating cells compared to 
treatment with non-preconditioned MSCs, highlighting the importance of MSC resilience in 
the IRI microenvironment (Qiao et al. 2015). 
 
3D (versus 2D) cultured stem cells have also been found to enhance stem cell survival and 
efficacy in IRI models of both hepatic and renal injury. 3D cultured cells exhibit an increased 
anti-inflammatory phenotype and exhibit a higher expression of angiogenesis genes. This 
anti-inflammatory effect may be explained by upregulated levels of ZC3H12A RNase, 
which destabilizes mRNAs of pro-inflammatory cytokines and chemokines like IL-6, 
CXCL1, CXCL2, and CXCL3 (Y. Xu et al. 2016). In addition, MSCs from a 3D culture 
were smaller in size which may allow them better penetration through the microvasculature 
of the lungs when administered intravenously, and in effect lower doses to be administered. 
In addition, multiple publications have documented improved angiogenic and anti- apoptotic 
effects of 3D versus 2D cultured cells and have demonstrated enhanced survival supporting 
the claim that they are less susceptible to the harsh IRI environment (Y. Xu et al. 2016; X. 
Zhao et al. 2016). 
 
Since MSC-induced expansion of regulatory immune cells in IRI is believed to be an 
important component of their pro- regenerative effect, group Bai et al. pre-treated cultured 
MSCs in a regulatory cell attractant, cytokine IL-17A, before injection in a mouse model of 
renal IRI, demonstrating significantly reduced renal damage compared to non-treated MSC 
controls (Bai et al. 2018). The increase in splenic and renal T-regs demonstrated, occurred 
through a cyclooxygenase-2/prostaglandin E2 (COX- 2/PGE2)-dependent pathway, as 
blockage of COX-2 reversed the protective effect and reduced levels of T-regs. The 
involvement of COX-2 and of PGE2, (a hormone upregulated by COX- 2) in T-reg 
production is likely due to the PGE2 effect of inducing differentiation of T cells to regulatory 
T cells (Baratelli et al. 2005). A particularly interesting observation about IL-17A pre-
treatment, not evident for other cytokine MSC pre-treatments such as IFNγ is that IL-17A 
enhanced downstream immunosuppressive effectors without inducing upregulation of 
histocompatibility molecules (MHC I and MHC II) and maintained normal MSC 
morphology—both of which could potentiate immunogenicity and harmful MSC properties 
(Sivanathan et al. 2015). 
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Genetic modification of pluripotent stem cells in humans has been possible and 
progressively refined since the 1990s (Thomson et al. 1998). More recently, this approach 
has been applied to improve stem cells’ ability to ameliorate IRI. Administration of amniotic 
fluid stem cells expressing upregulated vascular endothelial growth factor (VEGF), via a 
lentiviral vector expressing VEGF, reduced tubular cell necrosis and improved renal 
function compared to treatment with non-transduced stem cells in a rat IRI model. 
Additionally, transduced stem cells had a mitogenic effect on tubular cells, increased the 
levels of T-regs and decreased pro-inflammatory M1 macrophage infiltration (Mori da 
Cunha et al. 2017). Similarly, bone marrow MSCs transduced to increase antioxidant, heme-
oxygenase-1 expression, were more resilient to the IRI environment surviving longer, 
decreasing the number of tubular epithelial cells in the G0/G1 (resting/ interphase) stage, 
and significantly increasing proliferating cells (N. Liu et al. 2018). However, although gene 
modulation appears to be an attractive tool, safety issues remain a fundamental issue. 
 
 
1.7.6 LIFESPAN AND ELIMINATION OF STEM CELLS 
  
The fate of administered stem cells is still not fully understood. Very few living stem cells 
are detected 48-hour post-injection and almost none by one week (R. Zhang et al. 2015; 
Schmuck et al. 2016; Eggenhofer et al. 2013). These first hours are enough for the stem cells 
to exert their paracrine effect and reduce damage and increase repair. Many cells are thought 
to be destroyed during the turbulent administration process with their fragments being 
phagocytosed then cleared by the liver and spleen. The remaining cells may get trapped in 
the microvasculature where they exert their therapeutic effect and then die and eventually 
get phagocytosed.  
 
Recent evidence moves away from the theory that stem cells integrate into the structure they 
home to and develop into the resident cell types. The fact that this is technically difficult to 
demonstrate contributes to the shift away from this theory. A small percentage of 
administered cells may home to the injured site and interact with the endothelial cells where 
they can reside long-term, but the numbers are small and perhaps under detected by 
imagining techniques.  
 
With their low expression of major histocompatibility complex (MHC), one would think that 
the stem cells are not susceptible to NK cell detection and hence survive acute host rejection 
in the blood, but this theory is currently being debated and investigated (Leibacher & 
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Henschler 2016). There also does not seem to be a destructive T cell response to injected 
stem cells (Nauta & Fibbe 2007).  That does not mean there is not some other form of 
interaction between stem cells and host cells in the bloodstream on administration such as 
that of the complement system (Leibacher & Henschler 2016). In summary, only a minority 
of injected cells can be traced once they have been administered, and the fate of stem cells 
cannot be confidently defined at present. The destiny of administered stem cells is dependent 
on many factors including route of administration, source and preparation, and the injury 
model in which they are administered. 
 
During the kidney transplantation process, the surgeon has easy access to major recipient 
vessels, usually the internal, external, and common iliac arteries and veins and the kidney 
graft artery and vein. Therefore, clinical arterial administration of regenerative cell therapies 
at the time of transplantation would be straight-forward and would add little extra time to 
the procedure. As far as we are aware, there have been no studies tracking the biodistribution 
of uncultured MSCs delivered directly into the renal artery of the kidney graft just before 
reperfusion. The renal artery is a major medium-sized artery, but unlike other major intra-
arterial injections, the artery is feeding directly into one organ (kidney) which will 
immediately face microvasculature and an evolving inflammatory response.  
 
 
1.7.7 STEM CELL SOURCE AND PREPARATION AND ITS EFFECT ON 
BIODISTRIBUTION 
 
Other major factors that can alter the biodistribution of stem cells are the methods in which 
they are prepared and their source. To be considered a MSC, the international society for 
cellular therapies proposed a standardised phenotype. Even after expressing this phenotype, 
there are still many variations, and this may affect the therapeutic potential and 
biodistribution. Furthermore, stem or stromal cells from the same source can have different 
biodistribution properties because of the method in which they are prepared. Rombouts et 
al. found that the percentage of MSC homing to the bone was drastically reduced when the 
MSC were cultured compared to primary non-cultured MSC. Many other studies have 
shown reduced homing and survival of cultured cells compared to freshly isolated cells with 
a resultant reduction in the therapeutic effect (Rombouts & Ploemacher 2003). Technique 
and environment, the stem cells are exposed to during culturing can also drastically change 
the phenotype like the loss of stromal cell derived factor 1 (SDF-1) (Wynn et al. 2004). 
However, this does not always have to be for the worse.  
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Altering the culture environment by adding cytokines, preconditioning the culturing process 
with heat shock or hypoxia can change the expression of the cultured cells to reverse the 
effects of the culturing process or even enhance the homing capacity beyond that of 
uncultured cells. Hypoxia can increase the expression of MMPs, which play a role in cell 
migration and adding cytokines such as stem cell factor (SCF) or IL-3 can re-establish the 
expression of SDF-1 (Shi et al. 2007; Annabi et al. 2003). 2D cultured stem cells are larger 
than uncultured stem cells of the same class; however, 3D culturing of cells can reduce this 
size discrepancy which theoretically would make them less susceptible to becoming 
entrapped in the microcirculation. Also, 3D cultured cells are more resilient to the harsh 
environment of IRI and have a stronger therapeutic effect. (Y. Xu et al. 2016; X. Zhao et al. 
2016) 
 
When discussing the biodistribution, we also must be mindful that studies do not always 
evaluate isolated stem cells. Whole stromal vascular fraction or extracellular vesicles, for 
example, have been used to treat many conditions and come under the umbrella term of 
“stem cells” or “cellular therapies” or “regenerative therapies”. We discuss the nomenclature 
of regenerative cellular therapies in chapter three, but with regards to biodistribution, the 
results can be drastically altered depending on what specific cell population is utilised. For 
example, EV from stem cells or stromal cells are much smaller than whole stem cells; 
therefore, less affected by the capillary size and can cross the blood-brain barrier (Bang & 
E. H. Kim 2019). Also, EV may not possess the ligands to respond to chemo-attractants of 
injured cells. Therefore, the biodistribution of stem cell therapy made up of EV could differ 
than from complete stem cells from the same source.  
 
 
1.7.8 MOBILIZING ENDOGENOUS STEM CELLS IN TRANSPLANT 
RECIPIENTS 
 
Exogenous administration of cells carries the risk of infection, immune-sensitivity, 
teratogenicity, microvascular thrombosis as well as the possible logistical and cost issues 
associated with administration. To address some of these concerns, several groups have 
investigated methods to increase the production and mobilization of stem cells from one’s 
own resident stem cell populations. Rats treated with SCF and granulocyte macrophage 
colony-stimulating factor (GM-CSF) in renal models of IRI were found to have increased 
mobilization of endogenous stem cells, which homed to the injured kidney and ameliorated 
IR through mechanisms associated with up- regulation of angiogenic factor, VEGF and anti-
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oxidant factor, hypoxia-inducible factor (HIF)-1alpha. Treated rats displayed reduced 
kidney apoptosis and increased tubular repair (Bi et al. 2015). However, as an IRI treatment, 
there is concern with systemic administration of growth factors related to high bioactive 
effects which can lead to deleterious side-effects including tumorigenesis (Carragee et al. 
2011). Additionally, evidence indicates that resident stem cells become depleted or 
dysfunctional with in- creasing age, limiting this approach in older patients (Woolthuis et al. 
2014). There may however be potential for this approach if stem cell mobilization therapies 
can be rendered organ and/or signalling pathway specific. 
 
In a novel attempt to reduce injury from IRI by recruitment of endogenous stem cells, Tan 
et al. investigated postconditioning kidneys with supplementary mechanical injury insult in 
their rat model (X. Tan et al. 2015). The postconditioning model consisted of 3 cycles of 30 
s of ischemia followed by 30 s of reperfusion in a kidney which previously sustained 45 min 
of ischemia followed by 7 min of reperfusion. Postconditioning markedly reduced features 
of renal injury including kidney necrosis, neutrophil infiltration, and cellular vacuolization, 
and significantly reduced creatinine levels compared to non- preconditioned rats (X. Tan et 
al. 2015). Importantly, the Tan et al. group illustrated that this technique mobilized 
endogenous stem cells as blood from preconditioned rats had increased levels of CXCR4+ 
and CD34+ (haemopoietic) bone-derived stem cells. They concluded that preconditioning 
regulated oxidative stress and increased HIF-1alpha levels which then in- creased stromal 
cell-derived factor expression, a stem cell attractant, resulting in stem cell migration and 
homing to ischemic tissues (L. Liu et al. 2011; Ceradini et al. 2004). MacAllister et al. 
performed a similar preconditioning technique in a trial of 406 live donor kidney transplants. 
Though there was only mild improvement in glomerular filtration rate when compared to 
control, the trend of graft functional improvement appeared promising and may be greater 
in deceased donor transplantation where IRI is more significant (MacAllister et al. 2015). 
 
In an innovative attempt to mobilize resident stem cells, Wang et al. used low-level laser 
therapy (LLT) treatment of bone marrow in rats before renal IRI. By exposing both tibiae to 
two episodes of 100 s each of LLT they significantly in- creased bone marrow-derived stem 
cell infiltrates in the glomerulus and renal tubules but not in the peripheral blood. 
Interestingly, rats undergoing LLT without IRI had elevated levels of bone marrow-derived 
stem cells in the peripheral blood, indicating that injury status affected migration. Notably, 
LLT-treated rats had significantly improved renal function and kidney histology indicating 
the potential value of LLT mobilized stem cells as an IRI therapy. They hypothesized that 
LLT induces proliferation of bone marrow-derived mesenchymal stem cells, which home to 
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injured kidney tissue and elicit repair (Oron et al. 2014). Promising as this seems, further 
studies are required to understand if enough ameliorative endogenous stem cells can be 
mobilized to influence larger human organs that have sustained clinically significant tissue 
injury. There is also a potential limit in elderly or physiologically unfit patients where the 
capacity of endogenous stem cells to replicate may be significantly impaired. 
 
 
1.7.9 ROUTE, DOSAGE, AND TIMING OF ADMINISTRATION OF STEM CELLS  
 
Clinical considerations also include, but are not limited to the route, dosage, and timing of 
administration. Injecting ADSVF before ischemia in a rat model of renal IRI demonstrated 
more ameliorative properties and significantly reduced tubulointerstitial fibrosis than when 
injected post-ischemia (Zhou et al. 2016). However, the clinical nature of transplantation 
may provide greater freedom in choosing exactly when to administer the regenerative 
therapy compared to other indications.  
 
The route of administration should also not be overlooked, as many studies have shown that 
MSCs injected into the venous system often become trapped in the microvasculature of the 
lungs (Leibacher & Henschler 2016). Compared to systemic arterial or venous injection of 
stem cell therapies, studies have found that direct MSC injection (in this case into the renal 
artery in a renal model of IRI) has the most profound effect on the injured organ and also 
required much lower doses (Cai et al. 2014). Direct intraparenchymal or intra/subcapsular 
routes have also been utilized in stem cell renal IRI research as direct renal artery injection 
can be associated with renal microvasculature occlusion at higher therapeutic doses. The 
nature of solid organ transplantation, however, may allow beneficial flexibility in the choice 
of administration route since the organ’s vessels are at least transiently accessible. Lam et 
al. also tested the topical route of application to the liver in a rat hepatic IRI model. with 
promising effects (Lam et al. 2017). Lastly, the clinical setting of administration may also 
be important. MSCs may be altered by commonly used anaesthetic agents as highlighted in 
a recent rat model of hepatic IRI. Intravenously administered dexmedetomidine and 
midazolam enhanced the protective effects of MSC during liver IRI more effectively than 
propofol by binding to MSC receptors and regulating a downstream paracrine effect (J. Feng 
et al. 2018). Collectively, this is a reminder that other manipulations during organ repair 
could also have an opposing effect on MSC regenerative properties, thus reducing their 
potential benefits. 
 61 
In the future, the increasing accessibility of ex vivo perfusion technologies may provide an 
ideal setting to address the many remaining questions around stem cell therapy’s role in 




1.8 INTRODUCING STEM CELL THERAPY TO CLINICAL PRACTISE 
 
For over six years, our group have been studying the application of stem cells in renal IRI, 
with animal models at the core of our research. Moving forward towards clinical translation, 
we envisage the use of adipose derived stromal vascular fraction (ADSVF) as our choice 
source of stem cells. In brief, ADSVF is the heterogenous cell population that persists when 
the adipocytes are removed from adipose tissue. Within this heterogenous population are the 
ASC. ADSVF possess favourable therapeutic stem cell criteria: safe, effective, ethically 
acceptable, easily sourced and require minimal preparation. For clinical translation we aim 
to focus efforts particularly on uncultured ADSVF administered via the renal artery at the 
time of transplantation for the following reasons:  
 
1. Adipose tissue is easily accessible throughout the body. At the time of 
transplantation, subcutaneous adipose tissue can be easily obtained within minutes 
after making the skin incision. There is also easily accessible preperitoneal adipose 
tissue during the traditional right iliac fossa approach of a kidney transplant 
procedure. Also, the kidney graft arrives at the implanting centre wrapped in donor 
adipose tissue. 
2. The whole adipose derived stromal vascular fraction is key to minimal preparation. 
ADSVF can be obtained within an hour from a batch of adipose tissue. ADSVF is 
discussed in detail in chapter three but in essence this is what remains from adipose 
tissue once all the adipocytes and connective tissue are removed. This heterogeneous 
solution, among other cells, contains the adipose-derived stem cells adipose derived 
mesenchymal stromal cells. In some studies, the ADSVF is more effective than 
isolated stem cells at ameliorating IRI. With no culturing, isolation of stem cells or 
pre-treatment/conditioning, the ADSVF is ready immediately. 
3. As the adipose tissue is coming from the recipient or the graft, there will be no 
additional immunogenicity issues. In addition, ADSVF do not express HLA-DR. 
Using the recipients own adipose tissue reduces regulatory criteria.  
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4. Culturing, gene modification and pre-conditioning donor stem cells could all 
drastically alter the outcome and would require extensive safety studies in addition 
to a preparation room or facility which would further complicate implementation. 
Therefore, we focus on fresh uncultured ADSVF that can be extracted from the 
adipose tissue in the same theatre suite as the transplant operation or perfusion rig.  
4. Administering the ADSVF via the renal artery reduces systemic interactions and 
ensures maximum delivery to the kidney. In addition, the renal artery is easily 
accessible at the time of transplantation. They could also be administered via the 
renal artery while on an ex vivo organ perfusion rig.  
5. Clinical trials using ADSVF have not identified any significant contraindications. 
However, the mechanism of action of ADSVF administered via the renal artery to 
treat IRI has not been studied – although it is likely to be like other routes of 
administration of stem cells. 
 
In 2020 Thompson et al. performed the first administration of cultured bone marrow-derived 
adult stem cells into a human kidney on an ex vivo kidney perfusion rig. The kidneys that 
received the stem cells demonstrated improved urine output, reduced injury markers and 
reduced microvascular injury (Thompson et al. 2020).  Before we can replicate a similar 
model on human kidneys using uncultured ADSVF, further research is required to add to the 


















1.9 HYPOTHESES  
 
Uncultured adipose derived stromal vascular fraction demonstrates favourable 
characteristics which make them an effective therapy in ameliorating renal transplant 





The main emphasis of this thesis is to bridge the void between promising preclinical 
models and utilization in the clinical setting; specifically, administration of uncultured 
ADSVF via the renal artery around the time of transplantation.  
 
We need to establish whether there are significant differences in rodent ADSVF, which 
has shown promise in animal models, and human peri-renal or subcutaneous ADSVF, 
which will be the likely sources in clinical translation. Furthermore, most current studies 
look at cultured stem cells as opposed to the whole fresh uncultured ADSVF in which the 
stem cells reside. Therefore prior to clinical translation we need to determine the 
biodistribution and potential mechanism of action of uncultured ADSVF administered 
via the renal artery into an environment of renal IRI. 
 
To achieve this, I focussed on three main aims: 
 
1. To further characterise the ADSVF and demonstrate similarities between rat 
ADSVF, used in the animal models, and human ADSVF, which will be used in 
the clinical setting. 
2. To demonstrate the biodistribution of uncultured ADSVF when it is administered 
via the renal artery  
3. To identify some of the mechanisms of action of the fresh uncultured ADSVF in 
ameliorating IRI 
 
In addition, I aim to develop a novel animal model which more closely mimics the 
transplant recipient. This will facilitate accurate investigation of the ADSVF when 
accomplishing the proposed aims.  
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This thesis is split into five main chapters. Chapter two details all methods used. Chapter 
three aims to characterise the ADSVF obtained from inguinal and peri-renal adipose tissue. 
Chapter four describes a novel rat model of renal transplant related IRI to accurately assess 
the ADSVF. Chapter five demonstrates the biodistribution of ADSVF when administered 
via the renal artery, and chapter six attempts to delineate some of the mechanisms of actions 
of ADSVF.  
 
The effectiveness of ADSVF in ameliorating IRI and improving kidney function has 
previously been demonstrated by our group and others and is therefore not a focus of this 
research. The final chapter aims to summarise all the findings and bring together a proposal 























In 2019 a proportion of this introduction was published in Current Transplantation 
Reports. Permission has been granted by the Editor, Dr Lockhart, for it to be included in 
this thesis and be available in Glasgow University’s online theses repository. 
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CHAPTER 2: 
GENERAL MATERIAL AND METHODS 
 
 
The materials and methods described apply to all results chapters. The animal model of renal 
IRI used is described separately and in detail in chapter 4. Additional materials and methods 
specific to individual chapters are detailed within that chapter 
 
 
2.1 ANIMAL HOUSING AND HUSBANDRY 
 
Fischer 344 rat strain was used for all surgical experiments reported in this thesis. Rats were 
either purchased from Charles River (Kent, United Kingdom) or bred in the Joint Research 
Facility at the University of Glasgow. Rats transferred from Charles River were housed for 
at least two weeks before any procedure. All rats were a minimum of 12 weeks old at the 
time of the first procedure. Rodents were house in plastic metal cages with a maximum of 
two adult rats per cage. They were fed a standard diet of rodent chow and had free access to 
tap water. Room temperatures were kept a 22oC +/- 2oC, humidity 55%+/-5% and light-dark-
cycling of 12/12 hours. 
 
 
2.2 RETRIEVAL OF RAT ADIPOSE TISSUE  
 
All rat adipose tissue was obtained from Fischer 344 adult rats. Rats were terminated using 
CO2.  Once terminated, the rats were immediately transferred to a sterilised operating bay. 
Chlorhexidine was used to sterilise thoracic region, abdominal midline and both groin 
regions. Once dry, blood was taken via a cardiac puncture. An incision was made over both 
inguinal regions. Using toothed forceps to hold skin edge, scissor dissection of the inguinal 
fat pad was performed taking care not to take any connective tissue off the skin or the 
underlying muscle tissue. The inguinal lymph nodes were not dissected out. Care was taken 
to avoid transecting blood vessels as this would contaminate the fat tissue. Once the inguinal 
fat pad was dissected out, it was placed in a tube with cold phosphate-buffered saline (PBS), 
weighed and then placed on ice. The same technique was used for the inguinal fat pad on 
the contralateral side. A midline laparotomy incision was then made, and the peritoneum 
opened. The perirenal fats were excised from both kidneys and put in a separate tube with 
PBS. The tube was weighed, labelled, and put on ice.   
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Adipose tissue was then immediately taken for isolation of the ADSVF. Blood taken was 
spun down for eight minutes (800x g at 4oC) and the serum extracted and stored in a-20oC 




2.3 RETRIEVAL OF HUMAN ADIPOSE TISSUE  
 
Human peri-renal adipose tissue was obtained from patients undergoing hand-assisted donor 
nephrectomy at the Queen Elizabeth University Hospital of Glasgow, United Kingdom. 
Once retrieved, the kidney was transferred to a sterile bench in theatre for preparation for 
implantation. Peri-renal adipose tissue was removed from the kidney by the operating 
surgeon and placed in a sterile tube containing cold PBS then placed on ice. The sample was 
then immediately taken to the onsite Greater Glasgow and Clyde biorepository unit. An 
arrangement was made with the biorepository department, through the appropriate 
regulatory channels and approval, for this adipose tissue to be returned for research. 
Returned samples were anonymised and available for collection almost immediately. 
Samples were then transported on ice to our laboratory at the University of Glasgow for 
processing (see section below). 
 
 
2.4 ISOLATION OF ADIPOSE DERIVED STROMAL VASCULAR FRACTION 
 
Adipose tissue is excised from either the inguinal, peri renal or subcutaneous region of 
Fischer 344 rats or humans as described above. The adipose tissue is homogenised with 
scissors. Homogenised adipose tissue is processed with Celase and Intravase (Cytori 
Therapeutics Inc., San Diego, USA) and then filtered to separate the ADSVF from the rest 
of the adipose tissue. A detailed SOP is provided in Appendix 1. 
 
 
2.5 QUANTIFICATION, STORAGE AND PREPARATION OF ADSVF FOR 
ANALYSIS 
 
ADSVF cells were counted using the ChemoMetec NC-100 Mamillian NucleoCounter 
(Allerod, Denmark, Product number 900-0004) and its associated Reagent A100 (lysis 
buffer) & Reagent B (stabilizing buffer) and Nucleocounter cassettes.  
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Once counted, the ADSVF was prepared for storage if they were not going to be used 
immediately. For storage they were suspended with Dulbecco's Modified Eagle Medium 
(DMEM) (Life Technologies Corporation. Paisley, UK), Dimethyl sulfoxide (Fisher 
Scientific UK Ltd. Loughborough, UK) and rat serum. They were then stored in liquid 
nitrogen until required.  
 
When required the ADSVF were thawed from the liquid nitrogen, washed, and resuspended 
with PBS. They were counted prior to administration or interrogation.  
 
A detailed SOP of quantification, storage and preparation is provided in Appendix 2. 
 
 
2.6 RODENT ORGAN RETRIEVAL AND PROCESSING AFTER IRI 
 
Carbon dioxide euthanasia was performed on the rats at the desired time points post-IRI 
surgery (1 hour, 24 hours, 48hours and one week). Once the rat was confirmed dead, cardiac 
puncture was performed to collect a blood sample. The serous fraction of the blood was 
stored in minus 20oC freezer and used in microparticle measurement, which is described in 
chapter 5.3.6. 
 
Immediately after cardiac puncture, the incision sites were prepped with chlorhexidine. A 
midline laparotomy and bilateral thoracotomy were performed, and in the following order, 
the organs are removed: left kidney, right kidney, spleen, liver, lungs, heart, and brain.  
 
Depending on the planned investigation for each organ it was processed accordingly and 






















Adipose Tissue as a Source of Stromal and Stem Cells 
 
ASCs have several characteristics which make them stand out. Firstly, adipose tissue is 
easily accessible and abundant when compared to other sources of stem cells. Tissue can 
be obtained at the time of open surgery or from liposuction procedures which can be 
performed under local anaesthetic. From the same weight of tissue, there are tenfold as 
many mesenchymal stem cells in adipose tissue than bone marrow. Plus, humans have 
considerably more adipose tissue than bone marrow (X. Zhu et al. 2012). Compared to 
embryonic stem cells, adult stem cells also evade much of the ethical issues around 
retrieval and subsequent research. 
 
The ADSVF, which contains the ASC, can be extracted from the adipose tissue in less 
than an hour. Currently, there are several different techniques in use for extracting the 
ADSVF. Through a process of enzymatic digestion and centrifugation (see chapter 2 and 
Appendix 1), adipocytes and connective tissue are removed from the adipose tissue to 
leave a solution termed the ADSVF. Even after the ADSVF has been extracted from the 
adipose tissue, cellular viability remains high. This solution consists of a heterogeneous 
cell population. MSCs can then be isolated from the ADSVF, which are termed ASC (Fig. 
3.1). If any subpopulation of the ASC can stringently be shown to have more specific 
stem cell-like characteristics (as described above), then they could be termed stem cells, 
or in this case, adipose-derived stem cells (Horwitz et al. 2005).  
 
With adipose tissue relatively easy to access, quick and straightforward extraction of their 
ADSVF, a high return of ASC and surrounded by less ethical controversy, they make an 
attractive source of stromal/stem cells. Unlike most other stromal or stem cell 




Figure 3.1 The heterogenous subpopulations extracted from adipose tissue. Adipose 
tissue can be obtained from many regions of the body. After removing the connective 
tissue and adipocytes from the adipose tissue you are left with the ADSVF. ADSVF 
consists of multiple cell populations. Through further preparation more of these 
subpopulations can be extracted - in particular, the ASC. 
 
 
Adipose Derived Stem and Stromal Cells 
 
Another substantial advantage of ASC (compared to an embryonic stem cell line), is the 
absence of (MHC) HLA-class II antigens on the cell surface. Therefore, they can evade 
the host immune surveillance and be used for xenogenic transplantation (Lin et al. 2012). 
Also, human ASC have been shown to have a lower susceptibility to natural killer cells 
compared to BM MSC cells, further supporting the consensus that ASC can evade the 
host immune system (delaRosa et al. 2012). Initially, adipose-derived stem cells 
demonstrated mesodermal multipotency, but they have since been expanded into 
ectodermal and endodermal lineages and therefore potentially possess trigerm lineage 
and pluripotency capacity like embryonic stem cells(Zuk 2013).  Although in vitro 
differentiation into the three germ layers has been demonstrated, differentiation into 
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confidently demonstrated unlike induced adipose-derived stem cells (Harn et al. 2012). 
Conflicting evidence also exists if adipose-derived stem cells express embryonic stem 
cell-like pluripotent markers (A. S. Lee et al. 2011; Tat et al. 2010; Gu et al. 2012). 
Induced pluripotent adipose stem cells do, however, carry the burden of an increased risk 
of teratoma formation.  
 
Other (minor and disputed) differences between BM MSC and ASC exist not just in their 
immunophenotype but in their ability to develop into certain lineages. ASC have less 
robust chondrogenic and osteogenic properties, although this may be secondary to the 
microenvironment where these cells reside (Choi et al. 2012) (Im et al. 2005).  It should 
also be noted that mesenchymal heterogenicity may exist not only between different 
tissues but even within the same tissues (Hardy et al. 2017). CD34+ subpopulations of 
adventitial MSC and CD34- pericyte MSC are both found to reside in adipose tissue. 
Differences are also seen in their functional ability, such as CD34-ve MSCs greater 
angiogenic influence. (Esteves et al. 2017).  
 
With much of the research, especially when adult stem cell research was in its infancy, it 
is often not entirely clear if the author is referring to ASC or specifically adipose-derived 
stem cells. Again, like bone marrow stromal fraction, the ADSVF consists of cells which 
show multipotency but do not meet the exact criteria to be classified as a stem cell. For 
that reason, the International Federation of Adipose Therapeutics and Science and the 
International Society for Cellular Therapy have set out criteria that the population should 
be referred to as adipose-derived stromal cells (ASC).  The umbrella term covers all the 
cell types with stem cell-like characteristics, including adipose-derived stem cells 
themselves (Bourin et al. 2013). Adipose-derived stem cells should only be used if the 
cells have stringently been demonstrated to be stem cells. 
 
 
Adipose Derived Stromal Vascular Fraction 
 
For many proposes the ADSVF may be more advantageous than isolated ASC. Other 
cells within the ADSVF other than ASC include immune cells and endothelial cells. 
Studies comparing ASC and ADSVF in myocardial infarction and ischaemia reperfusion 
injury found the therapeutic effect, fibrosis formation and expression of favourable 
markers (like anti-inflammation, anti-apoptosis, angiogenesis) to be superior in the 
stromal vascular fraction group (Sheu et al. 2019; Zhou et al. 2017). Using fresh ADSVF 
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versus ASC has a significant advantage in that it does not need to go through further 
isolation or culturing and can be ready for administration within one hour of retrieving 
the adipose tissue. With minimal expertise, ADSVF can be prepared quickly for clinical 
use onsite. Using requires more technically demanding isolation and likely culturing, 
which would take weeks and have the added risk of human and microbial contamination. 
Pre-prepared ASC that are thawed at the time of administration is also an attractive option 
but again would be more complicated with storage, transportation and preparation factors 
compared to using fresh uncultured ADSVF. Also, depending on the culturing 
environment, there is the risk of unintentionally immortalising the ASC. Although some 
groups intentionally attempt to immortalise the cells in order to prolong their life span 
and therapeutic potential (Balducci et al. 2014). 
 
Details on how we envisage the use of the regenerative potential of adipose tissue is 
described in chapter one. In brief, the fresh, uncultured ADSVF isolated from either donor 
peri-renal adipose tissue or recipient adipose tissue is administered via the renal artery at 
the time of transplantation. For this reason, we are focussing our research on the ADSVF.  
 
Our research uses an animal model of renal ischaemia reperfusion injury (IRI) to 
investigate the therapeutic effects of ADSVF on Fischer 344 rats. The animal model 
utilises ADSVF from the inguinal and peri-renal adipose tissue of Fischer 344 rats; 
therefore, we need first to confirm we have a viable cell population after the extraction 
of the ADSVF from the adipose tissue. Secondly, we need to characterise the ADSVF to 
establish if its phenotype is in keeping with current evidence and is like the ADSVF from 
human adipose tissue. To help guide future mechanistic studies of ADSVF, it will also 
be valuable to determine their gene expression profile.  
 
In keeping with the positions of the International Federation of Adipose Therapeutics and 
Science and the International Society for Cellular Therapy, the heterogeneous collection 
of cells obtained from adipose tissue will be referred to as ADSVF. In the literature, it 
has been referred to as processed lipoaspirate and adipose-derived regenerative cells.  At 
the time of writing, those nomenclatures were perhaps not inappropriate, but as our 
knowledge has grown, so has our need and ability to classify better and sub-classify. 
Likewise, cells extracted from the ADSVF, which are stem cells or demonstrate stem 
cell-like characteristics will collectively be termed ASC. In the literature, they have also 
been referred to as adipose-derived adult stem cells, adipose-derived mesenchymal stem 




1. ADSVF from inguinal and peri-renal adipose tissue of Fischer 344 rats will 
consist of a heterogeneous population of viable cells including stem/stromal cells  
 
2. ADSVF from human peri-renal adipose tissue will consist of a heterogeneous 
population of viable cells including stem/stromal cells 
 
3. Adipose SVF from inguinal adipose tissue of Fischer 344 rats will express 































3.3.1 ANIMAL HOUSING AND HUSBANDRY 
 




3.3.2 RETRIEVAL OF RAT ADIPOSE TISSUE  
 




3.3.3 RETRIEVAL OF HUMAN ADIPOSE TISSUE  
 




3.3.4 ISOLATION OF ADIPOSE DERIVED STROMAL VASCULAR FRACTION 
 
Isolation of adipose derived stromal vascular fraction was standard throughout all 
procedures and is described in chapter 2.4. 
 
 
3.3.5 QUANTIFICATION, STORAGE AND PREPARATION OF SVF FOR 
ANALYSIS  
 
Quantification, storage, and preparation of ADSVF for analysis was standard throughout all 






3.3.6 MAGNETIC BEAD SEPERATION 
 
Quantification and preparation of ADSVF for administration was conducted in standard 
fashion, as described above. Magnetic bead separation was used to separate the cell 
population into leukocyte (CD45+) and non-leukocyte (CD45-) fractions by antibody based 
magnetic bead separation protocol (Miltenyi Biotech, UK). Fractions were washed in buffer 
before use.  
 
 
3.3.7 FLOW CYTOMETRY ANALYSIS  
 
Cells were incubated with the rat 2.4G2 Fcyll blocker (BD Biosciences, San Jose, CA) and 
surface markers for 60 minutes. Cells were then fixed in 4% solution and resuspended in 2% 
albumin (PAN-Biotech, Aidenbach, Germany) in PBS. For intracellular staining, cells were 
treated with a permeabilization buffer (eBioscience, San Diego, CA).  Antibodies used for 
staining are listed in Table 3.1. Leukocytes were classified as CD45+; t-cells as CD3+: 
CD45+ CD3+; killer t-cells as CD45+ CD3+CD8+; mesenchymal stem cells as CD45-
CD90+CD34-; pericyte-like cells as CD146+: CD45- CD146+; macrophages as CD45+ 
CD11b+ CD11c-; cytotoxic T-cells as CD45+ CD3e+ CD8+; helper T-cells as CD45+ 
CD3e+ CD4+; and conventional dendritic cells (DCs) as CD45+, CD1b+, CD11c+. 
Fluorescence was measured using a Fortessa flow cytometry (BD Biosciences). Each sample 
contained at least 200,000 viable cells using FSC x SSC gating and viability (e780) negative. 
Typical gating scheme is shown in the results section. Gating was determined by both single-
stained control and fluorescence minus one control (Table 3.1). FlowJo software version 10 




Table 3.1 Rat flow cytometric markers used to assess ADSVF 
 
 
3.3.8 SINGLE-CELL RNA-SEQUENCING PREPARATION AND ANALYSIS 
 
A frozen aliquot of pooled ADSVF was thawed and acclimated in PBS with 10% rat serum. 
Cells were stained with DAPI and flow assisted cytometry sorted by DAPI exclusion 
(removing dead cells). Ten thousand cells were loaded on a droplet-based Chromium Next 
GEM Single Cell 3’ v3 kit (10X Genomics) and cDNA was low depth pair-end sequenced 
on a NextSeq500 (Illumina). Demultiplexing and alignment to rat genome (build 
Rnor_6.0.97) was performed on Cell Ranger and STAR (Glasgow Polyomics) before 
downstream analysis in R using the Seurat method. Since clustering identity can be inferred 
as a property of cell number sequenced and depth, gene transcript signatures were utilized 
for unbiased clustering and cell identification, but not function due to the low depth. Cell 
cluster transcript/read averages and comprehensive signature genes of each cluster provided 
in figure 2.5. Data files are accessible at NCBI GEO database (GSE139318). ADSVF 
preparation for single-cell sequencing and analysis of single-cell sequencing data 
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Supplemental Table 1.  Rat flow cytometric markers used to assess ADRC 14 
phenotype 15 
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3.3.9 QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION (PCR) 
ARRAY 
 
Total RNA was isolated from samples using QIAzol® RNA Lysis reagent (QIAGEN, 
Hilden, Germany). Centrifugation and chloroform were used to separate the aqueous and 
organic phases. The RNA was recovered from the aqueous phase by precipitation with 
isopropyl alcohol and resuspended in nuclease-free water. RNA was counted using 
Nanodrop (Nanodrop 2000, Thermoscientific), and RNA was purified by removing DNA 
with DNAs I, Amplification Grade (ThermoFischer/Invitrogen). A Nanodrop 
Spectrophotometer (Thermo scientific) was used to ensure the quality of the RNA and a 
260/280 ratio of around 2 was used as our threshold of acceptably pure RNA. Reverse 
transcriptase (ThermoFischer/Invitrogen) was used, following the protocol to create 
complement DNA (cDNA) from the RNA. The cDNA and fast master mix (ThermoFischer) 
were then prepared for the Taqman Array card and added to the custom Taqman array plates 
as per instructions. The custom made Taqman array plates assay candidate genes and 
housekeeping controls (Table 3.2) and was ran on a QuantStudio PCR cycler (Applied 
Biosystems, Foster City, CA, USA). Relative Ct levels were normalised by housekeeping 
controls (average of the same three housekeeping genes) and represented as dCt. Data are 
represented as mean ± SEM. Differences in average means between two groups determined 
by Mann-Whitney U test, differences between three groups by One-way ANOVA. *p<0.05, 





Table 3.2 RNA taqman array probes 
 
 
Statistics. A 2-way student’s t-test was carried out to determine the differences in the mean 
average for sample sizes >5 of equal variance. Mann-Whitney U test was used to analyse 
smaller sample sizes. One-way ANOVA and a Tukey post hoc test was used to detect 
Supplemental Table
Table 2.  RNA taqman array probes
Protein of interest Representative gene Gene Symbol Array # Notes
Markers of kidney injury
IL-18 interleukin 18 Il18 Rn01422083_m1
Atxn3 ataxin 3 Atxn3 Rn00572605_m1 alias: Rsca3
kidney injury molecule-1 (KIM-1) hepatitis A virus cellular receptor 1 Havcr1 Rn00597703_m1 upstream KIM-1 regulation
neutrophil gelatinase-associated lipocalin (NGAL) lipocalin 2 Lcn2 Rn00590612_m1 aliases: Sip24 , NGAL
B2-microglobulin (B2M) beta-2 microglobulin B2m Rn00560865_m1
retinol binding protein (RBP) retinol binding protein 7, cellular Rbp7 Rn01515537_m1 
HIF-1a hypoxia-inducible factor 1, alpha subunit Hif1a Rn01472831_m1 alias: MOP1
HO-1 heme oxygenase (decycling) 1 Hmox1 Rn00561387_m1 aliases: HEOXG, Heox, Hmox, Ho-1, Ho1, hsp32 
Nox1 NADPH oxidase 1 Nox1 Rn00586652_m1
Nox4 NADPH oxidase 4 Nox4 Rn00585380_m1 
Slc7a11 solute carrier family 7 (anionic amino acid transporter light chain, xc- system), member Slc7a11 Rn01495123_m1 
Immune Regulation
IL-4 interleukin 4 Il4 Rn01456866_m1 
IL-10 interleukin 10 Il10 Rn01644839_m1 
TGFb transforming growth factor, beta 1 Tgfb1 Rn00572010_m1 
IL-1a interleukin 1 alpha Il1a Rn00566700_m1 
IL-1b interleukin 1 beta Il1b Rn00580432_m1 
IFNg interferon gamma Ifng Rn00594078_m1
IL-6 interleukin 6 Il6 Rn01410330_m1
CCL2 chemokine (C-C motif) ligand 2 Ccl2 Rn00580555_m1 
CXCL2 chemokine (C-X-C motif) ligand 2 Cxcl2 Rn00586403_m1 
G-CSF colony stimulating factor 3 (granulocyte) Csf3 Rn00567344_m1 
GM-CSF colony stimulating factor 2 (granulocyte-macrophage) Csf2 Rn01456850_m1 
KC chemokine (C-X-C motif) ligand 1 Cxcl1 Rn00578225_m1 alternate name, incl CINC-1, Gro1 
MIP3a chemokine (C-C motif) ligand 20 Ccl20 Rn00570287_m1 aliases: ST38, Scya20 , mip3a
CTL-A4 cytotoxic T-lymphocyte-associated protein 4 Ctla4 Rn01437152_m1
indoleamine 2,3-dioxygenase indoleamine 2,3-dioxygenase 1 Ido1 Rn01482210_m1
Markers of growth and repair
EPO-1 erythropoietin Epo Rn01481376_m1 
FGF-2 fibroblast growth factor 2 Fgf2 Rn00570809_m1 
IGF-1 insulin-like growth factor 1 Igf1 Rn00710306_m1 
VEGF vascular endothelial growth factor A Vegfa Rn01511602_m1
HGF hepatocyte growth factor Hgf Rn00566673_m1 
Met receptor MET proto-oncogene, receptor tyrosine kinase Met Rn00580462_m1 alias: Hgfr 
SDF-1 chemokine (C-X-C motif) ligand 12 Cxcl12 Rn00573260_m1 alias: Sdf1
LIF leukemia inhibitory factor Lif Rn01443011_m1 
EGF epidermal growth factor Egf Rn00563336_m1
TIMP-1 TIMP metallopeptidase inhibitor 1 Timp1 Rn00587558_m1  aliases: TIMP-1, Timp 
MMP-2 matrix metallopeptidase 2 Mmp2 Rn01538170_m1 
adiponectin adiponectin, C1Q and collagen domain containing Adipoq Rn00595250_m1 aliases: Acdc, Acrp30
ADAM-19 ADAM metallopeptidase domain 19 Adam19 Rn01751344_m1 
Col4a1 collagen, type IV, alpha 1 Col4a1 Rn01482927_m1 
Collagen I collagen, type I, alpha 2 Col1a2 Rn01526713_m1 
Wnt5a wingless-type MMTV integration site family, member 5A Wnt5a Rn01402000_m1 
Tie-2 TEK tyrosine kinase, endothelial Tek Rn01433346_m1 
Ang2 angiogenin, ribonuclease A family, member 2 Ang Rn01768764_m1 
RT-PCR housekeeping gene controls
Actb Actin beta  Actb Rn00667869_m1 alias: Actx
Ring1 ring finger protein 1 Ring1 Rn01429209_m1 alias: Ring1A 
Mapk14 mitogen activated protein kinase 14 Mapk14 Rn00578842_m1 aliases: CRK1, CSBP, CSPB1, Csbp1, Csbp2, Exip, Hog, Mxi2, Prkm14, Prkm15, RK, Sapk2A, p38, p38Hog, p38alpha 
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differences between the means of the three groups. Analyses was performed with Prism 6.02 
(GraphPad, San Diego, CA). Mean and standard error of mean (SEM) are displayed. 
Significance was considered for p values <0.05 (*) but included p values <0.01 (**), and 


































3.4 RESULTS  
 
 
3.4.1 FLOW CYTOMETRIC PROFILING AND SINGLE CELL SEQUENCING OF 
ADSVF  
 
Adipose tissue was collected from the inguinal region and peri-renal region of Fischer 344 
rats. Frozen and thawed ADSVF were used in experimentation since fresh and frozen ASC 
have been shown to maintain comparable phenotypes (Z. Feng et al. 2010). Peri-renal 
adipose tissue was also obtained from healthy human living kidney donors. There was 
limited availability of subcutaneous human fat. No red blood cell lysis was used on the 
ADSVF before flow cytometric analysis. This was deemed unnecessary as the adipose tissue 
was minimally contaminated with blood vessels. Also, as cells are destroyed when lysis 
buffer is used, it was felt not worth the potential advantages. Being small, the red blood cells 
were gated out as debris.  
 
A high level of heterogenicity was seen in flow cytometric profiling of ADSVF from all 
sources investigated. Cell types identified include leukocytes (defined as CD45+), in 
particular CD8+ T cells (CD45+CD8+) and CD3+ T cells (CD45+CD3+), mesenchymal 
stem cell-like cells (CD45-CD90+CD34-) and pericyte like cells (CD45-CD146+). Further 
analysis of rat inguinal ADSVF established evidence of other leukocytes such as 
macrophages and dendritic cells (Fig. 3.2). 
 
Cell viability remained high from all sources. Rat peri-renal and inguinal and human peri-
renal viability was around 60% after going through retrieval, extraction from adipose tissue, 
freezing in liquid nitrogen, thawing and then processing for analysis (Fig. 3.3 and 3.4). 
 
Mesenchymal stem cell-like cells (CD45-CD90+CD34-) were found in ADSVF from all 
sources. Rat inguinal fat contained the highest percentage followed by rat peri-renal (mean 
22.71%, SEM +/- 3.45% and 10.39% SEM +/- 3.95% ) then human peri-renal (Fig. 3.3 and 
3.4). Human peri-renal and inguinal fat appear to have the same numbers of mesenchymal 
stem cell-like cells, but we only have an n of 1 for human inguinal fat. Rat inguinal ADSVF 
single-cell sequencing confirmed transcript signatures representative of mesenchymal stem 
cells (Fig. 3.5).  
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Rat inguinal adipose tissue appear to have a lower composition of pericyte like cells, 
identified as CD45-CD146+, compared to rat peri-renal adipose tissue (mean inguinal = 
3.21%, perirenal = 15.02%, SEM +/- 1.46 and 3.77 % respectively, **p=0.0047). From the 
1 sample of human inguinal adipose tissue tested the opposite is the case with human 
inguinal fat having more pericyte like cells compared to the human peri-renal fat. Their 
concentration is likely determined by the location in which the subcutaneous fat is retrieved, 
with adipose tissue with more capillaries running through it containing more pericytes. 
Either way, a pericyte population is likely to be present. 
 
Rat inguinal tissue contains a significantly higher percentage of leukocytes, as defined as 
CD45+cells, compared to rat peri-renal fat (mean inguinal = 72.35%, perirenal = 16.21%, 
SEM +/- 6.89 and 4.70 respectively, **p=0.0026). This may be due to the presence of lymph 
nodes within the inguinal tissue (Fig. 3.3). Human and rat peri-renal tissue had similar levels 
of CD45+ cells of around 20%. Within the leukocytes, there was a robust T cell population. 
Flow analysis suggests the presence of CD8+ T cell and CD3+ T cells in both humans and 
rats. Single-cell sequencing confirms the presence of a strong T cell population, in particular 
a CD4+ T cell population (Fig. 3.5). The inguinal depot had a significantly greater 
percentage of killer T cells (CD3+CD8+) compared to the perirenal depot (34.05%, SEM 
+/- 3.50% versus 11.33% SEM +/- 3.20%). Despite human and rats having similar levels of 
leukocytes, human fat reservoirs have a significantly higher percentage of CD3+ T cells and 
CD8+ T cells (Fig. 3.4). 
 
Single-cell sequencing added a few new cell populations not tested for by flow cytometry 
with the majority being immune-related. Many of the leukocytes are B 
lymphocytes/lymphoblasts with NK cells and macrophages decently represented. 
Interestingly there was quite a high proportion of T regulator cells which may play a 
significant role in the therapeutic potential of ADSVF. The rest of the population is largely 
as expected and confirmed the heterogeneous nature of ADSVF.   
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Figure 3.2 Gating strategy for cell subsets representative of the ADSVF from rat 
inguinal tissue. Typical gating scheme used to identify immune and stromal cell 
populations. Example of leukocytes (CD45+) that were positive taken from adipose tissue 
of a F344 rat. Each sample consisted of at least 200,000 viable cells (FSC × SSC gated and 
viability e780 negative). Gating was determined by both single-stained control, and 







Figure 3.3 ADSVF from inguinal and perirenal adipose tissue have diverse and similar 
cell subsets but vary in the proportion of some of the cell subsets. Flow cytometric 
profiling of ADSVF extracted from rat inguinal and peri-renal adipose tissue was performed. 
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adipose tissue. Profiling of the ADSVF leukocytes (CD45+), t-cells (CD3+: CD45+ CD3+), 
killer t-cells (CD45+ CD3+ CD8+), mesenchymal stem cells (CD45-CD90+CD34-) and 
pericyte-like cells (CD146+: CD45-, CD146+) confirms diverse cell subsets. Over 60% of 
cells remain viable in ADSVF from both regions. Both regions contained similar proportions 
of MSCs. Inguinal ADSVF consisted of a higher percentage of leukocytes and killer T cells. 
Significance was considered for p values <0.05 (*) but included p values <0.01 (**), and 













Figure 3.4 ADSVF from human peri-renal and rat peri-renal adipose tissue have 
diverse and similar cell subsets but vary in the proportion of some of the cell subsets. 
 Flow cytometric profiling of ADSVF extracted from rat peri-renal, human peri-renal and 
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from rat peri-renal (n=6), human peri-renal (n=6) and human inguinal (n=1) adipose tissue. 
Profiling of the ADSVF leukocytes (CD45+), t-cells (CD3+: CD45+ CD3+), killer t-cells 
(CD45+ CD3+ CD8+), mesenchymal stem cells (CD45-CD90+CD34-) and pericyte-like 
cells (CD146+: CD45-, CD146+) confirms diverse cell subsets. Over 60% of cells remain 
viable from both human and rat peri-renal ADSVF. There is a significantly higher proportion 
of t-cells and killer t-cells in the human peri-renal ADSVF. Significance was considered for 
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Figure 3.5 Single cell sequencing of ADSVF  from rat inguinal adipose tissue 
confirms a diverse cell population. Single cell sequencing performed on ADSVF from 
rat inguinal adipose tissue. 3 runs performed in total. (A)  Inguinal ADRC yielded 4,251 
cell transcriptomes through scRNA-seq that by unsupervised clustering identified 10 
distinct populations. Umap indicates a diverse population of cells, abundant in 
leukocytes including robust T-cell and myeloid populations, but also included cells with 
transcript signatures representative of adipocytes and mesenchymal cells. (B) Umap plot 
showing expression of selected genes among single cells. (C) cell populations identified 






























































































3.4.2 RAT INGUINAL ADSVF REAL TIME PCR 
 
 
As peri-renal adipose tissue yielded a significantly lower number of total cells compared to 
inguinal adipose tissue (223,997 cells/gram versus 1,626,164 cells/gram, respectively) and 
rat inguinal tissue is analogous to subcutaneous fat tissue in humans, we conducted all 
following experiments with inguinal-derived ADSVF. 
 
The list of genes of interest tested for by real-time PCR can be found in Table 3.2 and 
included genes involved in immune regulation, growth and repair. ADSVF from rat inguinal 
adipose tissue had mRNA expression for over 50% of the tested genes (Fig. 3.6). Real-time 
PCR results are represented as the delta cycle threshold (dCt). The Ct of the gene of interest 
was subtracted from the Ct of the housekeeping genes giving a representation of gene 
expression from the standard number of RNA in each sample. Emphasis is on the amount of 
mRNA present relative to other genes and tissue subsets than the absolute amount of mRNA.  
 
After testing for mRNA expression of whole ADSVF population, the ADSVF was separated 
into ADSVF leukocytes (CD45+) and ADSVF stomal (CD45-) subsets, by magnetic bead 
separation, to help understand if any particular subset played a more significant role in the 
therapeutic effects.  
 
For most genes, there were no significant differences identified between the two subsets in 
the loosely divided categories of immune regulation, protection, growth and repair. There 
was a statistically significant difference between groups expressing TGFB1 as determined 
by one-way ANOVA (F(2,14) = 6.504, p = .0101). A Tukey post hoc test revealed that 
expression was statistically significantly lower in the CD45-ve subsets (-6.196 ±0.19, p = 
.0151) compared to the CD45+ve subsets (-3.885 ± 0.53). There was also a difference 
between groups expressing collagen type 1 alpha 2 chain (Col1a2) as determined by one-
way ANOVA (F(2,14) = 8.168, p = .0045). A Tukey post hoc test revealed that expression 
was statistically significantly lower in the CD45+ve subsets (-4.782 ±1.27, p =.0033) 
compared to the CD45-ve subsets (-0.5271 ± 0.4974).  Finally, a difference between groups 
expressing CXCL 12 was identified by one-way ANOVA (F(2,14) = 10.23, p = .0018). A 
Tukey post hoc test revealed that expression was statistically significantly lower in the 
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Figure 3.6 ADSVF from rat inguinal adipose tissue express a diverse array of genes 
involved in immune regulation, protection, growth and repair. Gene expression of 
ADSVF, derived from rat inguinal adipose tissue, using RT-PCR analysis. 26 of the 44 genes 
(Table 3.2) tested within the Taqman array panel were expressed and 20 of those 26 are 
shown in this figure (the remaining 6 are covered in more detail in the following figures). 
These were expressed over all the broad categories of injury, immune regulation and growth 
and repair. Table summarises expression.Represented as their delta CT (housekeeping genes 




















































  Whole ADSVF CD45-ve CD45+ve 
TGFb1      + (p=0.015) 
CXCL12   ++ (p=0.0018)   
Col1a2   ++ (p=0.0045)   
 
Figure 3.7 The leukocyte and stromal subsets of ADSVF have significant differences in 
gene expression.  ADSVF was divided into CD45+ (leukocytes) and CD45-ve (stromal) 
subsets. RT-PCR analysis of the subsets was then performed looking at selected genes 
described in Table 3.2 represented as their delta CT (housekeeping genes Ct minus gene of 
interest Ct) after 40 cycles (n=8 for CD45+ and CD45-ve subsets and n=3 for whole 
ADSVF).Results after 40 cycles. There was a statistically significant difference between 
groups expressing TGFB1as determined by one-way ANOVA (F(2,14) = 6.504, p = .0101). 
A Tukey post hoc test revealed that expression was statistically significantly lower in the 
CD45-ve subsets (-6.196 ±0.19, p = .0151) compared to the CD45+ve subsets (-3.885 ± 
0.53). There was also a difference between groups expressing collagen type 1 alpha 2 chain 
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hoc test revealed that expression was statistically significantly lower in the CD45+ve subsets 
(-4.782 ±1.27, p =.0033) compared to the CD45-ve subsets (-0.5271 ± 0.4974).  Finally, a 
difference between groups expressing C-X-C motif chemokine ligand 12 (CxCL12) was 
identified by one-way ANOVA (F(2,14) = 10.23, p = .0018). A Tukey post hoc test revealed 
that expression was statistically significantly lower in the CD45+ve subsets (-5.302 ±0.5813, 



































This chapter aimed to characterise ADSVF that have previously been demonstrated to 
ameliorate transplant related renal IRI. Going forward, this data will be used in studies 
looking at its biodistribution and mechanisms of action. Although articles exist on the 
characterisation of ADSVF, including from rat inguinal fat, this chapter focuses on Fischer 
344 rats. We looked at both inguinal and peri-renal fat sources. Looking to the future clinical 
translation, we were also able to study human peri-renal adipose tissue and compare that to 
the rat peri-renal tissue. Any significant discrepancies between the characteristics of human 
and rat ADSVF would add a layer of doubt over the translation from rat studies to clinical 
use of ADSVF.  
 
One of the first steps was to ensure after the retrieval process that there remains a viable 
population. After going through a standard process, ADSVF cell viability from Fischer 344 
rat inguinal adipose tissue was over 60%. Viability from human and rat peri-renal adipose 
tissue was similar. This is particularly reassuring as viability was not only after retrieval of 
adipose tissue and processing to extract the ADSVF but also after the cryogenically freezing 
then subsequent thawing. The human adipose tissue had a particularly long time between 
retrieval and processing as it had to be taken to the biorepository for processing before then 
being transferred from the hospital to the science laboratories. This added one hour before 
processing on the human adipose tissue could begin. Respectable viability partnered with 
adipose tissue’s high concentration of MSC and easy accessibility, compounds its position 
as one of the more favourable sources of adult stem cells. More than any other source adipose 
tissue offers the highest potential of obtaining therapeutic concentrations of fresh 
(uncultured) MSC for point of care use. 
 
Rat inguinal ADSVF had a significantly higher leukocyte population as defined as CD45+ 
when compared to both rat and human peri renal ADSVF. 73% of rat inguinal ADSVF cells 
expressed CD45 which was higher than previously published. In our case, this was likely 
due to the inguinal lymph node not been excised from the adipose tissue, which is often the 
case. The inguinal lymph node of the Fischer 344 rats was small and could not always be 
confidently excised. Therefore, in a bid to maintain consistency, it was left in all samples. 
Even with the inguinal lymph node excised we would still expect the CD45+ population to 
be higher from the inguinal ADSVF compared to the peri-renal ADSVF as major vessels 
and lymphatics draining the limbs will run close or even through the inguinal fat. The 
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inguinal area is more susceptible to infections spreading from the groin area than sterile 
intra-abdominal peri-renal fat. There was no significant difference in human and rat peri-
renal CD45+ ADSVF. The one sample of human inguinal tissue that we did manage to test 
unsurprisingly had a higher percentage of leukocytes compared to human peri-renal and was 
consistent with the normal range of CD45+ve cells of around 60% (Bourin et al. 2013). This 
is in keeping with another study which found 63% of the ADSVF from subcutaneous adipose 
tissue to be CD45+ve (Acosta et al. 2016). Similar reasons to rats likely explain why 
subcutaneous adipose tissue has higher leukocyte count than peri-renal tissue.  
 
Within the leukocyte population, a robust T cell population was seen in all tested adipose 
tissue. Human peri-renal tissue had a significantly higher T cell (CD3+) and killer T cell 
(CD8+) population compared to the rat peri-renal tissue. Inguinal tissue has a higher 
percentage of killer T cells compared to the peri-renal tissue, which is not surprising due to 
the higher number of leukocytes. Single-cell sequencing added B cells, T regulator cells, 
other CD4 T cells, NK cells, dendritic cells, monocytes, and neutrophils to the immune cell 
population which made up the most substantial representation within the ADSVF of rat 
inguinal depot. The single-cell sequencing is a non-biased approach using expression 
signatures to identify cell types. It is not as representative in composition as flow cytometric 
data. Low expressed cell groups may not be captured, and the single-cell sequencing 
interrogates 2000 cells compared to the 200,000 cells in flow cytometry analysis. Flow 
cytometric data was, therefore, more helpful in drawing quantitative conclusions compared 
to the single-cell sequencing data. 
 
With ADSVF showing to be as effective in ameliorating injury as isolated ASC in multiple 
animal models the leukocyte population at the very least are not detrimental to the 
therapeutic potential of ADSVF (with some studies finding the ADSVF more effective than 
ASC alone). To the best of our knowledge, no study has looked at the efficacy of ADSVF 
minus the ASC in renal IRI animal models. ADFSVF have the added advantage of being 
much quicker and simpler to obtain than isolated ASC and therefore carries fewer risks. The 
leukocyte population are likely contributors to the paracrine actions of ADSVF. Being 
extracted and expanded, ASC will lack many of the exosomes present within the ADSVF. 
The identification of a strong representation of T regs cells is interesting as many clinical 
studies are currently in phase II looking at their role in inducing and maintaining 
immunological tolerance in solid organ transplantation. So far, they have found to be safe 
when expanded and administered peri and post-transplant. With their potent anti-
inflammatory and suppressive properties, their role within ADSVF at ameliorating renal 
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transplant-related IRI has not been thoroughly investigated (Alessandrini & Turka 2017; van 
der Veeken et al. 2016; Feuerer et al. 2009). T regs may be the tip of the iceberg when it 
comes to other cell populations within the leukocyte population with therapeutic potential 
against IRI. 
 
The mesenchymal stem cell-like cell fraction was identified as CD90+ CD45- and CD34-. 
CD34 expression can vary depending on the retrieval process and in culturing expansion of 
ASC, and it tends to be present at the beginning and less frequent at the end phases. As true 
mesenchymal stem cells are CD34- we went with that in our criteria for ASC. Also, 
angiogenesis was an essential part of recovery post-IRI and CD34-ve  MSCs promote greater 
angiogenicity. As there will be mesenchymal stem cell-like cells which are CD34+ve, they 
are likely underrepresented in our flow cytometric studies of the ADSVF. Despite that, there 
was mesenchymal stem cell-like cell population in all inguinal and peri-renal adipose tissue 
of humans and rats. The inguinal region may have a higher concentration of ASC but going 
to clinical translation, it is not just the ASC that hold the therapeutic benefit. If higher 
concentrations of ASC were deemed necessary, then the plentiful supply of adipose tissue 
will make the need for culturing unnecessary. MSC were identified in the single-cell 
sequencing. The majority identified as mesenchymal stem cells but a small population of 
adipocyte specific MSC. As further single-cell sequencing data becomes available on 
uncultured ASC, we will develop a better understanding of the stromal and stem cell 
population. Undoubtedly it will be complex and dynamic with retrieval techniques, 
processing and depot sites all effecting the phenotype of stem cells and stromal cells present.  
 
Deeper interrogation of ADSVF from human subcutaneous adipose tissue was planned. 
Unfortunately, obtaining significant human sample sizes was not possible. However, 
recently a laboratory in Montreal performed single cells analysis of visceral ADSVF 
(represented by omental fat) and subcutaneous fat of both diabetic and non-diabetic patients. 
They characterised the similarities and differences in the populations, in particular, the 
unique adipocyte progenitors found in visceral adipose tissue (Vijay et al. 2020). Data on 
the human peri-renal ADSVF overall in the literature is limited and there has been no single-
cell sequencing on uncultured human peri-renal ADSVF. With the samples we have this 
could be performed by our group moving forward and would add to conclusions generated 
from flow cytometric and gene expression data.  
 
The real-time PCR studies, as predicted given the heterogeneous cell population of the 
ADSVF, demonstrated gene expression for proteins that cover an array of functions. Given 
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they have shown to improve the functional status in models of ischaemia reperfusion injury, 
it is not surprising that genes expressed are related to growth, repair and immune regulation. 
Markers of injury were also included on the array panel, which will be valuable when 
analysing kidney that has undergone IRI and treated with ADSVF and controls.  
 
The panel represents an array of genes that in literature have been demonstrated to play a 
role in the recovery after IRI. Other proteins were chosen as their role in likely mechanisms 
of recovery and the limitations of the array card. From the custom selected array panel over 
half of the proteins, we looked at tested positive. These proteins covered all the loosely 
grouped functions. Results indicated expression of angiogenic genes, VEGF-a and anabolic 
genes such as insulin growth factor-1 (IGF-1). Also, genes involved in fibrogenesis (TGFB1 
and Collagen type 1a2) and inflammation (IL-6 and chemokine, CXCL12) were expressed. 
 
Specific proteins were singled out for having notably higher levels relative to the others. 
These were then tested again in CD45+ve and CD45-ve subgroups. In the majority, there 
was no significant difference between the groups. The leukocyte population expressed 
higher levels of the immunomodulatory protein TGFB1. The mesenchymal stem cell-like 
population expressed higher levels of CXCL12 and collagen type 1a2 (Col1a2). As 
leukocyte and stromal fractions contributed differentially in transcript expression relative to 
each other and with the whole ADSVF, it is possible cell-subset synergism may be 
responsible for the overall ADSVF expression effect.  
 
To speculate the potential mechanism each protein may play in IRI would be a laborious 
task. Gene expression of tissues treated with ADSVF could help narrow down key pathways.  
 
Although we were only able to test gene expression studies on rat ADSVF recent data has 
been published on human ADSVF by Baer et al. (Baer et al. 2019). They demonstrated the 
similar immunomodulatory potential of human peri-renal adipose tissue through PCR 
studies; however, their work was performed on cultured adipose-derived stem cells and not 
on the whole ADSVF. Another publication by Na Eun Lee et al. found that cultured MSC 
from subcutaneous tissue vs retroperitoneal adipose tissue (peri-renal adipose tissue is 
retroperitoneal) had a faster growth rate and was more angiogenic (Lee NE 2019).. This 
would be favourable in pathologies with underlying vascular disease (they propose this is 
due to their high CD146 positivity). They also showed their morphology and 
immunophenotype to be similar. All of which confirms our work on the demonstrated 
benefits of each source but also on their general overall similarity. More specific 
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characterisation of the peri-renal adipose tissue may support future uses of peri-renal-derived 
ADSVF. 
 
In summary, the ADSVF from the inguinal depot of Fischer 344 rats consist of a 
heterogeneous population of viable cells. In particular, there is a strong B lymphocyte and T 
cell representation within the leukocytes. Human peri-renal tissue consists of a similarly 
heterogeneous population but with a reduced proportion of leukocytes. Single-cell 
sequencing supports the presence of MSC within the ADSVF. Having less mesenchymal 
stromal like cells from the human tissues is not necessarily a problem as humans have large 
depots of adipose tissue.  
 
From this data and the literature, it seems overall different sources of adipose tissue have 
differing proportions of a similar cell population. Further complex and expensive research 
on the exact composition of ADSVF from different human sources would be an interesting 
intellectual exercise. However, perhaps not a priority from a translational perspective if the 
intention is to use the whole population of ADSVF. When moving to clinical trials, both 
subcutaneous and peri-renal adipose tissue should be considered. 
 
The rat inguinal ADSVF express an array of transcripts that are related to repair, growth and 
immune regulation which are adventitious traits to have when faced with IRI. Some 
transcripts are differentially contributed by the leukocyte and stromal fraction, suggesting a 
synergistic contribution of repair factors.  Mechanistic studies could focus on where these 
proteins interact within the pathways of IRI. Other future studies could concentrate on 
administering only the leukocyte population to see if it still has the desired or potentially 


















DEVELOPMENT OF A NOVEL RAT MODEL OF RENAL TRANSPLANT 





Animal models have been a vital tool in the research of many human and animal conditions. 
They will remain for the foreseeable future until such time that we have the technology or 
in vitro experiments that can accurately replicate the human physiology and interconnected 
environment between organs and systems. Animal models have been vital in the discovery 
of therapies that have saved millions of human and animal lives. The complexity of the 
human body currently makes animal models indispensable if research is to continue to 
develop therapies. The similarities between human and animal anatomy and physiology 
make animal models an applicable method to guide therapies. However, no animal model 
can accurately mimic human disease and along with animal research come the ethical and 
political debate on its existence.  
 
Opinion polls have shown acceptance to animal testing if it practises a strict code of conduct 
(the 3Rs: Refine, Reduce, Replace). The United Kingdom has some of the most stringent 
laws in the world, protecting animals and is covered in the UK Animals (Scientific 
Procedures) Act 1986. Many of the principles of this Act was replicated in the European 
Directive 2010/63/EU. Animal licence applicants must demonstrate the cost (non-financial) 
benefit assessment of requesting permission of animal testing. Any project plan must 
demonstrate strict adherence to the 3R principles – Replace, Reduce, Refine. Avoiding the 
use of animals where possible and reducing the number of animals required by carefully 
planned projects. Refinement of the research at conception and throughout the project 
licence term that reduces suffering and improves welfare. This can be achieved by applying 
new technologies, methods, and research. Before the animal licence is granted, the person, 
project and place or establishment must also satisfy the strict criteria of training, 
competency, regulation, and facilities. An animal ethics committee that includes members 
concerned with animal protection and not involved in animal research shall decide if the 




As described in the introduction section the widely used models of kidney IRI is short 
bilateral ischaemia or a longer unilateral ischaemia. Bilateral ischaemia has the major 
drawback in that it does not inflict a severe enough ischaemia representative of a transplant 
related IRI. Longer ischaemic times in a unilateral ischaemia model are possible and inflict 
a severe and permanent injury to the kidney, but the contralateral untouched kidney can 
effectively increase its functional capacity and meet the renal requirements of the rat 
including the “mopping up” of metabolic disturbances. A summary of current popular 
animal models is shown in figure 1.6.  
 
To address the issue of having an untouched fully functioning contralateral kidney a 
hybridization of a severe unilateral renal ischaemia model and the traditional 5/6 
nephrectomy model may provide a solution. Since the 1970s, the 5/6 nephrectomy model 
has been used as a way of inducing chronic renal failure in rodents. This animal model 
involves the removal of one kidney and ligation of 2/3 of the blood supply or 2/3 resection 
of the remaining kidney. After an initial period of hypertrophy and hyperplasia of the 
remnant kidney tissue there is progressive tubulointerstitial injury and glomerulosclerosis 
(Chanutin & Ferris 1932; Olivetti et al. 1977; Shea et al. 1978; Olson et al. 1982; Purkerson 
et al. 1976). Features of chronic renal failure can be seen with increased blood pressure, urea, 
creatinine, sodium and potassium (Baracho et al. 2016; R.-Z. Tan et al. 2019). Significant 
changes are also seen in calcium, magnesium and phosphate (R.-Z. Tan et al. 2019). The 
homeostasis of uremic toxins, metabolites, peptides, proteins, and electrolyte are all 
disturbed in CKD. 
 
Therefore, the potential interference the renal failure environment may have on a kidney 
recovering for IR should not be ignored. Metabolite changes following the 5/6 nephrectomy 
are involved in many pathways including ROS, acid-base balance, energy metabolism and 
the gut-kidney axis (Hanifa et al. 2019). Disturbances in uremic toxins, metabolites and 
electrolytes affect the recovery of transplanted grafts (Duranton et al. 2012; K. Wang & 
Kestenbaum 2018; Y.-Y. Zhao 2013). Hyperuricemia may itself have direct involvement in 
the development of chronic kidney disease and increases the risk of cardiovascular disease 
(Grassi et al. 2013; Dousdampanis et al. 2014; R. J. Johnson et al. 2013). High blood pressure 
and increased renal flow, because of chronic renal failure, exert a pressure on the kidneys 
that would be present in the transplant recipient but not replicated in current animal models.  
 
The 5/6 model has excellent translation to human disease as it represents a significant 
decrease in renal function due to loss of functional nephrons, glomerulosclerosis, 
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tubulointerstitial fibrosis and proteinuria (Platt 1952; Shimamura & Morrison 1975; Kwon 
et al. 1998). Other models of chronic kidney disease exist such as glomerulonephritis 
induced, radiation-induced and ureter occlusion (R.-Z. Tan et al. 2019). However, in these 
models, it is difficult to accurately reduce the function of just one of the kidneys.  
 
One drawback of the 5/6 nephrectomy model is the inconsistency in achieving exactly 2/3 
nephrectomy, which results in varying degrees of uraemia and creatine clearance (Z. C. Liu 
et al. 2003). Surgical ligation of the kidney tissue can offer a more precise nephrectomy over 
renal artery branch ligation but does carry an increased risk of haemorrhage and infection.  
 
Rodent allograft kidney transplantation into a nephrectomised animal would most closely 
represent clinical transplantation. However, this is technically very challenging with a long 
learning curve, high risk of stenosis, thrombosis, and bleeding. Plus, removal of the kidneys 
at the time of transplantation will result in unacceptable numbers of animal deaths as there 
is no capacity to perform rodent dialysis.  It also requires a further sacrificial rodent for the 
kidney graft and is more time-consuming.  
 
To refine the measurement of GFR, novel methods have been developed that removes some 
of the drawbacks of inulin clearance studies (time-consuming, technically challenging, often 
terminal, serial blood or urine measurements). One such technique is the administration of a 
florescent labelled polysaccharide (FITC-sinistrin, Fresenius Kabi, Linz, Austria) then 
measuring the light emitted transcutaneously with a fluorescent imager once it has been 
excited. This method progressed to using a small device attached to the rat for a few hours, 
in a jacket. The device which would transcutaneously excite the FITC-sinistrin at 480nm 
and detect the emitted light at 520nm (Schock-Kusch et al. 2011). This allows longitudinal 
detection of emitted light in freely moving rats. Thousands of data points are taken over the 
120minutes, and the elimination half-life is determined using an established one-
compartment model (Schock-Kusch et al. 2009; Pill et al. 2006; Pill et al. 2005). The GFR 
can then be derived from the half-life as a linear relationship is expected between GFR and 
half-life. A deduced conversion factor to calculate the GFR was obtained from enzymatically 
measuring Sinistrin clearance (Schock-Kusch et al. 2009). GFR results using this method 
are highly comparable to the gold standard plasma clearance studies (Schock-Kusch et al. 
2009). Also, temporarily attaching a small transcutaneous device, with a jacket, to the rodent 
versus anaesthetising the rodent to go under a fluorescent imager reduces the need for 
anaesthesia which can alter GFR. 
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A modified Whalen et al. animal model which better mimics the transplant patient and 
technically easier to perform without long, laborious terminal renal function testing could 
potentially be the optimal model for testing therapies against transplant-related IR. 
 
Fischer 344 rats are well suited to renal IRI as they are large enough to allow for dissection, 
cannulation, and anastomosis of the renal artery. In addition, they are robust and recover 





The severe unilateral ischaemia reperfusion injury model can be further modified to better 



























Ethics: All animal procedures were performed in accordance with the Animals 
(Scientific Procedures) Act 1986 (ASPA) and approved by the Home Office (England, 
Scotland, and Wales) and University of Glasgow Animal Welfare and Ethical Review 
Body. Methods of sterility, intraoperative monitoring and positioning, anaesthesia, 




4.3.1 ANIMAL HOUSING AND HUSBANDRY 
 







• Wild Heerbrugg Ltd operating microscope – zoom 10-30x 60mm LED light ring 
(Microscope Systems Scotland) 
• Far infrared heating pad and infrared thermometer (Kent Scientific: DCT-15) 
• Operating board (30x30cm). Covered with disposable plastic sheeting, held in place 
with adhesive tape. 
• The following microsurgical instruments were obtained from Mercian® (Mercian 
Surgical Supply Co Ltd, Worcestershire, United Kingdom) 
o – Microsurgical vessel dilators with 0.1mm tips. (D-5a.1) 
o – Microsurgical vessel dilators with 0.2mm tips. (D-5a.2) 
o – Microsurgical vessel dilators with 0.3mm tips. (D-5a.3) 
o – Angulated forceps with 0.3mm tips. (JFA-5b) 
o – Dissecting microsurgical scissors with curved tips (SDC-15) 
o – Adventitia microsurgical scissors with sharp tips (SAS-15) 
o – Microsurgical needle holder without a lock, curved tips 0.4mm. (B-15-8) 
o – Tubing introducing forceps, tips 0.35mm. (TIF02) 
o – Clamp applying forceps. (CAF-4) 
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o – Atraumatic vascular clamps. (B1-V and B2-V)) 
• Electric hair clippers 
• 15G Scalpel 
• Sterile Dressing packs (Nu-care Products Ltd, Bedfordshire, United Kingdom: 
DP10025) 
• Sterile Cautery (John Weiss & Son Ltd, Milton Keynes, United Kingdom: 0111122) 
• 30G Rycroft Cannula (0108003) 
• Blunt retractors (18200-12) and elastomers (18200-07) (Fine Science Tools, 
Heidelberg) 
• Sterile cotton tip applicators (Nu-care Products Ltd, Bedfordshire, United Kingdom: 
M982S) 
• 10/0 nylon sutures. (Schuco Ltd, ZX-AK-0105, DR4 needle) or Ethilon® Suture, 
10/0 non absorbable, monofilament, 13cm, 3.8mm, 3/8 circle taper point needle 
(Ethicon, Inc. W2870) 
• Vicryl® Suture, 4/0 undyed, 19mm, 45cm, circle reverse cutting (Ethicon, Inc. 
W9925) 
• Prestige Latex Sterile Gloves (Nu-care Products Ltd, Bedfordshire, United Kingdom: 
GS33LE) 
• 365 Standard Sterile Gowns (Nu-care Products Ltd, Bedfordshire, United Kingdom: 
D20304) 
 
Non-terminal / non-invasive renal function measurement equipment: 
• Electric hair clippers 
• Depilatory cream 
• Double sided adhesive patch 
• Transcutaneous optical device (MediBeacon, Mannheim, Germany formerly known 
as Mannheim Pharma & Diagnostic GmbH, Mannheim, Germany prior to 
acquisition) 
• Fluorescein isothiocyanate (FITC)-sinistrin (MediBeacon, Mannheim, Germany) 







4.3.3 RODENT ANAESTHESIA  
 
Animals were weight before surgery. Surgical induction was performed in the animal 
operating suite using an anaesthetic chamber. 5% isoflurane was used for induction, and 
anaesthesia was maintained using an inhaled mix of 5% isoflurane and 1litre/minute oxygen 
via a face mask. According to the animal’s respiratory rate and pain withdrawal reflexes, the 
flow could be adjusted by the surgical assistant. 
 
 
4.3.4 INTRA-OPERATIVE MONITORING AND POSITIONING  
 
Rats placed supine under a sterile drape on a board which has heating mat incorporated into 
it—placing the rodent on a board allowed for easy mobilization of the rodent while being 
able to maintain sterility. The temperature was monitored using an infrared thermometer and 
maintained between 36.9oC-37.3oC. The far-infrared heating mat and built-in procedural 
table heater were used to control rodent body temperature. 
 
 
4.3.5 SURGICAL STERILITY 
 
Surgery was performed in a dedicated animal surgical suite. Only the surgeon and assistants 
present in the operating suite. Green scrubs and dedicated surgical footwear were required 
throughout the facility. Before any procedure, the operating table, microscope, and 
surrounding areas were sprayed down with chlorhexidine. After surgical scrubbing of 
forearms and hands with chlorhexidine surgical scrub, sterile gown and gloves were worn. 
Sterile drapes were placed on the surgical field, over a microscope and on top of the rodent 
(Fig 4.1). Rodents were then prepped with 2% chlorhexidine solution which was left to dry 
before starting procedure. Surgical instruments are autoclaved 30 minutes before the start of 
operation (30minutes at 134oC). Any consumables were opened from their sterile pack and 
dropped onto the sterile field. Postoperatively, surgical instruments were washed with warm 







4.3.6 PERI-OPERATIVE ANALGESIA AND POST-OPERATIVE MANAGEMENT 
 
At induction of general anaesthesia for any operation, the rodent is administered 
buprenorphine (0.005mg per 100g) subcutaneously. Viscotears was applied to both eyes. 
Before wakening, 4ml of sterile saline was administered subcutaneously but can be increased 
if the procedure took longer than usual or if there was slightly more blood loss than average. 
Immediately post-operative the rodent is recovered and monitored closely in a heated 
recovery cage with free access to food and water. Once the rat has fully recovered from the 
anaesthetic, they are placed back into their home cage. Buprenorphine (100ug) is given 
orally on days one and two post-operative. Daily weights for at least seven days post-surgery 
plus the NC3Rs grimace scales were used to make sure rodent pain was controlled and to 
identify any complications as early as possible (National Centre for the Replacement, 
Refinement and Reduction of Animals in Research, London, United Kingdom). The 
operating surgeon, project licence holder or the named veterinary officer were available 24 
hours a day if there were any concerns with operated rats. 
 
 
4.3.7 STAGE 1 – 2/3 NEPHRECTOMY OF RIGHT KIDNEY 
 
Young adult male Fisher 344 rats were anaesthetised with isoflurane. Abdominal hair was 
shaved, and the rat was placed on a heating mat. The skin was prepped with chlorhexidine 
and draped to obtain a sterile field. A two-centimetre upper midline incision was made using 
a fully aseptic technique. Using scissors, the peritoneum was opened. Bowel contents were 
gently retracted to the left to reveal the right kidney. The fascia surrounding the renal hilum 
was opened and the renal artery identified. Due to varying anatomy, non-traumatic micro-
forceps were used to briefly (3 seconds) clamp branches of the renal artery in order to 
determine blood distribution form that particular artery. Using 10-0 Nylon one or two or 
three branches of the renal artery were ligated to leave only 1/3 of the kidney perfused with 
arterial blood (Fig 4.2). Bowel retraction was then removed to return the normal positioning 
of the bowel. Peritoneum and skin were closed individually using a continuous 4-0 
polyglactin suture (Vicryl®). Total surgical time ranged from 15-30minutes. Post-surgical 
care:  The animal was injected with 4ml of subcutaneous 0.9% saline postoperatively and 
placed alone in the warmed recovery cage with free access to food and water. Buprenorphine 
analgesia was injected subcutaneously, at 0.005mg per 100g of body weight. The animal 
was returned to its home cage once fully recovered from the anaesthesia. 
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4.3.8 STAGE 2 – ISCHAEMIA REPERFUSION INJURY OF LEFT KIDNEY AND 
CANNULATION OF RENAL ARTERY  
 
Once recovered from the right partial nephrectomy procedure for at least two weeks the rats 
were anaesthetised with isoflurane (Fig 4.3). Abdominal hair was shaved, and the rat was 
placed on a heating mat. The temperature was adjusted to maintain the core temperature of 
36.5-37oC. The skin was prepped with chlorhexidine and draped to obtain a sterile field. 
Using a fully aseptic technique, the previous midline incision was reopened and extended to 
around five centimetres. Bowels were gently retracted to expose the left kidney. The fascia 
surrounding the renal hilum was opened, and the left renal artery was identified. A segment 
of the renal artery was carefully cleared of fascia and its attachment to the renal vein with 
blunt dissection using cotton tips and forceps. Two non-traumatic vascular micro clamps 
were placed on the renal artery to induce renal ischaemia and the time noted (Fig 4.4). The 
kidney was inspected to make sure the clamps have entirely occluded perfusion. If the animal 
is to receive an intervention via the renal artery (as in our research) then 20 minutes before 
the end of the ischaemia (minute 100) an incision large enough to fit a 30-gauge catheter 
was made to the anterior wall of the renal artery between the clamps. 7x105 ADSVF cells 
in 0.3ml PBS was administered with a 1ml syringe and a 30-gauge catheter through the 
incision. The distal clamp was momentarily released to allow the infusion to travel through 
the renal artery and into the kidney. Perfusion of the kidney with the ADSVF/PBS was 
confirmed by the visualisation of the kidney changing colour. The distal clamp was re-
applied to prevent back bleeding from the kidney. The renal artery incision was repaired 
longitudinally with interrupted 10-0 Nylon.  Clamps were removed after 120 minutes of 
warm ischaemia. Bowel retraction was removed to allow the normal positioning of the 
bowel. Peritoneum and skin were closed individually using a continuous 4-0 polyglactin 
suture (Vicryl®). Total surgical time ranged from 140-160minutes. Post-surgical care: The 
animal was injected with 2.5ml of subcutaneous 0.9% saline postoperatively and placed 
alone in the warmed recovery cage with free access to food and water. Buprenorphine 
analgesia was injected subcutaneously, at 0.005mg per 100g of body weight. The animal 








4.3.9 NON-INVASIVE MEASUREMENT OF RENAL FUNCTION  
 
Preparation of FITC-sinistrin Injection Solution 
1. FITC-sinistrin (MediBeacon, Mannheim, Germany) was dissolved in physiological 
saline to prepare a stock solution. The recommended dose in in rats is 5 mg/100 g 
BW FITC-sinistrin.  
Animal Preparation 
2. Induction and maintenance of general anaesthesia if rat not already under general 
anaesthesia for another procedure. The level of anaesthesia should be sufficient so as 
to prevent the animal experiencing any discomfort or distress. 
3. Fur is removed from the back of the animal using an electric shaver. An area slightly 
bigger than the area that will be occupied by the double-sided adhesive patch, which 
has dimensions of 3cm x 6cm will be shaved.  
4. Depilatory cream will be applied for a short period (2-3 min) to remove the remaining 
fur. 
5. The cream will be thoroughly washed off. 
Fixation of the Device on the Animal 
6. The optical device is placed onto one side of the adhesive patch and device and patch 
are then placed onto the shaved area on the back of the animal. 
7. For animal comfort, and to secure the device, tubular elastic gauze bandage is 
stretched over the abdomen of the animal, ensuring that the limbs can move freely 
(Fig 4.5). 
FITC-sinistrin Administration and Measurement Procedure 
8. FITC-sinistrin stock solution is injected into the tail vein. 
9. The animal is returned to its home cage and is recovered from the short anaesthetic. 
The animal is left in its cage with the device attached for 2 hours. 
Note: During the recording period the animal will be individually housed in a cage 
with no protruding structures, such as  wire lids,  to avoid damaging of the electronic 
device and movement artefacts due to impacts with objects. 
Device Removal 
10. Once the recording period is over, the tubular bandage and adhesive tape with the 
device is gently removed without the need of anaesthesia and the animal is returned 
to its normal home cage. 
11. The device is then connected to a PC via a micro USB for data analysis. 
Data Analysis 
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12. FITC-sinistrin reading software (Sensor_ctrl_app.exe. MediBeacon, Mannheim, 
Germany) is used to extract the data from the device.  
13. The shape of the graph displaying time versus signal can be visualised to ensure 
FITC-sinistrin was administered adequately and detected by the optical device. 
14. The software will calculate the half-life of the FITC-sinistrin. The following formula 
is then used to calculate the GFR: 
                                  
 
 
4.3.10 DEVELOPED STANDARD OPERATING SURGICAL PROCEDURE 
 
Operating personal licensees underwent an approved animal microsurgery training course 
or were trained by a personal licence holder with vast experience in this type of 
microsurgery. 
 
When learning either the 2/3 nephrectomy procedure or the IRI with renal artery cannulation 
procedure, there is initially a period of training on humanely killed rats. The number varies 
as per trainee but is approximately five. Then, under supervision, the trainee will commence 
a period of training on several live animals which will be humanely killed before recovery 
(5 to 10 depending on trainee progress).  The trainee will commence to operate, supervised, 
on experimental rats that will be recovered. Once a success rate of >80% is achieved, then 
they are approved for independent practice. 
 
To reduce animal numbers during training, the 2/3 nephrectomy procedure can be performed 
on both the left and right kidneys of the cadaveric and non-recovered rats. Similarly, the IR 
with renal artery cannulation training can be performed on both the right and left kidney of 
the cadaveric and non-recovered rats. 
 
The Named Veterinary Officer was informed and observed multiple stages of the training. 
Only once deemed competent by the trainer and the Named Veterinary Officer was the 
















Figure 4.2 Images of 2/3 nephrectomy surgery. (A)Discolouration of the right kidney after 
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Figure 4.4 Left kidney IRI surgery and renal artery cannulisation. (A) Bowel retracted 
and protected in swab soaked in sterile water. Surgical exposure with retractors. Sterile 
cotton tip applicators ideal for retracting tissue and displaying the planes for dissection. (B) 
Macroscopic view of claps on renal artery within 15minutes of starting operation. Note 
discoloration of kidney confirms occlusion of renal artery and 120-minute countdown can 
commence. (C) Microscope view of clamps on renal artery which can now be dissected 
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Figure 4.5 Transcutaneous GFR measurement. Rat is briefly anaesthetised, and the skin 
is shaved, and depilatory cream is applied. Transcutaneous device attached to back. FITC-
sinistrin injected via tail vein then rat is recovered and allowed to roam free with 







Whalen et al. eloquently demonstrated the long-term reduction of renal function with 
correlating histological findings such as epithelial breaks and hyaline cast formation. At six 
weeks post-IRI surgery there is a persistent, significant reduction in renal function compared 
to sham-operated rats (Fig. 1.5). When looking at the rat kidneys that underwent 2/3 
nephrectomy, it is clear to see the degree of necrosis and remaining functional mass (Fig. 
4.6).  In our model, we identified features of tubular injury, at 48 hours post 120-minute 











Figure 4.6 Kidneys retrieved 48 hours post IRI surgery confirm injury secondary to 
2/3 nephrectomy surgery and IRI surgery. Left and right kidneys retrieved 48 hours post 
IRI surgery which is 2 weeks and 48 hours post 2/3 nephrectomy surgery. (A) Macroscopic 
picture of 2/3 necrosis of right kidney. (B) Left kidney recovering from severe IRI with no 
evidence of macroscopic necrosis. (C) Typical histological slide of left kidney. (D) 4x 
magnification of naïve left kidney for reference (E) 4x magnification of left kidney that 
underwent 120 minutes ischaemia with histological features of injury. Not possible to 
perform histological analysis on the necrosed right kidney 
 
 
4.4.2 OPERATING TIME  
 
The 2/3 nephrectomy operating time from the skin to skin varied between 15 and 30 minutes, 
depending on how quickly it took to identify the relevant vessels that supply two-thirds of 
the kidney. This does not include the time to get the equipment ready and to prep and drape 
the animal. The rats recover fast as the anaesthesia time is short, and the incision is small 
compared to other major abdominal surgeries. Three 2/3 nephrectomy procedures were 
comfortably achievable in a three-hour morning session.  
 
The modified IRI of the left kidney operating time varied between 140 minutes and 160 
minutes. Much of this time is waiting for the 120minutes of ischaemia to be reached. In this 
modified version, a puncture was made in the renal artery instead of completely transecting 
it. The puncture was large enough to allow the 30G Reycroft cannula to cannulate the vessel. 








The first advantage of this was that there was a tighter seal around the cannula; therefore, no 
need for a rubber sloop and less spillage and more accurate delivery of the therapies. 
Secondly, repair of this puncture is quicker, less intensive and uses less suture material. On 
average, two interrupted sutures were required to close the defect compared to 12 interrupted 
sutures when the artery is completely transected. We had no instances of catching the back 
wall when closing the defect, but there is likely a higher chance of this happening compared 
to repairing a completely transected artery in the frame clamp. To test the artery is patent 
post suture repair the proximal clamp can be released to ensure there is no haemorrhage from 
the anastomosis and to see the vessel distal to the anastomosis expand. The distal clamp will 
stop any premature reperfusion of the kidney during this test. 
 
The non-invasive renal function measurement takes around 15minutes to instigate once the 
rat has been anaesthetised. Once the device is attached, and the FITC-sinistrin has been 
administered data collection from the device begins and last for two hours. During this 
period the rat is placed back in its home cage where it can recover from the anaesthetic and 
roam freely. The rat does not have to be supervised, but regular checks can ensure the device 
remains in the right position. Removing the device does not require an anaesthetic and takes 
just a couple of minutes. 
 
 
4.4.3 NON-INVASIVE RENAL FUNTION MEASUREMENT 
 
The transcutaneous renal function measurement (Fig. 4.7) detects a significant reduction in 




Figure 4.7 48 hour post IRI surgery there is a detectable reduction in renal function 
using the transcutaneous non-terminal renal function measurement device. A) Renal 
function 48 hours post full animal model (n=4) vs naïve rats (n=6) B) Typical FITC-sinistrin 
clearance post injection in a healthy rat taken from data collected from transcutaneous 
































































4.4.4 MORBIDITY AND MORTALITY 
 
On average weight dropped 5% by day five post-op then consistently increases after that 
back towards pre-operative weight and continues to increase (Fig. 4.8). Pre IR surgery 
weight was higher than pre 2/3 nephrectomy weight. A steady increase in weight in post 2/3 
nephrectomy surgery (after the initial post-operative weight drop) supports the notion that 
rats recover well from the brief operation and suffer no significant sequelae from the 2/3 
nephrectomy alone. During the two weeks between procedures, the healthy untouched left 
kidney ensures that the rat is not suffering from renal impairment. Weight and no concerning 
scoring on the grimace scales suggest the rats have minimal suffering and physiological 
upset postoperatively and has likely made a full recovery by the time of the second surgery.   
 
There was an incisional hernia identified in the recovery of one rat that underwent the IRI 
surgery. The rat was taken back to theatre, and the suture was taken out and the abdomen re-
closed. The animal made a full uneventful recovery afterwards. 
 
There were two rat deaths after 2/3 nephrectomy procedure within a short period. The deaths 
were reviewed by the chief veterinary officer who also performed a post-mortem on both 
rats. The chief veterinary officer concluded that the deaths were not the result of the 2/3 
nephrectomy surgery as there was no evidence of bleeding, wound infection, thrombosis or 
injury to surrounding structures. All other organs looked unremarkable except an enlarged 
spleen. It was concluded that an unknown infection was the cause and measures were taken 
to investigate the unit, but nothing was identified. Out of 47 2/3 nephrectomy procedures, 
there were no other deaths. 
 
One rat died after IR surgery. The cause was intra-abdominal sepsis. During surgery (likely 
when retracting the bowel) there was what appeared to be a small serosal tear of the large 
bowel. As there was no visible contamination at the time a suture repair of the tear was 
performed, and the animal was closed as usual. The rat was kept under intensive observation 
postoperatively, but it was clear he was not recovering, and the decision was made to kill 
the rat humanely.  
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Due to the lower-than-expected morbidity and mortality, the named veterinary officer 




Figure 4.8 Rats recover well from 2/3 nephrectomy surgery. Mean rat weights pre and 
post 2/3 nephrectomy and pre IRI surgery measured in grams. (n=47). Rat surpass their pre 




4.4.5 DEVELOPED SURGICAL GUIDELINES 
 
After performing over 200 microsurgical procedures, we have found the following tips to be 
helpful: 
• 10-0 monofilament suture is expensive and was not always straightforward to source. 
After using it use the remaining suture was soaked in chlorhexidine, rinsed and 
stored. Before the next operation, the suture was then autoclaved in autoclave 
approved box. The same suture could be used to perform multiple procedures. We 
had no issue with infection or suture fracture, causing the breakdown of the 
anastomosis. 
• Closing peritoneum with a continuous suture (3-0 Vicryl®), locking it then running 
the stitch back to close the skin allows for a two-layer closure with one stitch. We 
































• Having two sets of microsurgical instruments makes it possible to perform multiple 
2/3 nephrectomy surgeries in a morning session. One set can be sterilised as the other 
is in use. 
• Precise, sharp and undamaged microsurgical scissors are essential to make a small 
clean hole in the renal artery. We had our scissors refurbished and realigned if they 
were dropped or not cutting cleanly. 
• Surgery should be stopped, and rat terminated if any bowel injury occurs. Suture 
repair of the bowel, washout of abdomen and antibiotics postoperatively is unlikely 
to be successful and can lead to unnecessary distress to the rat postoperatively. 
• When performing IR surgery, a 1cm x 1cm cutting of a sterile swab rolled up can be 
placed in the abdomen to gently wedge the spleen up into the left upper quadrant out 
of the operating field. Good surgical exposure is essential for efficient and safe 
operation. Make sure to remove at the end of the operation. 
• Opening the avascular tissue between the kidney hilum and peri-renal fat and then 
following this plane up the medial edge of the kidney is a quick route to get behind 
the fat covering the renal artery. Once making this incision, the fat medial to the 
kidney can be lifted, and the renal artery can be easily identified and traced back to 
the aorta.  Not only is this route quick and causes minimal bleeding it also avoids the 
need to tie off the suprarenal vein. 
• During IRI surgery locating the renal artery should be the priority after creating 
adequate exposure. Once the artery has been located, it should be clamped. This will 
start the 120 minutes of ischaemia. Then skeletonising the rest of the renal artery can 
begin, so it is ready for cannulation. Skeletonising the artery may take up to 30 
minutes, and if this is done before clamping it is essentially adding 30 minutes on to 
the operation. From knife to skin to clamping the renal artery takes around 15 
minutes. After the 120 minutes ischaemia, it takes around 10 minutes for a final 
inspection to ensure no bleeding, placement of organs back into their anatomical 
position and closure of peritoneum and skin. Total operative time can, therefore, be 
as little as 2hour 30minutes. Two per day is feasible. 
• Cannulating the renal artery with the 30G Rycroft cannula in the right hand and using 
not traumatic forceps in the left hand to gently clamp around the artery cannulated 
by the catheter allows administration of therapy in a more controlled manner with 
minimal spillage and minimal damage to the artery. 
• Opening the proximal renal artery clamp but leaving the distal clamp can allow 
testing of renal artery suture repair without reperfusion of the kidneys. Patency and 
haemostasis of the repair are assessed. Once the repair is proven to be adequate, the 
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distal clamp remains on until the desired 120minutes of ischaemia has been achieved 
then the distal clamp can be removed at exactly 120minutes. 
• Some bleeding after suture closure of the renal artery defect does not necessarily 
mean a further suture is required. Some very light pressure with a cotton tip 
applicator (just enough pressure to stop bleeding but not occlude the vessel - often 
the weight of the applicator alone is enough) for one full minute can often be enough 

































The transplant recipient often has little to no residual renal function at the time of 
transplantation. If the kidney graft does not recover quick enough, the patient can survive on 
dialysis until the graft kidney function picks up. This means the transplanted kidney graft 
recovers in an environment of renal failure. As far as we are aware, there is no rodent model 
of IRI in which the injured kidney recovers in and environment of renal failure. In the rat 
model of renal IRI described in this chapter, the 2/3 nephrectomy of the right kidney before 
the severe ischaemia reperfusion injury (IRI) of the left kidney creates an environment of 
reduced renal function. Therefore, the left kidney is recovering in an environment closer to 
mimicking renal failure and better representing the transplant patient.  
 
One reason this had not been tested before is the fear of increased rat deaths. Whalen et al. 
severe rat model of IR results in kidney nephropathology seen in transplanted human kidney 
grafts (Whalen et al. 2016; Salahudeen 2004). The untouched contralateral kidney in that 
model protects the rat from acute kidney injury and death (Zager et al. 2011). If we then look 
at the 5/6 nephrectomy model of chronic renal failure (CRF) the rat is left with only 1/6th of 
its renal function. Despite this survival rates are high, and due to its excellent translation to 
human diseases, it has commonly been used in models of CRF over the last 50 years. 
Therefore, a hybrid Whalen et al. model and 5/6 nephrectomy animal model would leave the 
rat with 1/6th of its renal function and a recovering kidney. In theory, this type of model 
should not carry a significant risk of animal death and proving this was one of the main 
focuses of this chapter. 
 
Performing a 2/3 nephrectomy on the right kidney prior to the severe IR of the left kidney, 
we can see that the survival was excellent and did not change compared to when the 
contralateral (right) kidney was untouched. Renal function tests confirmed that the IR kidney 
is recovering in an environment of reduced renal function. We can presume Ur, Cr, Mg, P, 
urea, uremic toxins will be increased, as this has been proven in 5/6 nephrectomy models; 
however, this was not tested on this occasion. There is an argument that the effects of a 5/6 
nephrectomy have been well studied and documented so it will likely not add to the existing 
data and is not worth further animal studies. It remains unknown what effect the renal failure 
environment will have on a recovering kidney but the potential of the renal failure 
environment to interact with the many hundreds of pathways that are taking place after IRI 
cannot be ignored. It should be noted that this model represents a kidney recovering in a new 
environment of renal failure, not a longstanding “chronic” renal failure environment. 
 125 
Therefore, although not fully representative of the transplant recipient, performing the 2/3 
nephrectomy is a worthy addition as it does take the animal model one step closer without 
sacrificing animal welfare or research time and resources.   
 
Tying a suture around the top and lower 1/3 of the right kidney instead of locating branches 
of the renal artery which supply 2/3 of the kidney would simplify the procedure even further. 
Not only would it be quicker but likely more accurate as some of the nephrectomised kidneys 
had slightly more than 2/3 nephrectomy and some slightly less – all depending on the renal 
artery branches which were tied. 
 
As it has been proven to be safe, considering the 2/3 nephrectomy at the same time of IRI 
surgery is now also a possibility. Especially as a 2/3 nephrectomy will not create an 
immediate environment of renal failure as the untouched left kidney is enough to maintain 
sufficient renal function (until it undergoes the IRI). The argument against performing the 
2/3 nephrectomy at the same time as the IRI surgery is that the inflammation and necrosis 
from the 2/3 nephrectomy may affect data analysis – especially if research is focusing on 
inflammation or immune response. The ischaemia of the right kidney at the time of IRI on 
the left kidney may also alter left kidney recovery like the distal ischaemia preconditioning 
discussed in chapter one. 
 
This animal model has pushed the boundaries in terms of mimicking the transplant patient, 
and there is likely no further reduction of renal function that will be survivable (Craddock 
1976). It may be possible to increase the 120minutes of IR, as 190minutes has been observed, 
but with 120 minutes already achieving a severe, longstanding injury there may not be much 
more to be gained versus the associated increased risks. The only animal model that would 
be more representative of the transplant patient would be to implant a kidney graft into a rat 
that has had a 5/6 nephrectomy. However, such a transplant model will be more time 
consuming, require a donor rat, be technically more challenging and carry more risks of 
surgery such as thrombosis and stenosis. A transplant model like that could still have its 
place in testing promising therapies developed on lesser severe models like the one described 
in this chapter. 
 
The 2/3 nephrectomy surgery is an additional step to the Whalen et al. model. Once 
competent in the procedure, skin to skin operating time was quick and through a small 
midline laparotomy incision. All rats recovered swiftly apart from the two deaths that were 
concluded as not being a direct surgical complication by a post-mortem performed by the 
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chief veterinary officer for the University of Glasgow. After the 2/3 nephrectomy surgery, 
the rat does not suffer from any sequelae of CRF as they still have a healthy contralateral 
kidney. Weights did not take any continuous unexpected drop supporting the notion that 
there was minimal suffering and physiological stress after the surgery. Two weeks recovery 
before embarking on IRI surgery ensures the rat is fully recovered and there is no ongoing 
post-operative inflammatory response which could interfere with the IRI and therapies being 
tested. The IRI surgery was not any more difficult because of the 2/3 nephrectomy surgery 
two weeks prior.  There were no adhesions, altered anatomy or difficulty dissecting out the 
left kidney and the midline laparotomy wound healed the same as it did after the first 
operation. Two methods which could potentially reduce the operative time further are 
cauterisation of the renal artery branches or ligation of the top and lower poles of the kidney. 
Ligation of the kidney itself has been reported to be quicker with less associated 
complications of bleeding and infection compared to kidney pole excision (R.-Z. Tan et al. 
2019)  
 
Whalen et al. successfully transected the renal artery, and eloquently demonstrated how it 
was possible to administer therapies via the renal artery in the animal model of severe IRI. 
Human transplantation gives unique easy access to the renal artery at the time of 
transplantation and could be the optimum route for many therapies with less biodistribution, 
avoidance of first-pass metabolism and optimal dosing. However, completely transecting the 
renal artery to administer the therapies is technically very challenging as two ends need to 
be anastomosed together using multiple interrupted sutures. The learning process is also 
long, and the risks of complications are not insignificant. To address these issues, an 
alternative method of renal artery cannulisation was attempted. Instead of transecting the 
renal artery completely, a puncture was made in the artery, with the microsurgical scissors, 
big enough to allow the 30G cannula to pass. Cannulation via this puncture was straight 
forward with 100% success and perfusion of the kidney was confirmed by colour changes 
of the kidney on the administration of vehicle control or therapy. There was also no need to 
sloop the artery. Closing of the hole was achieved with 1 to 3 interrupted sutures. This is 
significantly easier, less intensive and less time consuming than anastomosing two 
completely transected ends together. Although Whalen et al. did not experience any 
unacceptable levels of complications, in theory, this newer technique would reduce the risk 
of thrombosis or stenosis as there is fewer sutures, scarring and no chance of the vessels 
becoming twisted when brought together all of which could cause bleeding, stenosis or 
thrombosis. No kidney was ischaemic when retrieved at a later date and being more 
comfortable to perform made it is easier to teach and learn. 
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Another shortcoming of the Whalen et al. model was the time consuming, terminal and 
technically challenging inulin plasma clearance studies.  Although inulin clearance studies 
are considered the gold standard in measuring the glomerular filtration rate the FITC-
sinistrin transcutaneous clearance measurement method offers a means of measuring renal 
function that is still significantly more sensitive than serum Ur and Cr. GFR results using 
this method are highly comparable to the gold standard plasma inulin clearance studies 
(Schock-Kusch et al. 2009). The novel transdermal transducer which measures FITC-
sinistrin is a much easier alternative. Administration of the FITC-sinistrin and application of 
the device is straightforward and can be completed under a brief general anaesthetic. The 
device is then left on the rat for two hours in an unmonitored cage. Removal of the device is 
straight forward and did not require a further anaesthetic. The animal is free to roam the cage 
with the device attached, and the light device stuck to the back does not seem to cause much 
discomfort. If multiple devices are available, it is possible to measure the renal function of 
multiple rats in a short period. This is not possible with inulin plasma clearance studies as 
the whole procedure takes around 6 hours; therefore, limited to one per day. Being able to 
measure the renal function at multiple time point on the same rat reduces rat numbers 
compared to the terminal inulin studies and satisfies 2 of the 3R principles - reduce and 
refine. In chapter five, FITC-sinistrin transcutaneous measurement is used to compare rats 
treated with vehicle control and adipose-derived stromal vascular fraction. Serum Ur and Cr 
measurement would not be sensitive enough to detect differences between the two groups.  
 
Replacing the inulin clearance studies and modifying the renal artery cannulation technique 
has made the Whalen et al. model less technically challenging, less time consuming and 
quicker to learn. An experienced rodent microsurgeon or human surgeon can competently 
perform the procedures after a short period of training, especially as the complex inulin 
studies have been replaced. Non-experienced surgeons will likely take longer, but careful 
planning can reduce the number of rats required for training and ensure maximum usage of 
the rat (such as removing the inguinal fat pad beforehand for extraction of stem cells). Early 
involvement of the named veterinary officer during training and subsequent experiments is 
essential for animal welfare, training, and experimental support and to ensure the principles 
of 3Rs are being upheld. 
 
In conclusion, this animal model better mimics the transplant patient, is less technically 
challenging and is less time-consuming. It has pushed the boundaries of the severe renal IRI 
rodent model. By reducing rat numbers required for training and experiments and reducing 
the potential risks of surgery, this model adheres to and promotes the 3R principles. 
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However, it has yet to be demonstrated if these renal failure changes caused by the 2/3 
nephrectomy have a significant impact on the kidney recovering from IRI or the therapies 



































CHAPTER 5:  
BIODISTRIBUTION OF ADIPOSE DERIVED STROMAL VASCULAR FRACTION 





A vast array of factors can alter the biodistribution of administered regenerative cells such 
as route of administration, cell source, method of cell preparation. Recipient inflammation, 
hypoxia, repair, and malignancy can also modify their movements. To our knowledge little 
data exists on the biodistribution of ADSVF administered via the renal artery in a bid to 
ameliorate renal IRI. 
 
It is essential that we better understand the biodistribution of administered cells to ensure 
safety, effectiveness, and aid mechanistic understanding. Furthermore, biodistribution 
knowledge is crucial when it comes to dosage regimes as we know from some safety studies 
that thromboembolic events are a potential risk from high dosage regenerative cell therapies. 
 
 
Stem Cell Labelling and Tracking 
 
To acquire biodistribution data, a variety of labelling and imaging techniques are available. 
Popular methods of imaging include bioluminescence, fluorescent, MRI, CT, ultrasound, 
and nuclear imaging. Each has its advantages and limitations. Considerations when choosing 
the right modality include resources, experience, available expertise, the size of the animal 
or tissue and the length of time tracking is required. Often a combination of modalities is 
used, and with each modality, there is an ever-expanding repository of labelling techniques 
and molecules.  
 
The PerkinElmer In Vivo Imaging System® (IVIS) (PerkinElmer, Massachusetts, USA) is 
an optical imager that can perform either trans-illumination or epi-illumination with its range 
of 28 high-efficiency filters. It can detect bioluminescent and fluorescent reporters from the 
blue to near-infrared wavelength {PerkinElmer:va}. Its high sensitivity and resolution make 
it suited to in vivo small animal imaging or ex vivo imaging of harvested organs for higher 
sensitivity. In vivo, imaging also allows for longitudinal imaging if required, and the lack of 
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radiation makes it a safer alternative to modalities such as Computed Tomography and 
positron emission tomography. 
 
Unlike pharmacological agents, regenerative cells may not merely be metabolised and 
excreted. They can migrate, proliferate, and integrate. To track administered cells with a 
fluorescent imaging modality like the IVIS, the administered cells of interest need to be 
labelled. An ideal label will be non-toxic, stable, highly fluorescent, have minimal cross-
contamination and have a cost-effective and straight-forward labelling process.  Widely used 
cell tracking labels include carboxyfluorescein diacetate succinimidyl ester (CFDA-SE), 
carboxyfluorescein succinimidyl ester (CFSE) and PKH26. Lipophilic dyes in the far-red 
spectrum, such as carbocyanine DiOC18 (DiR), have excellent fluorescent properties and 
make them an attractive label, particularly with whole-body imaging. However, like all dyes, 
contamination of dye to the microenvironment can be an issue; therefore, cross-validation 
with another dye or modality is necessary (Lassailly et al. 2010). 
 
 
Routes of Administration of Regenerative Cells  
 
There are multiple routes in which stem cells can be administered for therapeutic use. Intra-
arterial and intra-venous administrations via major arteries and veins such as those in the 
neck provide an easily accessible route of administration. High doses can be given in a short 
period, and the risk of clogging up vessels is reduced compared to using smaller vessels, and 
in many clinical studies, this route is safe. Other research has looked at more targeted 
administration to aid the therapeutic intent, such as into the supplying artery of a particular 
organ of interest. However, the technical difficulties and risks can diminish the advantage of 
direct injection to the organ. Non-intravascular routes like intraperitoneally, subcutaneously, 
intramuscularly, and direct injection into organs such, as the liver or heart, have also been 
researched. 
 
Stem cells delivered into major veins, such as the external jugular, appear to get trapped in 
the microvasculature of the lungs as described since 2003 by Barbas et al. and has 
subsequently been reproduced in several other studies (Barbash et al. 2003). Initially, what 
was not clear was whether the trapped cells in the lung were living and continue to have the 
pluripotent capacity. However, in more recent studies of cells injected into the lung, it seems 
that the cells remain living for the first 24hr and soon after disappear (Eggenhofer et al. 
2013). The majority of the signal seen 24 hours post-administration via a major vein, is 
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within the liver but on analysis, these cells are not living, and the signal represents cell debris 
or phagocytosed labelled cells (Eggenhofer et al. 2012).  
 
To get around the microvasculature of the lung, intra-arterial administration or direct organ 
arterial administration has been attempted. There has been a particularly abundant volume 
of research in using intra-arterial administration in cardiology and the management of 
ischaemia of the heart. Intracoronary and intracardiac administration of stem cells has 
advanced to clinical trials with favourable outcomes on ventricular function (Brehm & 
Strauer 2006; Strauer et al. 2005). Many studies have demonstrated the administration of 
cells intra-arterially significantly reduces the incidence of stem cells becoming trapped 
within the lung microvasculature (Mäkelä et al. 2015) and have increased uptake at target 
organs (Toupet et al. 2015). There have also been studies looking at direct renal artery 
injections as we propose. Previously concern was raised that intra-arterial administration 
caused entrapment and occlusion in the microvasculature of first-pass organs. However, a 
study found that bone marrow-derived stem cells injected directly into the renal artery of 
cats with IRI did not have a detrimental clogging effect. Similar to the rodent models, the 
stem cell recipient cats had fewer degenerative changes on histology and less apoptotic renal 
tubular epithelial cells (L.-J. Wang et al. 2019). A multicentre randomised control trial 
involving 21 cases found umbilical cord-derived stem cells delivered directly into the renal 
artery at the time of transplantation to be safe and feasible (Q. Sun et al. 2017). Nevertheless, 
there is evidence that once a threshold concentration is reached there can be occlusion of the 
microvessels when administered intra-arterially, especially into arteries directed to single 
organs with microvasculature such as the kidney or brain. Li-li A Tan et al. also found that 
velocity of administration can enhance the micro-embolic complication; however, these 
effects as far as we can see have not been seen in human-sized organs (Cui et al. 2015).  
 
 
5.2 HYPOTHESIS  
 
Administration of adipose-derived stromal vascular fraction, via the renal artery in an animal 









Adipose tissue was retrieved from the inguinal fat pad of adult Fischer 344 rats. The stromal 
vascular fraction (containing the adipose-derived stem cells) was isolated from the adipose 
tissue, and the cells were labelled. The labelled ADSVF was then administered via the renal 
artery in our model of rat renal ischaemia reperfusion injury. The rats were sacrificed at 1 
hour, 24 hours, 48 hours, and 1-week post-administration of ADSVF. Organs were retrieved, 
directly imaged in the IVIS, and processed for histological analysis to determine the location 
of labelled cells in the major organs or processed for flow cytometric analysis. 
 
Total radiance efficiency was used to measure the fluorescence of each organ. Weights of 
animals were recorded at multiple time points, including at termination. All rats used were 
adult Fischer 344 of similar ages and size. Organs were imaged ex-vivo.  
 
 
5.3.1 ANIMAL HOUSING AND HUSBANDRY 
 




5.3.2 ISOLATION OF ADIPOSE DERIVED STOMAL VASCULAR FRACTION 
FROM ADIPOSE TISSUE 
 
Adipose tissue was obtained from the inguinal region of adult Fischer 344 rats. The retrieval 
of rat adipose tissue is described in chapter 2.2. Isolation of adipose-derived stromal vascular 
fraction were conducted in a standard fashion, as previously described in section 2.4. 
 
 
5.3.3 QUANTIFICATION, STORAGE AND PREPARATION OF ADSVF FOR 
ADMINISTRATION 
 
Quantification, storage, and then subsequent preparation of ADSVF for administration was 
conducted in standard fashion, as previously described in section 2.5. 
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5.3.4 LABELLING OF ADIPOSE DERIVED STOMAL VASCULAR FRACTION 
FOR ADMINISTRATION 
 
For IVIS imaging and flow cytometric analysis, ADSVF were labelled with the near-infrared 
fluorescent lipophilic DIR (ThermoFisher Scientific). The cellular membranes were labelled 
according to the manufacturer's protocol. For rats that would undergo fluorescent imaging 
of organ sections, PKH26 (Sigma-Aldrich, UK) lipophilic dye was used. Cells were labelled 
as per recommended Sigma-Aldrich protocol. 
 
 
5.3.5 GROUP SELECTION 
 
Adult male Fischer 344 rats were randomly assigned to either a control group or treatment 
group. Control group received PBS with 10% rat serum, and the treatment group received 
7E+5 to 1E+6 labelled ADSVF. The different time points at which the rats were terminated 
are 1 hour, 24 hours, 48 hours and one week. 
 
 
5.3.6 RENAL ISCHAEMIA REPERFUSION INJURY MODEL, ADMINISTRATION 
OF THERAPIES AND PERIOPERATIVE CARE 
 
The ischaemia reperfusion injury model is described in detail in chapter 4. In brief, male 
adult Fischer 344 rats undergo a 2/3 nephrectomy of the right kidney. The rat is recovered 
for at least two weeks before undergoing surgery in which the left renal artery is clamped 
for 120 minutes. Prior to releasing the clamp, the labelled ADSVF or control is administered 
via the left renal artery. At 120 minutes the clamp is removed, and reperfusion of the left 
kidney ensues. The animal is then recovered, and its post-operative care is given as described 
in chapter 4.3.6. Rats were then terminated at specific timepoints and organs analysed for 
biodistribution of ADSVF. 
 
 
5.3.7 ORGAN RETRIEVAL AND PROCESSING 
 




5.3.8 WHOLE ORGAN FLUORESCENT IMAGING 
 
As each organ was retrieved, it was individually placed in a Petri dish containing PBS to rid 
surface blood then placed in another Petri dish with PBS. The organs were stored at 4oC in 
darkness as the rest of the organs are being retrieved. Time for all organs to be retrieved 
averaged less than 10 minutes. The organs were then immediately taken to the IVIS scanner 
(covered from light) for imaging located in the same facility. 
 
Figure 5.1. Retrieved rat organs in standard position ready of IVIS imaging.  
 
 
The PerkinElmer In Vivo Imaging System® (IVIS) is a non-invasive imaging device that 
uses a set of filters which allow detection of bioluminescent and fluorescent reporters across 
the blue to near infrared wavelength region {PerkinElmer:va}. Organs were laid out in the 
IVIS in a standard layout mimicking in vivo positioning (Fig. 4.1) and scanned using the 
following settings:  
• Epi-illumination 
• 2D imaging only 
• Fluorescence is measured in Radiant efficiency (total) 









• Binning: small (see IVIS tips and trick at CTAC.mbi.ufl.edu) 
• Excitation filter 680 for DiR and 551 for PKH26 
• Emission filter 700 for DiR and 567 for PKH26 
• The aperture (f/stop) was set at 2 
Images were saved and analysed using the PerkinElmer In Vivo Imaging Software for the 
IVIS imaging systems®. The software was used to identify regions of interest, label organs 
and measure the radiant efficiency so that organ fluorescence could be analysed. 
 
 
5.3.9 RENAL HISTOLOGY PREPARATION 
 
Organ retrieval was described in chapter 2.6 and organs were imaged as described in chapter 
5.3.8. After imaging in the PerkinElmer In Vivo Imaging System® they were immediately 
removed two thirds of the organ was stored in 10% formalin. The remaining third was used 
for flow cytometry described below. After three to seven days of being fixed in 10% formalin 
the organs were then transferred to 70% ethanol for a further 48 hours before being subjected 
to a tissue dehydration and paraffin embedding process. All tissues were then sectioned at 5 
micrometres. During storage and transportation, the tissues were kept in darkness. 
 
 
5.3.10 SECTIONED TISSUE FLUORESCENT IMAGING 
 
Paraffin embedded organs were sectioned into a thickness of 5 micrometres then transferred 
to histological glass slides. Unstained sections were imaged using the Odyssey CLx, LI-
COR® (Biosciences Ltd.) fluorescent imager. Scanning was performed using the 700 
Channel Laser Sources (which is the lowest and has a wavelength of 685 nm nanometres) 
for detecting PHK26 labelled ADSVF. Program was set at 42 µm resolution and 0 mm offset 
with the lowest quality. Scan setting were the same throughout all section imaging. A 
freehand region of interest (ROI) was created to define the outline of the organ using 
Odyssey software. To determine the organ biodistribution of ADSVF within the kidney, ROI 
were measured in two areas, renal cortex, and renal medulla. Signal intensity was measured 





5.3.11 FLOW CYTOMETRIC ANALYSIS 
 
Once the rat was terminated at the designated time point, the organs were retrieved as 
described in section 4.3.7. One third of each organ was immediately stored in 20mM HEPES 
PBS (Sigma Aldrich) at 4oC. The organ was then mechanically homogenised to 1mmx1mm 
then incubated with a digestive enzyme solution (hyaluarinase 1.33mg/ml, collagenase 1S 
18.36 mg/ml, collagenase X1 1.56mg/ml, Sigma Aldrich). After red blood cell lysis buffer 
(Miltenyi Biotec SAS) was added to the suspension it was washed in PBS and diluted 1-8 
million cells/ml. Cells were incubated with the rat 2.4G2 Fcyll blocker (BD Biosciences, 
San Jose, CA) and surface markers for 60 minutes. Cells were then fixed in 4% solution, and 
resuspended in 2% albumin (PAN-Biotech, Aidenbach, Germany) in PBS. Fluorescence was 
measured using a Fortessa flow cytometry (BD Biosciences). Each sample contained at least 
200,000 viable cells using FSC x SSC gating and viability (e780) negative. Gating was 
determined by both single-stained control and fluorescence minus one control. FlowJo 
software version 10 (Ashland, OR) was used for data analysis. Table 3.1 describe the 
markers used to interrogate ADSVF. 
 
Statistics. A 2-way student’s t-test was carried out to determine the differences in the mean 
average for sample sizes >5 of equal variance. Mann-Whitney U test was used to analyse 
smaller sample sizes. One-way ANOVA and a Tukey post hoc test was used to detect 
differences between the means of two or more groups. Analyses was performed with Prism 
6.02 (GraphPad, San Diego, CA). Mean and standard error of mean (SEM) are displayed. 
Significance was considered for p values <0.05 (*) but included p values <0.01 (**), and 

















5.4.1 EX-VIVO FLUORESCENT IMAGING OF ORGANS  
 
In each rat after 24 hours, the highest signal, on IVIS scanning, is seen in the liver, followed 
by both kidneys then spleen and lungs (Fig. 5.2a). Due to scale settings, fluorescence in the 
lungs of rat 2 is likely autofluorescence. Focal hot spots can be seen in the left kidney in rat 
two even under IVIS scanning. In comparison to other organs within the rat, there is no 
signal in the brain. Imaged sections of the left kidney better demonstrated the focal signal 
spots seen on whole organ IVIS imaging (Fig. 5.2b). In particular, the signal is around the 
edges likely representing the renal cortex. No such focal spots of DiR labelled cells were 
seen in any other slides under LI-COR imaging, including the liver.  
 
In F344 rats 48 hours post-ADSVF injection, intense focal signal points are seen within the 
left kidney (Fig. 5.3). Again, the liver had a diffuse signal. The spleen after 48 hours appears 
to fluoresce brighter when compared to 24 hours.  No evidence of signal in the remaining 
organs relative to the kidneys, liver, and spleen. The picture was similar after one week (Fig. 
5.4). However, this time signal was now more prominent in the spleen and liver compared 
to the other organs. The left kidney still showed some focal spots of signal.  
 
IVIS images of rats treated with PBS and 10% rat serum did not have any of the focal 
hotspots seen in rats that received labelled ADSVF (Fig. 5.5). The liver did not overly emit 
signal compared to other organs. The organs with the highest radiant efficiency were the 
kidneys. Nevertheless, imaging sections of these control kidney did not identify any signal 
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Figure 5.2 DiR labelled ADSVF can be seen in the left kidney 24 hours post 
administration via the left renal artery. Fluorescent images of experimental rats which 
underwent severe renal IRI of the left kidney, as described in chapter 4, then received DiR 
labelled ADSVF via the renal artery and terminated 24 hours later. (A) Ex vivo IVIS imaging 
of organs from 2 rats demonstrated the appearance of increased signal within both kidneys 
and the liver with intense hotspots within the left kidney. (B) LI-COR® images of organ 
sections from the same 2 experimental rats confirms signal within the left kidney but no 














Figure 5.3 DiR labelled ADSVF can be seen in the left kidney 48 hours post 
administration via the left renal artery.  Fluorescent images of experimental rats which 
underwent severe renal IRI of the left kidney, as described in chapter 4, then received DiR 
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labelled ADSVF via the renal artery and terminated 48 hours later. Ex vivo IVIS imaging of 
organs from 4 rats demonstrated the appearance of strong signal hotspots within the left 
kidneys only of 3 out of the 4 rats. There is the appearance of some increased signal to a 
lesser degree from the liver. No signal emitted from lungs, heart, and brain in comparison to 





Figure 5.4 DiR labelled ADSVF can be seen in the left kidney 1 week post 
administration via the left renal artery. Fluorescent image of the experimental rat which 
underwent severe renal IRI of the left kidney, as described in chapter 4, then received DiR 
labelled ADSVF via the renal artery and terminated 1 week later. Ex vivo IVIS imaging of 
the rat demonstrated the appearance of strong signal hotspots within the left kidney, liver, 
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Figure 5.5 Rats which receive unlabelled ADSVF demonstrate no signal hotspots in the 
left kidneys. Fluorescent images of experimental rats which underwent severe renal IRI of 
the left kidney, as described in chapter 4, then received unlabelled ADSVF via the renal 
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artery and terminated at various time points. (A) Ex vivo IVIS imaging of organs from 2 rats 
terminated after 48 hours have no increased signal within the left kidney. Although no 
hotspots are seen there is the appearance of increased signal in the right kidney compared to 
other organs. (B) Similar appearances are seen after 1 week. (C) LI-COR® images of organ 




5.4.2 SECTIONED TISSUE FLUORESCENT IMAGING 
 
Comparisons were made between left kidney sections of rats that were given vehicle control, 
labelled ADSVF but no IRI or labelled ADSVF in a rat model of renal IRI. For the following 
analysis, cells were labelled with PKH26 as the LI-COR® fluorescent imager has the optimal 
filters for its excitation and emission range. Although DiR emitted a strong signal detectable 
in the IVIS animal scanner, the LI-COR fluorescent imager available, used for imaging 
sections, did not have the optimal filters for the DiR excitation and emission range.  
 
Four rats were in each group and four sections, each containing two slices of the kidney, 
were imaged from each rat. The left kidney of rats that received labelled ADSVF had higher 
signal than the vehicle control-treated rats (Fig. 5.6). A statistically significant difference 
between groups was determined by one-way ANOVA (F (2,9) = 8.738, p =0.0078). A Tukey 
post hoc test revealed that vehicle control group had statistically significantly lower signal 
intensity (56963 ± 22421, p = 0.0061) compared to the labelled ADSVF, no IRI, group 
(252000 ± 42994). 
 
Looking at the labelled ADSVF treated kidneys in more detail, regions of interest were 
drawn round the medulla and cortex regions of the kidney. The medullary regions of vehicle 
control and labelled ADSVF treated kidneys did not seem to have any difference in signal 
intensity. However, in the cortex of the kidney there was an increase in signal in the labelled 
ADSVF treated kidneys (Fig. 5.7). Referring to the preliminary LICOR images (Fig 5.2b) 
in which the cells were labelled with DiR, the labelled cells again appear to be collecting 
within the cortex. 
 
Only the left kidney had a significant increase in signal intensity after injection of labelled 
ADSVF. No increase was seen in the lungs. There is an increase in signal, above 
autofluorescence, seen in the liver sections after the administration of labelled ADSVF but 
 147 





Figure 5.6. Kidneys which receive fluorescently labelled ADSVF via their renal artery 
have significantly higher signal compared to kidneys which receive non-labelled vehicle 
control. Fluorescent imaging of sections performed on left kidneys post treatment with 
PKH26 labelled ADSVF or vehicle control in rats terminated 48 hours post administration. 
Labelled ADSVF no IRI, n=4, labelled ADSVF with IRI, n=4, vehicle control with IRI, n=4. 
4 sections taken of each kidney. (A) LI-COR® images of corresponding kidney section (B) 








































labelled cells have increased fluorescence. There is a significant increase in signal between 
left kidneys which received labelled ADSVF and had no IRI and kidneys that underwent IRI 
and received vehicle control. Significance was considered for p values <0.05 (*) but included 




Figure 5.7. The cortex of kidneys which receive labelled ADSVF via the renal artery 
has higher signal intensity compared to the medulla. Signal intensity measured from 
fluorescent imaging of sections of left kidneys, divided into medullary and cortex regions, 
post treatment with PKH26 labelled ADSVF or vehicle control in rats that undergo IRI. Rats 
terminated 48 hours post IRI/administration of cells.  PKH26 labelled ADSVF, n=4, vehicle 
control, n=3 4 sections were measured for each organ. (A) LI-COR® images with marking 
separating cortex region and medullary region. (B) Quantification of LI-COR® scans of 
cortex and medullary region of left kidney tissue sections. In the labelled ADRC group, 
sections demonstrate an increase in signal intensity in the cortex compared to the medulla. 
Comparing the cortex of kidneys which received labelled and unlabelled cells there is an 
increase in signal in the cortex of the labelled cells group compared to the cortex of the 
unlabelled cells group. Significance was considered for p values <0.05 (*) but included p 











































Figure 5.8. In rats that receive labelled ADSVF, apart from the liver, no organs have 
increased signal intensity when compared to rats that receive vehicle control. 
Fluorescent imaging of sections of organs (except left kidney which is described in figures 
5.6 and 5.7) from rats administered, via the renal artery, with PKH26 labelled ADSVF with 
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terminated 48 hours post IRI and administration of ADSVF/vehicle. Summary of 
quantification of LI-COR® scans. The liver in rats that receive labelled ADSVF have 
increased signal intensity compared to the liver of rats that receive vehicle control. However, 
the increase was not significant.  There is no increase in signal intensity in any organ that 
receives labelled ADSVF compared to organs which received vehicle control. Significance 




5.4.3 FLOW CYTOMETRIC ANALYSIS 
 
To confirm that administered ADSVF are present within the kidney, as demonstrated by 
fluorescent imaging, flow cytometric analysis of the left kidney was performed. After gating 
for the viable cell population, over 1000 viable labelled ADSVF were detected after 
interrogating 2 million kidney cells (Fig. 4.9). Unpublished work by Dr 
Chawangwongsanukun, on organs retrieved from the rats used in this thesis, nicely 
demonstrates PKH26 cells within the glomerulus under fluorescent confocal microscopy at 
40x magnification (Fig. 5.9).  
 
Further analysing demonstrates an almost 50:50 distribution of CD45+ and CD45- cells. 
Almost all the CD45+ cells were CD8 T cells. The majority of the CD45- cells were pericyte 
like cells. There was also a respectable mesenchymal stem cell-like population identified 
(Fig. 5.10). Comparing this to the ADSVF population prior to injection via the renal artery 



















Figure 5.9. ADSVF administered via the renal artery collect within the cortex and 
strongly associate with the capillary bed of the glomeruli. Rats underwent renal IRI and 
received PKH26 labelled ADSVF via the renal artery. 48 hours later rats were terminated, 





























microscopy and homogenated kidney analysed by flow cytometry to look for viable labelled 
cells. (A) ADSVF are seen in the injured kidney collecting within the cortex and strongly 
associated with the capillary bed of the glomeruli. (B) Interrogating 2 million events with 
flow cytometry approximately 1000 viable DiR labelled cells could be recovered from the 
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Figure 5.10 Of the ADSVF detected in the kidney after renal artery injection, there is 
an equal split of leukocyte and stomal cells. Flow cytometric extraction of DiR labelled 
cells from left kidney 48 hours post administration of DiR labelled ADSVF, via the renal 
artery, in rat model of IRI (n=4). Extracted cells interrogated further using flow cytometry. 
(A) The majority of CD45+ cell found to be CD8 T cells. The majority of CD45- cells found 
to be pericyte like cells (CD146+) with some mesenchymal stromal cells also identified 
(CD90+ CD34-). (B) Comparing the CD8 T cell and pericyte like cell population of ADSVF 
prior to administration and from recovered ADSVF post administration demonstrates that 
the CD8T cells and pericyte like cells now make up a far larger proportion of the ADFSVF 
population once extracted from the injured kidney. Significance was considered for p values 


































































































From published studies and our groups own work, most injected ADSVF are not detectable 
after one week and likely have their ameliorative effect within the first 48 hours; therefore, 
we concentrated on 24- and 48-hours post-injection and limited operations on rats at one 
week. For this section of the analysis, ADSVF was labelled with DiR as this gave a much 
better signal on IVIS scanning of ex vivo organs compared to PKH26 labelled cells. PKH26 
was used for the fluorescent imaging of tissue sections, therefore, using two different 
modalities to label the administered ADSVF. Particular attention was given to the kidneys 
and liver as they had the most prominent signal on IVIS imaging. The lung was also of 
particular importance as evidence suggests that systemic intravenous administration of 
stem/stromal cells get trapped in the lung. 
 
Many variables make it difficult to quantify and directly compare different organs, including 
the same organs from different rats using a fluorescent optical imager. Fluorescence can be 
affected by the size of the organ and composition, the volume and efficacy of administration, 
the labelling process and efficacy, the retrieval of the organs and the regions of interest 
created for analysis. Many of these factors could be counteracted by high sample numbers, 
but in keeping with the principles of the 3Rs and due to the complex surgery and long 
recovery, this was not an attractive option. However, analysis comparing organs taken from 
the same rat and viewed under identical parameters can allow for some qualitative analysis 
and indication of distribution. 
 
The ex-vivo fluorescent imaging provides an initial overall indication of any hotspots or 
increased uptake in a particular organ. Imaging settings for each rat is identical, but the scale 
used when producing the visual pictures were adjusted to fully represent as best as possible 
the fluorescence of the organs. Autofluorescence is a significant limitation, making small 
quantities of labelled ADSVF within the tissue undetectable.  Therefore, the IVIS images 
were not used to quantify fluorescence. However, the images were used to gauge changes in 
the distribution of fluorescence between organs at different time points. IVIS imaging was 
also able to pick up focal signal hotspots in the left kidney, which persisted for up to 1 week. 
We then focused on sectioned imaging to get more accurate analysis and validate the signal 
increase found from the IVIS images. 
 
IVIS images taken 24 hours post-injection of the ADSVF (Fig. 5.2) show high fluorescence 
within the liver. This most likely represents autofluorescence, cell debris containing the dye 
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or dye itself. From other studies, we know cell debris and dye can be phagocytosed and end 
up in the liver where it is likely metabolised (Schmuck et al. 2016; Leibacher & Henschler 
2016; Eggenhofer et al. 2013). Therefore, we cannot evaluate the liver the same way we 
would other organs which may have had increased signal due to ADSVF homing or 
entrapment within that organ. When looking at imaged histological sections of liver, there 
are no focal hotspots, unlike the section of the left kidney, further supporting the 
fluorescence of the liver as autofluorescence or diffuse infiltration of dye/cell debris. The 
liver is the largest organ imaged and sectioning it did not detect a significant increase in 
fluorescence, but perhaps if experimental rat numbers were higher, it might detect an 
increase. Alternatively, the IVIS images were perhaps able to detect potentials differences 
as it looks at the whole liver which will contain an increased number of total labelled cells, 
but when divided into thin sections, the concentration of fluorescence per section is only 
modestly increased. 
 
After 48 hours and one week, the liver remains one of the most fluorescent images for likely 
the same reasons and not dissimilar to other studies. Following on from this it would be 
worth testing for any viable ADSVF within the liver at different the time points (as we did 
with the left kidney). If a viable ADSVF cell population is present, like the flow cytometry 
findings of the injected kidney, then monitoring of liver function should be a consideration 
if ever using ADSVF in a clinical setting. 
 
In addition to the liver, the left kidney was found to have very high signal intensity. The left 
kidney, which is the kidney that undergoes IRI and injection of labelled ADSVF, appears to 
have very high focal areas of signal intensity which differs from the liver’s diffuse signal. 
When the left kidney is sectioned and imaged, there are hotspots throughout the kidney 
which is not seen in any other organ. Whole organ IVIS imaging and kidney sectioning 
imaging highly suggests that DiR labelled ADSVF remain in the kidney for at least 24 hours 
(Fig. 5.2). From the whole organ IVIS images taken at 48 hours (Fig. 5.3) the picture is 
similar with robust focal hotspots remaining. Fluorescent imaging of the left kidney sections 
looking for PKH26 labelled ADSVF (Fig. 5.6) confirmed a significant increase in the signal 
intensity of rats that received ADSVF labelled with PKH26 compared to the control. It was 
initially surprising that there was a significant increase in the ADSVF no IRI group 
compared to the control and not between the ADSVF IRI and control group (Fig. 5.6). If 
anything, the addition of IRI would have further increased the signal intensity of the ADSVF 
IRI group. Qualitatively there looked to be more signal intensity within the ADSVF IRI 
group compared to control. Perhaps if the number of samples in each group was increased, 
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reducing the effect of the many variables described before, then this increase in the signal 
would have reached significance. 
 
When these sections are analysed further, we can see that the signal intensity of the renal 
cortex of PKH26 labelled ADSVF treated kidneys has a significantly higher signal compared 
to the medulla. The medulla signal intensity from labelled ADSVF treated kidneys and 
vehicle control-treated kidneys remain similar (Fig.5.7) indicating that by 48 hours, the 
majority of ADSVF within the kidney are residing within the cortex. No increased uptake in 
the medulla suggests that administered cells or associated EV are not being filtered out. The 
labelled cells are potentially being trapped by the microvasculature of the glomerulus which 
resides in the renal corpuscle and cortex. Nevertheless, we know form histological and 
functional studies if this is the case then it is not detrimental to organ function up to a 
particular concentration of cell therapy. Fluorescent confocal microscopy confirms the 
presence of PKH26 labelled cells within the glomerulus of the renal corpuscle (Fig. 5.9).  
 
Within a specific concentration range, the administered ADSVF improves renal function 
(chapter 1 Fig. 1.5). This clogging effect of high dosages will likely be less of an issue on 
larger human-sized organs, and will likely allow for higher concentrations of ADSVF, but 
further studies or porcine kidneys may be necessary to safely titrate up to find a maximum 
dose with no occlusive effect. An alternative theory is that the ADSVF may have a strong 
affinity to remain within the damaged renal cells due to chemo-attractants released by the 
damaged renal cells and adhesion molecules of the ASC. From here within the renal cortex, 
and likely the renal corpuscle, the ADRCs can exert their paracrine effect. Kidneys that 
received ADSVF but did not undergo IRI continue to have an increase signal intensity within 
the cortex. This does not rule out the chemo-attractant effect of the injured renal cells. Even 
in the non-IRI model, there is still a period of ischaemia when the renal artery is transected 
for ADSVF injection (around 20 minutes ischaemia compared to 120 minutes ischaemia in 
the full IRI model). Flow cytometry of ADSVF injected left kidneys (Fig. 5.9) further 
confirms the presence of viable ADSVF within the kidney at 48 hours; likely secondary to 
a combination of being trapped in the microvasculature and the chemo-attractant/homing 
properties of injured kidney cells. 
 
In some imaging, the right kidney displayed high signal intensity; however, this is unlikely 
due to the presence of labelled ADSVF. For labelled ADSVF to get trapped in the right 
kidney, they would need to pass through the left kidney microvasculature then into the 
inferior vena cava, through the heart and lungs before potentially entering the right kidney. 
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From previous studies in which labelled, stromal cells have been injected into major veins 
they are detected in the lung microvasculature and not in any significant numbers within the 
kidneys (Eggenhofer et al. 2012; Gao et al. 2001; Schrepfer et al. 2007).Therefore high 
signal intensity is likely due to necrosis of the right kidney as a result of 2/3 nephrectomy. 
The nephrectomy causes 2/3 of the kidney to become necrosed and hard, almost crystal-like, 
(Fig. 4.2). This could explain the appearances seen on IVIS imaging. It is not possible to 
create histological slides of the hard necrosed tissue, but slides created from the remaining 
healthy 1/3 of the kidney did not demonstrate any evidence of labelled cells.   
 
Lungs, heart, and brain did not show any fluctuance of fluorescence compared to the other 
organs in the same rat when imaged as whole organs under the IVIS. When these organs 
were prepared into histology slides and analysed under the LI-COR, there were no 
significant changes in fluorescence like seen in the left kidney. That does not necessarily 
mean there are no ADSVF in theses organs but just not a detectable concentration. It is 
unlikely that any cells that do manage to travel to any of these organs will be in any 
significant quantity to have any detrimental effect. Particular attention was given to the lungs 
due to reason described in the introduction, but there is no convincing evidence of any viable 
ADSVF trapped within the microvasculature. Therefore, it is likely that the highest 
concentration of ADSVF is in the left kidney compared to any other organ and the concern 
of ADRCs getting trapped in the lungs may be bypassed by administration via the renal 
artery. Also, we had no unexplained deaths in control or treatment group despite over 70 
operation, further supporting no significant occlusion of the lungs. To further emphasise this 
point we could in the future perform flow cytometric analysis on the lungs to look for any 
viable ADSVF and 40x magnification of lung microvasculature to look for any vessel 
“clogging” as seen in intravenous administration.  
 
The spleen at 24 and 48 hours seem to show some increased fluorescence compared to lung, 
heart, and brain, but this was likely due to autofluorescence as sectioned images did not show 
increased fluorescence. At one week, there was strong signal intensity with some hotspot’s 
matching that of the left kidney. The spleen was not sectioned at one week and it would be 
sensible to consider doing this in the future. Currently, it would not be unreasonable to 
suggest that this increase in splenic signal represents diffuse infiltration of non-viable 
ADSVF, ADSVF debris or dye being collected by the splenic macrophages or ADSVF 
leukocytes homing as they filter the blood (Bronte & Pittet 2013). 
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The majority of the biodistribution studies concentrated on the first 48 hours. PKH26 is not 
ideal for long term tracing. Peng Li et al. found that debris from PKH26 labelled ADRCs 
when injected without ADRCs can be detected by immunofluorescence microscopy at day 
7 post-injection in the liver, spleen, kidney and brain (P. Li et al. 2013). In our mechanistic 
studies, described in chapter 5, a major therapeutic effect of the ADSVF was detected within 
the first 48 hours. In addition, studies have failed to detect any living stem cells long-term 
reliably; hence the biodistribution study here concentrate 48 hours post-injection.  
 
From initial clinical trials using ADSVF, the leading potential causes of concern are 
thromboembolic events, tumorigenesis, and immune activation. From injecting the kidney 
via the renal artery, up to a particular therapeutic dose, we have not seen any evidence that 
ADSVF collects in high enough volumes to cause detrimental occlusion of the blood supply 
of the left kidney. Despite their presence confirmed within the kidney. Therefore, it is 
unlikely for ADSVF to pass through the microvasculature of the left kidney and cause 
occlusion in distant organs.  
 
Many factors affect the biodistribution of ADSVF and mesenchymal stromal cells other than 
the route of administration. Even studies investigating biodistribution after being 
administered via the same route have had different results.  Schmuck E et al. found the 
highest retention of stem cells within the liver after labelling them with Qdots, injecting them 
into the jugular vein and using three-dimensional cryo-imaging (Schmuck et al. 2016). 
Contradicting many studies that found the majority of the labelled cells administered via a 
central vein end up in the lung – Fischer et al. found 99% of administered MSCs in the lung 
(Fischer et al. 2009). These differences are likely contributable to the animal model, cell 
source and preparation, labelling and detection techniques and time intervals at which they 
are injected. All studies failed to find viable stem cells mid to long term. Like our flow 
cytometry results looking for viable ADSVF population after 48 hours, Eric Scmuck et al. 
detected less than 0.6% of the total cells infused by day 2, 4 and 8 (Schmuck et al. 2016).  
 
Superparamagnetic iron oxide nanoparticle (SPION) labelling of ADSVF and MRI scanning 
of the kidney in vivo was also attempted. Excellent MRI images of the kidney were obtained, 
but detection of the SPIONS were not demonstrated. Due to IVIS being more successful, 
technically easier, and more accessible compared to the MRI scanning, we continued with 
IVIS scanning. However, the MRI images could certainly be revisited in the future especially 
for longitudinal analysis of kidney injury over time within the same animal.  
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In conclusion, ADSVF injected via the renal artery in a model of renal IRI can be detected 
in the injected kidney up to 48 hours post-injection. They can be seen within the cortex of 
the kidney where they have potentially become entrapped in the microvasculature of the 
glomerulus or are encouraged to stay by the chemoattract of the injured kidney. In the 
glomerulus, the ADSVF exert their paracrine ameliorative effects against IRI. By 24 and 48 
hours, there does not seem to be any ADRCs in any other organ at a significant 
concentration. The brutality of the injection process, the harsh environment in which they 
enter, the microvasculature that they need to pass through, and their short life span make it 
unlikely that many living cells pass through the kidney into generic circulation and have any 
additional clinical significance. Renal artery injection prevents the immediate entrapment of 
cells in the lung. Therefore, administration of ADSVF via the renal artery in an animal model 
of renal ischaemia reperfusion injury is an effective method of delivery and reduces non-
targeted biodistribution. 
 
During human kidney transplantation, administration of ADSVF via the renal artery could 
allow for maximal delivery of ADSVF to the kidney with reduced risk of adverse or toxic 
effects of ADSVF in other organs and open the door to higher therapeutic dosage regimes. 
However, discrepancies between the calibre of rat and human renal microcirculation need to 
be further investigated. Porcine animal models or kidney perfusion rigs using human 
ADSVF are two potential methods that could be considered. Determining the therapeutic 























MECHANISM OF ACTION OF ADIPOSE DERIVED STROMAL VASCULAR 





Currently, there is no method to retrieve, store, transport and implant a kidney without it 
succumbing to injury from the ischaemia, which is initiated the moment the arterial blood 
supply to the kidney is reduced. This begins when the renal artery is clamped for resection 
or during suboptimal perfusion of retrieval from DBD and DCD donors. Ischaemia persists 
during the cold storage and transportation time and as the kidney is prepared and then 
implanted. The injury does not stop when the kidney has finally been implanted in the 
recipient. The arterial clamp is removed, and the kidney is reperfused with oxygenated blood 
once again. Ironically this essential reperfusion with oxygenated blood brings with it further 
injury. Together they are termed IRI. The pathophysiology of IRI (described in chapter one) 
involves hundreds of interconnected processes that alter cellular biology and physiology, 
which can ultimately lead to a permanent change in form and function. 
 
 
Improving Outcomes After Ischaemia Reperfusion Injury 
 
Historically as there was no clinically proven method of boosting the regenerative capacity 
of the kidney, most therapies targeting IRI have focused on reducing the extent of the injury. 
Streamlining the retrieval and transportation process, allocation tactics and implantation 
techniques have all helped reduce the CIT, and in return, the extent of the IRI. Other 
logistical techniques such as the development of rigs that allow the organ to be perfused 
during transportation or before implantation have become increasingly popular. Initially 
used in liver and thoracic organs they have recently seen increasing popularity in renal 
transplantation. They have the added advantage of allowing pre-implantation evaluation of 
perfusion and urine output. Perfusion rigs also offer the opportunity to administer therapies 
ex vivo. Techniques such as those described have certainly improved outcomes, but 
complexity and severity of IRI have so far defeated therapeutic strategies. 
 
Many therapies have been studied in the animal model of renal IRI, but only a minority of 
them have made it to clinical trials. Therapies showing promise in animal models include 
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hormonal therapies, such as oestrogen and beta-human chorionic gonadotropin and 
complement targeting therapies. Zheng et al. demonstration of improved renal function after 
the administration of an siRNA cocktail solution targeting complement 3, transcription 
factor RelB and apoptosis antigen 1 (Gueler et al. 2015; Zheng et al. 2016; Z. Feng et al. 
2010). Studies have also targeted the cell death pathways in renal IRI, including apoptosis, 
necroptosis, ferroptosis and MPT-driven necrosis. Lau et al. work that has shown mice 
receiving receptor-interacting serine/threonine kinase 3 (RIPK3) -/- kidney in a rat model of 
transplantation had better function and survival. They suggested this was due to the 
necroptosis pathway dependence on the RIPK1-RIPK3 complex and proposed inhibition of 
the cell death pathways could provide clinical benefit (Lau et al. 2013).   
 
Research has also focused on the immune system's response to IRI including the innate, 
adaptive and complement system. Reducing an exaggerated innate response, such as TLR 
inhibition or interleukin therapy or adenosine A2A receptor (A2AR) agonists therapy 
significantly reduces renal injury and improves function. All of which is promising, but these 
have not been successfully translated in clinical trials (Huang et al. 2015; Farrar et al. 2012).  
 
Despite all previous therapeutic interventions however, stem cells and their paracrine 
function demonstrate the greatest potential. They have been extensively researched in the 
battle against IRI for over 20 years. 
 
 
Stem Cells to Ameliorate Ischaemia Reperfusion Injury  
 
The definition, classification and terminology of stem cells are complex, disputed and 
evolving and is discussed in more details in chapter three. In brief, they can be classified 
based on their differentiation potential or their origin (Barzegar et al. 2019). Different 
sources, harvesting techniques, preparations such as cultured or uncultured, associated stem 
cell populations and extracellular vesicles, modifications and routes of administration make 
for thousands of combinations when it comes to stem cell therapy. That is one of the reasons 
that getting an exact mechanism of actions can be difficult. Also, stem cells have multiple 
mechanisms of action. They have shown to reduce cell damage and death and at the same 
time, increase proliferation and restore renal function after IRI.  
 
Chen et al. are one of many groups who have proposed that mesenchymal stem cells increase 
growth factors such as hepatocyte growth factor (HGF), IGF-1, TGF and VEGF improve 
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renal function after IRI (Xiaopeng Yuan et al. 2017). Reduction of pro-inflammatory 
cytokines such as CXCL12, IL- 6, TNF-α, IL-1β, IFN-γ, TNF, IFN-γ, TGF-β and increase 
of anti-inflammatory factors IL-10, fibroblast growth factor (FGF) have also been 
demonstrated (Sheashaa et al. 2016; Toyohara et al. 2015; J.-B. Zhang et al. 2017). It should 
be noted that the role of cytokines is dynamic; for example, CXCL12 increases after the 
injury to promote repair, but paradoxically can then become pro-inflammatory.  
 
Counteracting the injurious reperfusion aspect of IRI, stem cells in renal IRI have 
demonstrated properties that reduce oxidative stress by methods such as increasing the ROS 
scavenger glutothionine transferase and superoxide dismutase (Fahmy et al. 2017; Zhuo et 
al. 2013), reducing ROS production (Tarng et al. 2016) and preserving normal levels of 
electron fluxes in ATP synthesis (Lindoso et al. 2014). Paracrine effects are thought to be 
the mainstay of stem cell therapy in renal IRI. The old dogma that stem cells home to the 
area of injury, infiltrate and differentiate into renal cells has not been convincingly defined 
and is unlikely to play a significant role in the recovery after IRI. It is, however, likely that 
the stem cells encourage resident tubular cells to regenerate and to become more resistant to 
programmed cell death and injury.  
 
Of the stem cell sources, uncultured adult ASC could be considered one of the more easily 
accessible and abundant sources, especially intraoperatively at the time of transplantation. 
Besides, unlike other sources that require reprogramming and extensive lab preparation, this 
stem cell population can quickly be isolated from adipose tissue as part of the stromal 
vascular fraction (40 minutes using Cytori Celution CRS system, Cytori Therapeutics, San 
Diego, USA). They are safe for therapeutic use immediately or can be frozen for later use. 
The abundant supply reduces the need for culturing, but the option is available if desired.  
 
ASC and other components in the stromal vascular fraction have been used in numerous 
animal models of IRI. Sheashaa et al. found a significant reduction in serum creatinine, 
malondialdehyde and histological injury score in rats that received cultured adipose-derived 
mesenchymal cells (Sheashaa et al. 2016). They proposed that the stem cells, among other 
actions, ameliorated the oxidative stress and lipid peroxidation. A theory that was similarly 
demonstrated by Chen et al. (Yen-Ta Chen et al. 2011). The dampened ROS insult resulted 
in reduced cell death. 
 
Similarly, Zhang et al. demonstrated anti-apoptotic effects potentially due to a reduction in 
the anti-apoptotic regulator, B-cell lymphoma 2 (J.-B. Zhang et al. 2017). Also, they found 
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a significant decrease in pro-inflammatory cytokines (such as IL-6, IFN-y) and inflammation 
associated proteins (HGF and CXCL12) adding anti-inflammatory properties to the 
repertoire of adipose-derived mesenchymal stem cells. Moreover, many other studies can be 
found demonstrating the ameliorative effects ASC in renal IRI with anti-inflammatory, anti-
oxidant, and anti-apoptotic effects being the common demonstrated mechanisms (Yen-Ta 
Chen et al. 2011; Shih et al. 2013; K. Li et al. 2010; X. Zhao et al. 2016). There has been 
less evidence, however, to support the notion that adipose-derived mesenchymal stem cells 
home to the area of renal injury and differentiate into renal tubular like cells as suggested by 
the work of Li et al. (K. Li et al. 2010). 
 
However, most of these studies are looking at cultured ASC in animal models of IRI that are 
not as severe as the IRI sustained by the human kidney at the time of transplant. We envisage 
uncultured ADSVF directly injected into the renal artery at the time of transplantation as the 
artery is easily accessible. ADSVF can be processed from adipose tissue in less than 40mins 
therefore fat retrieval, processing, and subsequent stromal vascular fraction injection can all 
be achieved at the time of transplantation. Liuhua Zhou et al. have compared the efficacy of 
ADSVF and ASC and found the ADSVF to be just as effective at reducing inflammatory 
cytokines, promoting cell proliferation and reducing cell apoptosis resulting in reduced 
tubular injury score and improved renal function. ADSVF has been shown to ameliorate 
renal IRI in several further studies which attributed it to their paracrine effect (Z. Feng et al. 
2010; Yasuda et al. 2012; Zhou et al. 2016). In some studies, ADSVF has shown to be more 
effective than ASC alone (Sheu et al. 2019). However, more needs to be done to study the 
mechanism of action of ADSVF as it has not been as thoroughly researched compared to 
other stem cell sources and stromal fractions (Zhou et al. 2017).  
 
Despite studies showing the safe and effective use of xenotransplantation of human ASC in 
animal models, human clinical trials of ADSVF or ASC (have fallen behind those looking 
at other stem cell sources. However, clinical translation has started to pick up the pace. 
Clinical trials using ADSVF in osteoarthritis, soft tissue and gastrointestinal disorders seem 
to have advanced the most and a review by Toyserkani et al. looking at the safety of adipose-
derived cell therapy found them to show a favourable safety profile so far. Nevertheless, 
they cautioned that in a large proportion of the studies, safety assessment methods used were 
of subpar quality. (Toyserkani et al. 2017) A stand out observation and potentially fatal 
danger of ASC is the thromboembolic potential. Studies have reported thromboembolic 
events after administration such as myocardial infarction, transient ischaemic attack of the 
brain, and pulmonary embolism, but these were few and in a high-risk population (Comella 
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et al. 2016; Perin et al. 2014; Henry et al. 2017). Therefore, dosing is of extreme importance, 
especially as there needs to be a balance getting a high enough therapeutic dose but not too 
much that the risk of a thromboembolic event becomes unacceptable. In animal models, the 
lungs seem particularly vulnerable to thromboembolic events due to the pulmonary 
microvasculature being one of the first pass organs when injected intravenously. Oncological 
safety and immunological safety remain the other two main areas which require close 
observation when looking at ASC and ADSV. However, with the limited studies so far, that 
does not seem to be a concern with uncultured ADSVF 
 
Previously, our group demonstrated the efficacy of ADSVF at ameliorating kidney IRI in an 
animal model of severe renal IRI (Fig. 5.5). The abundant source of adipose tissue during 
transplantation, the quick processing of ADSVF from adipose tissue and the easy 
accessibility of the renal artery make the concept of delivering uncultured ADSVF directly 
into the kidney graft at the time of transplant attractive and easily translatable to clinical 
practice. However, before considering human trials further research on the mechanism, 
specific to this method, is required. As far as our knowledge there has been no study using 
uncultured ADSVF in an animal model of renal IRI as severe as ours in which the cell 
therapy is injected directly into the renal artery just before reperfusion. We hypothesise the 
mechanisms of action in ameliorating IRI in this model will be like those already described 





Uncultured adipose-derived stromal vascular fraction administered directly via the renal 
artery ameliorates the effect of ischaemia reperfusion injury by protecting the kidney, 














6.3.1 ANIMAL HOUSING AND HUSBANDRY 
 




6.3.2 RETRIEVAL OF RAT ADIPOSE TISSUE AND ISOLATION OF ADSVF 
 
Adipose tissue was obtained from the inguinal region of adult Fischer 344 rats. The retrieval 
of rat adipose tissue is described in chapter 2.2. Isolation and storage of adipose-derived 
stromal vascular fraction were conducted in a standard fashion, as previously described in 
section 2.4 and 2.5. 
 
 
6.3.3 QUANTIFICATION, STORAGE AND PREPARATION OF ADSVF FOR 
ADMINISTRATION 
 
Quantification, storage, and then subsequent preparation of ADSVF for administration was 
conducted in standard fashion, as previously described in section 2.5. 
 
 
6.3.4 RENAL ISCHAEMIA REPERFUSION INJURY MODEL, ADMINISTRATION 
OF CELLS AND PERIOPERATIVE CARE 
 
The ischaemia reperfusion injury model is described in detail in chapter four. In brief, male 
adult Fischer 344 rats undergo a 2/3 nephrectomy of the right kidney. The rat is recovered 
for at least two weeks before undergoing surgery in which the left renal artery is clamped 
for 120 minutes. Before releasing the clamp, the ADSVF or vehicle control is administered 
via the left renal artery, and the renal artery is repaired. At 120 minutes the clamp is removed, 
and reperfusion of the left kidney ensues. The animal is then recovered, and its post-
operative care is described in chapter 4.3.6. Rats will then be housed as described in section 
2.1 until it reaches a particular timepoint (depending on which experimental group it is in) 
when it will be terminated by carbon dioxide euthanasia. 
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6.3.5 ORGAN RETRIEVAL AND PROCESSING 
 
Organ retrieval and processing was conducted in a standard fashion as described in chapter 
2.6. After the organs were harvested a section of each organ was flash-frozen in liquid 
nitrogen and then stored in -80C freezer until required for further analysis later. Another 
section was placed in 20mM HEPES PBS (Sigma Aldrich) at 4oC and taken for flow 




6.3.6 SERUM MICROPARTICLE MEASUREMENT 
 
Serum from control and ADSVF injected rats are allowed to thaw then stored in -20C. 
Samples were diluted to 1:10000 with PBS. Samples were then run in the NanoSight LM10-
HS (NanoSight, Salsbury, UK) for size exclusion measurements (exosomal: 30-100 nm and 
microparticle: 100-1000nm) as per manufacturer instructions and with 70% ethanol cleaning 




6.3.7 QUANTITATIVE REAL-TIME PCR ARRAY 
 
Organs are taken from -80 freezer and homogenised in liquid nitrogen with mortar and 
pestle. 50-100mg of homogenised organ tissue was placed in 1ml of TRIzol 
(Thermofischer). Centrifugation and chloroform were used to separate the aqueous and 
organic phases. The RNA was recovered from the aqueous phase by precipitation with 
isopropyl alcohol and resuspended in nuclease-free water (QIAGEN, Hilden, Germany). 
RNA was counted using a Nanodrop (Thermofischer), and RNA was purified by removing 
DNA with DNAse I, Amplification Grade (Thermofischer). Reverse transcriptase 
(Thermofischer) was used, following its protocol to create complement DNA (cDNA) from 
the RNA. The cDNA and fast master mix (Thermofisher) were then prepared for the Taqman 
Array card and added to the custom Taqman array plates as per instructions. The custom 
made Taqman array plates assay 47 candidate genes and housekeeping controls (Table 3.2) 
and was ran on a QuantStudio PCR cycler (Applied Biosystems, Foster City, CA, USA). 
Relative Ct levels were normalised by housekeeping controls (average of the same three 
housekeeping genes) and represented as dCt. Data are represented as mean ± SEM. 
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Differences in average means between two groups determined by Mann-Whitney U test, 
differences between three groups by One-way ANOVA. *p<0.05, **p < 0.01. 
 
 
6.3.8 WESTER BLOTS AND PROTEIN ARRAYS 
 
A section from the kidneys retrieved from the terminated rats was immediately placed in 
protein lysis buffer. It was then homogenised and stored back in protein lysis buffer. Protein 
concentrations were determined using a Bradford assay. The proteins of homogenised 
kidneys sample were then separated on a voltage gradient through an acrylamide gel. Protein 
was transferred onto a nitrocellulose membrane and interrogated for protein detection by 
antibody reaction and using LI-COR Odyssey CLx fluorescent imager (Licor Biosciences, 
Nebraska, USA). Col1a2, Nox-1, and Nox-4 (Abcam) were measured and normalised to 
beta-actin controls. A 27-rat cytokine profiler array was assayed on the whole homogenised 
kidney of treated and untreated kidneys for cytokines related to inflammation and growth 
factors per Applied Biosystems protocol. 
 
 
6.3.9 FLOW CYTOMETRY 
 
Flow cytometric analysis was described in section 5.3.11.  
 
 
6.3.10 HISTOLOGICAL ANALYSIS 
 
After three to seven days of being fixed in 10% formalin, the organs were then transferred 
to 70% ethanol for a further 48 hours before being subjected to tissue dehydration and 
paraffin embedding process. All tissues were then sectioned at 5 micrometres and underwent 
staining with either haematoxylin and eosin (H&E) or Masson Trichrome for histological 
assessment.  
 
Histopathological scoring of kidneys was given based on 2-3 sections. A tubular injury score 




Statistics. A 2-way student’s t-test was carried out to determine the differences in the mean 
average for sample sizes >5 of equal variance. Mann-Whitney U test was used to analyse 
smaller sample sizes. A two-way ANOVA was used to evaluate changes over time. Analyses 
was performed with Prism 6.02 (GraphPad, San Diego, CA). Mean and standard error of 
mean (SEM) are displayed unless otherwise stated. Error bars on graphs represent SEM 
unless otherwise stated. Significance was considered for p values <0.05 (*) but included       p 


































6.4.1 ADSVF PROVIDE SOME PROTECTION FROM ISCHAEMIA 
REPERFUSION INJURY   
 
Real-time PCR was performed on the samples of the left kidney, which underwent severe 
IRI, at different timepoints looking at an array of genes associated with kidney injury and 
repair. Although the trend was the same for Kidney Injury Molecule-1 (KIM-1) and 
neutrophil gelatinase-associated Lipocalin (NGAL), there were significant differences with 
hypoxia-inducible factor 1 subunit alfa (HIF1A) between groups at one week suggesting 
increased kidney injury in the vehicle control group (Fig. 6.1a). IL-18 was raised after 
48hours in the ADSVF treated group, but this marker of increased injury settled by one 
week. The significantly lower detection of microparticles indicates lower levels of systemic 
injury in the sera of ADSVF treated rats (Fig. 6.1b). 
 
Tubular injury score by 48 hours already seems reduced in the ADSVF treated group, and 
this becomes significant by one week (Fig. 6.2). Rat weights for both groups follow the same 
trend with a dip of weight after surgery then a gradual increase however the ADSVF treated 
group lost less body weight and by day four are significantly heavier (Fig. 6.3) 
 
Renal function measured previously by our group, using inulin clearance studies, revealed 
rats treated with 7x105 ADSVF cells have a higher glomerular filtration rate (Fig. 1.5). 7x105 
ADSVF resulted in a significant improvement of renal function compared to all other 
dosages and vehicle control. Higher dosages result in reduced response. Renal function in 
rats treated with this optimal dose of ADSVF was comparable to sham-operated rats by week 
6. Non-invasive renal function measurement in the modified severe IRI model, as described 
in chapter 2, demonstrates at 48 hours, the ADSVF treated rats have improved residual renal 






















































































































Figure 6.1 ADSVF treated rats have reduced kidney injury and lower levels of systemic 
injury after IRI. RT-PCR analysis of kidneys which have sustained a renal IRI and then 
treated with ADSVF or vehicle control via the renal artery. Represented as their delta CT 
(housekeeping genes Ct minus gene of interest Ct) after 40 cycles. Kidneys retrieved at 
1hour (n=4), 24hours (n=5), 48hours (n=8) and 1 week (n=4) post IRI and administration of 
ADSVF. (A) HIF1A is significantly higher in the vehicle control group but NGAL and KIM-
1 follow a similar trend. IL-18 is raised in the ADSVF group at 48 hours before returning to 
similar levels by 1 week. (B) Microparticle analysis of the sera from ADSVF treated (n=8) 
and vehicle control (n=6) treated rats shows a significantly higher count of microparticles in 
the vehicle control group. Exosomal material defined as 30-100 nm and microparticles as 
100-1000nm. Represented as the mean and standard error of the mean. Significance was 






































Tubular Injury scoring 
0 Normal 
1 Loss of brush border <25% ,mild blebbing, basal membrane integrity 
2 Loss of brush border >25%, thick basal membrane, intensive blebbing, mild vacuolization 
3 shrunken nuclei, intensive vacuolization 
4 (plus) inflammation, cast formation, necrotic/apoptotic cell up to 60% 

















































































Figure 6.2 ADSVF treated rats have reduced renal tubular injury after renal IRI. 
Tubular injury score at 48 hours (vehicle n=12, ADSVF n=10) and 1 week (vehicle n=5, 
ADSVF n=6) of kidneys from rats that underwent renal IRI and where then treated with 
either ADSVF or vehicle control. Histopathological scoring of kidneys was given based on 
3 sections per kidney. A tubular injury score was given between zero and five. Three 
observers assessed the kidney injury score independently and mean score calculated. After 
48 hours there is a trend of increased tubular injury in the vehicle control group and by 1 
week there is now a significant increase in injury. Significance was considered for p values 





Figure 6.3 Rats treated with ADSVF lose less weight post IRI suggesting reduced post-
operative morbidity. Rats were weighed daily post IRI surgery during which they were  
administered with either ADSVF or vehicle control via the renal artery. The weight change 
of ADSVF treated rats was less from day one and by day four the difference was statistically 
significant. Significance was considered for p values <0.05 (*) but included p values <0.01 




























Figure 6.4 ADSVF improve renal function post IRI within a specific concentration 
range. Rats were subjected to a renal IRI then received ADSVF, at various concentrations, 
via the renal artery. Sham operated (n=6), vehicle control (n=6), 1x106 ADSVF (n=6), 
1.3x106 ADSVF (n=6) and 7x105 ADSVF (n=6). (A) After six weeks, rats that received 










































































































































sham operated rats that did not sustain any IRI. Measured using terminal inulin clearance 
studies performed by group member Dr H. Whalen. (B) Non-invasive measurement of 
glomerular filtration rate 48 hours post renal IRI and administration of either vehicle control 
(n=4) and the optimum 7x105 ADSVF cells (n=4) demonstrates at 48hours there is already 
a trend of improved renal function in the ADSVF treated group. 
 
 
6.4.2 ADSVF REDUCE PROGRESSION OF FIBROSIS 
 
Gene expression of collagen type IV alpha one chain (COL4A1), HIF1A, tissue inhibitor 
of metalloproteinases 1 (TIMP 1) and collagen type I alpha 2 chain (COL1A2) were all 
significantly higher in the vehicle-treated groups at one-week post-IRI (Fig. 6.5). CCL2 
was not quite significantly different. VEGF and FGF2 were both greater in the ADSVF 
treated group by 48 hours, but this did not turn out to be significant by one week. 
 
Protein detection of COL1A2 and VEGF at 48hours suggested the COL1A2 being higher 
in the vehicle-treated group and VEGF higher in the ADSVF treated group (Fig. 6.6) 
Histology slides with Masson Trichrome staining, looking at collagenous connective 
tissue fibres, in rats that were sacrificed at 48 hours, already shows a significant increase 











































































































































































































Figure 6.5 Kidneys treated with ADSVF have reduced expression of factors related 
with fibrosis formation. RT-PCR analysis of kidneys which have sustained a renal IRI 
and then treated with ADSVF or vehicle control via the renal artery. Represented as their 
delta CT (housekeeping genes Ct minus gene of interest Ct) after 40 cycles. Kidneys 
retrieved at 1 hour (n=4) 24hours (n=5), 48hours (n=8) and 1 week (n=4) post 
IRI/administration of ADSVF. Gene expression of COL4A1, HIF1A, TIMP 1 and  



































































































































































































COL1A2 were all significantly higher in the vehicle-treated groups at one-week post-IRI. 
CCL2 was not quite significantly different but followed a similar trend of being higher in 
the vehicle treated groups. VEGF and FGF2 were both greater in the ADSVF treated 
group by 48 hours, then returned to similar levels by one week. 
Significance was considered for p values <0.05 (*) but included p values <0.01 (**), and 








Figure 6.6 Kidneys treated with ADSVF have favourable levels of proteins related 
to reduced fibrosis formation. Protein analysis of kidneys which have sustained a renal 
IRI and then treated with ADSVF or vehicle control via the renal artery. Samples taken 














































vehicle               ADSVF
 179 
in the ADSVF treated group using western blot analysis (Vehicle n=4, ADSVF n=6) and 
(B) VEGF detection was higher in ADSVF group on rat cytokine protein array (vehicle 





Figure 6.7 Reduced fibrosis in the ADSVF groups seen on histological analysis. 
Representative Masson’s Trichrome staining of kidney tissue which have sustained a renal 
IRI and then treated with ADSVF or vehicle control via the renal artery. Tissues analysed 
one week post IRI and administration of ADSVF/vehicle control. Masson Trichrome 























image 20x magnification (blue-stained areas expressed as percentage of total surface area) . 
There was a significant increase of fibrosis in the vehicle treated group. Significance was 




6.4.3 ADSVFS REDUCE INFLAMMATION  
 
Pro-inflammatory chemokine CXCL 12 is significantly raised by one week in vehicle 
control-treated animals.  Cytokine colony-stimulating factor 2 (CSF2) which plays a role 
in the immune / inflammatory cascade, although not quite significant, follows a similar 
trend in each group (Fig. 6.8). However, when the protein levels of CSF2 are measured, 
the higher levels in the vehicle group at one week are significant (Fig. 6.9). Cytotoxic T-
lymphocyte-associated protein 4 (CTLA 4) which downregulates the immune response, 
on the other hand, is significantly lower in vehicle groups by one week. The CTLA 4 
ligand, CD86, is again significantly lower in the vehicle-treated group (Fig. 6.9)   
 
Flow cytometric analysis of the left kidney looking for leucocytes (CD45+) found a 
tendency for a higher level in control-treated rats by 48 hours. Histological analysis to 
assess leukocytes in the form of infiltrates again found higher levels in the control-treated 
kidney by 48 hours (Fig. 6.10) By one week the infiltrate lesion score was significantly 
higher in the vehicle control group. Horseshoe nucleated cells, characteristic of 








Figure 6.8 Gene expression of pro-inflammatory mediators are reduced in ADSVF 
treated rats. RT-PCR analysis of kidneys which have sustained a renal IRI and then treated 
with ADSVF or vehicle control via the renal artery. Represented as their delta CT 
(housekeeping genes Ct minus gene of interest Ct) after 40 cycles. Kidneys retrieved at 1 
hours (n=4), 24hours (n=5), 48hours (n=8) and 1 week (n=4) post IRI/administration of 
ADSVF. Pro-inflammatory chemokine CXCL 12 is significantly raised by one week in 
vehicle control-treated animals. CSF2 although not quite significant, follows a similar trend 



















































































of being higher in the vehicle treated group between 48 hours and 1 week. CTLA 4 on the 
other hand, is significantly higher in ADSVF groups by one week. Significance was 






Figure 6.9 Protein levels of inflammatory mediators demonstrate favourable anti-
inflammatory trends in ADSVF treated rats.  Protein analysis of kidneys which have 
sustained a renal IRI and then treated with ADSVF or vehicle control via the renal artery. 
(A) Rat cytokine array panel used to detect CSF at 1 (n=1), 24 (n=4), 48 (n=4) hours and 
one week (n=3). CSF is significantly lower in the ADSVF treated group by 1 week. (B) 
Samples taken 48hours demonstrate increased levels of CD86 in the ADRC treated group 
(vehicle n=3, ADSVF n=4). Significance was considered for p values <0.05 (*) but included 
p values <0.01 (**), and <0.001 (***) as indicated. 
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Figure 6. ADRC treated kidneys display lower inflammatory traits. mRNA and 3 
protein expression of the homogenized kidney of IRI rats after 1, 24, 48 hours and 4 
1 week post vehicle or ADRC -injection (n= 3-5/timepoint both groups) indicate an 5 
early anti- inflammatory response characterized by a decrease in A) CXCL12 gene 6 
expression and in GM-CSF cytokine expression, B) whereas, a t-regulatory related 7 
response was heightened as evidenced by high CTLA-4 transcript and CD86 8 
protein levels. C) Representative flow cytometry plots of CD45+ leukocytes levels 9 
at 48hours (n=4-5/group) indicated a tendency for vehicle control kidneys to have 10 
higher levels of immune infiltrate. D) The same tendency was evident by histological 11 
count of lesions and a significant difference was apparent by 1 week post-injection.  12 
Representative image 20X magnification, 50µm scale.  Data are represented as 13 
mean ± SEM. Differences over time in mRNA and protein expression between 14 
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Figure 6. ADRC treated kidneys display lower inflammatory traits. mRNA and 3 
protein expression of the homogenized kidney of IRI rats after 1, 24, 48 hours and 4 
1 week post vehicle or ADRC -injection (n= 3-5/timepoint both groups) indicate an 5 
early anti- inflammatory response characterized by a decrease in A) CXCL12 gene 6 
expression and in GM-CSF cytokine expression, B) whereas, a t-regulatory related 7 
esponse was heightened as evidenced by h gh CTLA-4 transcript and D86 8 
rotein levels. C) Representative flow cytometry plots of CD45+ leukocyt s levels 9 
at 48hours (n=4-5/group) indicated a tendency for vehicle control kidneys to have 10 
higher levels of immune infiltrate. D) The same tendency was evident by histological 11 
count of lesions and a significant difference was apparent by 1 week post-injection.  12 
Representative image 20X magnification, 50µm scale.  Data are represented as 13 
mean ± SEM. Differences over time in mRNA and protein expression between 14 







































Figure 6.10 ADSVF treated rats have lower levels of immune infiltrates. Flow 
cytometric and histological analysis was performed on kidneys which have sustained a 
renal IRI and then treated with ADSVF or vehicle control via the renal artery. (A) Flow 
cytometric analysis looking for CD45+ leucocyte levels at 48 hours in the left kidney of 
vehicle control (n=4,) and ADSVF treated (n=5) rats show an increased percentage of 
leukocytes in the vehicle control group. (B) Infiltrate lesion score at 48 hours (vehicle 
control n=6, ADSVF n=17) and one week (vehicle control n=4, ADSVF n=5) in vehicle 
control and ADSVF treated rats was calculated using histology. Horseshoe nucleated 
cells, characteristic of neutrophils and monocytes, clustered together, typically near a 
vessel, was considered a lesion, and was blinded analysed by three separate assessors. 
ADSVF treated rats has a significantly lower infiltrate lesion score. Significance was 














































Many research groups have demonstrated the ameliorative effects of ADSVF in renal 
ischaemia reperfusion injury. Although our model is unique in the severity of ischaemia 
reperfusion it induces, and the route of administration (via the renal artery) differs, the 
underlying mechanisms are likely to be similar. ADSVFs have proven regenerative, anti-
inflammatory, antioxidant, immune-modulatory properties, as demonstrated in a variety of 
bodily systems and diseases. In our research, an improvement in renal function can be seen 
within the first few days. In this short timeframe, it is unlikely the kidney has had an 
opportunity to regenerate the damaged tissue into functionally active tissue, although they 
may exert this regenerative effect in the long-term. Most likely, ADSVF can dampen the 
damaging factors associated with IRI or protect the kidney in some way, therefore, retaining 
a higher degree of renal function.  
 
HIF1A, a marker for injury and antioxidant, was significantly raised in the vehicle-treated 
group suggesting increased hypoxic injury. However, KIM -1, which is a marker for 
proximal tubule injury, and NGAL, which rises during renal ischaemia and excreted by the 
renal tubular cells, followed a similar trend in both groups. Perhaps the ADSVF have varying 
degrees of efficacy within the kidney and are more effective at reducing injury on other 
kidney structures, like the glomerulus. The reduced injury implied by HIF1A is further 
supported by the significant reduction in microparticles in the sera at just 48 hours, a 
significantly lower tubular injury score by one week and overall improved well-being 
(measured in rat weight) by as early as day four. This reduction in injury secondary to the 
severe IRI translates to improved renal function in the long-term as there is reduced nephron 
loss and therefore, a higher baseline for recovery. However, it is unclear if this protection or 
another mechanism provides most of the initial amelioration against the IRI.  
 
Kidney repair after an injury is a complex finely balanced process of formation and 
degradation. An exaggerated uncontrolled response to significant injury leads to renal 
fibrosis characterised as glomerulosclerosis, tubule-interstitial fibrosis (pathological 
deposits of extracellular matrix), inflammatory infiltrate and loss of renal parenchyma (Y. 
Liu 2011). The extracellular matrix (ECM) is in a constant dynamic state of remodelling. 
Many cell types and signalling mediators are involved in the development of fibrosis such 
as the activation of mesangial cells, fibroblasts and tubular epithelial cells that produce 
extracellular matrix components (Eddy 2000). TGF-b and its downstream Smad signalling 
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pathway is one of the most popular and studied pathways involved in cellular activation in 
renal fibrosis.  
 
Although we did not find any significant differences in TGF-b, there was a significant rise 
of COL4A1 and COL4A2 which is stimulated by TGF-b. Along with collagen type IV, there 
is a significant increase collagen type I expression and increased collagen type I and IV in 
the ECM of the kidney are cardinal features of renal fibrosis. MMPs have a complex role in 
renal fibrosis and not just in ECM degradation which was traditionally thought (Boor et al. 
2007; Catania et al. 2007; Pardo & Selman 2006). Although the major role of MMPs seems 
to be in ECM degradation, this process can be temporarily inhibited by TIMPs (Catania et 
al. 2007). TIMP 1, which was increased in the vehicle control group, has been associated 
with early events of renal disease progression in human and rodent models (Catania et al. 
2007; T. S. Johnson et al. 2002; Eddy 2000). 
 
Interestingly FGF-2 was significantly higher in the ADSVFs treated group at 48hours. 
However, excessive FGF-2 may play a role in the development of kidney fibrosis despite 
being necessary for the initial repair (Z. Xu & Dai 2017). Also, FGF2 protects against renal 
IRI by attenuating the inflammatory response (X.-H. Tan et al. 2017).  
 
VEGF is also significantly increased in the ADSVF group and may have a role in promoting 
endothelial survival and proliferation (Kanellis et al. 2002). A VEGF-A increase is not 
routinely seen after renal IRI and reducing it is associated with tubulointerstitial fibrosis. 
Increased expression is detrimental in various renal diseases and is likely dependent on the 
degree and timing of expression. Therefore, like many processes in kidney recovery, a 
delicate balance is fundamental. The VEGF-A may be induced by the increased of HIF1A, 
but as the expression of HIF1A did not significantly rise in the vehicle control group until 
five days after VEGF increase, this is not actively supported. HIF1A has, however, been 
linked with the development of fibrogenesis by increasing matrix modifying factors and 
facilitating epithelial to mesenchymal transition (Higgins et al. 2007). 
 
Masson Trichrome staining of ADSVF treated kidney sections demonstrated decreased 
expression of interstitial factors correlating with lower levels of fibrosis. Cumulatively this 
evidence may suggest that along with reducing the initial insult, ADSVFs decrease the 
progression to renal fibrosis by favourably altering the balancing of some of the key 
mediators involved in repair and fibrosis. 
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As seen in other bodily systems, it appears the ADSVFs have an immunomodulatory effect 
post renal IRI. Proinflammatory mediators like CXCL12 and CSF2 1-week post-
administration are reduced in the ADSVF treated groups while immunomodulatory 
receptors like CTLA4 are increased. Cumulatively this could result in a reduced 
inflammatory response involving a host of immune cells. T cells upregulate CTLA4 
expression and when bound to its ligand CD86, which is raised in ADSVF treated groups, it 
puts the brakes on T cells function. CTLA4 influence specifically on Treg function is 
particularly well studied, and although complex, the raised CTLA4 could exert an anti-
inflammatory influence in part through the Tregs as we know the Tregs rely heavily on 
CTLA4 (Walker 2013). As a result of these immunomodulatory actions, you would expect 
reduced infiltration of leukocytes into the injured kidney, and this was demonstrated by the 
reduced number of CD45+ cells, detected by flow cytometry, and lesion counts in histology. 
However, we do appreciate that it is difficult to get accurate quantitative data from histology. 
 
With all the RT PCR data, we must be cautious that there is not always a direct correlation 
to human pathophysiology. CXCL12 (SDF1) and its primary receptor, CXCR4, for example, 
have a higher expression in humans compared to rodents and humans have more splice 
variants compared to rodents, but compared to other cytokines there are high homology 
between human and rodents (Janssens et al. 2018). These differences, in all cytokines, can 
affect the activities they show in various processes and therefore will not necessarily be 
replicated in human trials. A further limitation of the RT PCR was the homogenate used. 
Using the whole kidney, and not focussing on a micro-section, dilutes the signal. Most of 
the interventions seem to be taking place around the glomerulus, or the cortex, and perhaps 
resecting the cortex and homogenising that instead of the whole kidney would be a more 
refined method. Also, with gene expression studies cytokines and proteins can be anti-
inflammatory in one state or environment and the opposite in another. RNA analysis alone 
does not explain the full picture and further investigation into these pathways is necessary if 
we are to get a deeper understanding of how ADSVF ameliorates IRI. A final consideration 
is that these mechanistic studies did not investigate the differentiation potential of ADSVF. 
It is difficult to prove that ADSVF, in particular the ASC, integrate into the kidney and 
divide and develop into functional kidney cells. Attempting to reveal an increased 
proliferation of resident renal cells, due to the paracrine effect of administered ADSVF in 
the kidney could be considered in the future. However, tracing ADSVF to show that they 




In summary, maintaining balance is essential to well-being. ADSVF does not stop the 
necessary repair and regeneration of the kidney but may regulate its response to reduce 
fibrosis and detrimental inflammation. The diverse ADSVF population contain a variety of 
mediators in the form of cytokines, chemokines, exosomes and undoubtedly have thousands 
of effects on the injured kidney. Not all these effects will be advantageous, but the overall 
impact of ADSVF results in improved renal function. Added to the notion that the presence 
of the ADSVF reduces the degree of IRI, they show high potential for clinical translation in 
the transplant setting. It is not possible to conclude whether it is the ability to reduce the 
injury or the ability to balance the response, which has the most significant effect on the 
long-term renal function. The necessity to determine this answer depends on the proposed 
timing of ADSVF administration in the clinical setting. The regenerative and reparative 
effect of ADSVF could also be used in other renal pathologies and interventional radiology 



































CHAPTER 7:  
GENERAL DISCUSSION  
 
 
7.1.1 SUMMARY OF KEY FINDINGS 
 
This thesis had a particular remit; to investigate how non-cultured regenerative cell therapy 
could be implemented with a single dose at the time of kidney transplantation in a bid to 
ameliorate IRI. The introduction chapter justified why we chose fresh uncultured ADSVF 
and our proposed clinical model of implementing stem cell therapy to ameliorate transplant 
related IRI. In brief, cellular therapies have been used in many clinical trials, and ASC so 
far have demonstrated a promising safety profile. ADSVF was chosen as the regenerative 
cellular therapy of choice due to the high concentration of stem cells, ease of accessibility to 
adipose tissue and a reasonably simple extraction process. Cytori Therapeutics (San Diego, 
USA) has developed a machine that can process adipose tissue into ADSVF, in the clinical 
setting, within 60 minutes with minimal expertise required: yielding fresh uncultured cells 
quickly and reproducibly.  
 
To the best of our knowledge, no group has administered fresh, uncultured, ADSVF via the 
renal artery peri-transplant, in humans or in human kidneys ex vivo, in a bid to ameliorate 
IRI. Data exists on ADSVF use in renal IRI and the use of cellular therapies via the renal 
artery of a graft but not in the combination we propose. Before considering clinical trials, 
basic science specific to this methodology is required, to build on current related and generic 
data. Outcomes of this thesis will build on the animal model functional data that already 
exists, add to the safety profile of using ADSVF and form the foundations of future planning, 
clinical study design and ethics approval. 
 
 
Aims 1 & 2: Characterisation of ADSVF 
 
The aim of this chapter is twofold. Firstly, to add data on fresh ADSVF obtained from the 
rat inguinal fat depot as this is what our group has demonstrated to have ameliorative 
properties in renal IRI. This knowledge is essential if we are to determine the mechanism of 
action, and later the safety profile. Secondly, very little data exist on the peri-renal depot as 
a source of ADSVF. It is essential to determine any potential difference between inguinal 
and peri-renal adipose tissue, especially as our clinical model could utilise peri-renal adipose 
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tissue as a source of ADSVF. We also wanted to compare rat adipose tissue used in our 
animal models with human adipose tissue which will be used in the clinical setting to ensure 
there are no concerning major differences. 
 
The analysis of this chapter confirmed a viable cell population from both adipose depots 
even after storage in liquid nitrogen and subsequent thawing.  The cell populations were 
similar between inguinal and peri-renal sources but demonstrated a significantly higher 
leucocyte population in the inguinal depot – the clinical relevance when administering 
inguinal ADSVF via the renal artery is unknown.  
 
Due to the lower amount of adipose tissue stored in peri-renal tissue (and therefore reduced 
ADSVF yield), we did not use peri-renal-derived ADSVF in our animal model of renal IRI. 
However, humans store considerably more peri-renal adipose tissue (enough to obtain a 
therapeutic volume of ADSVF) therefore this would be less of an issue in clinical translation. 
The similar viability and heterogenicity of the peri-renal ADSVF, from both human and rats, 
is reassuring for moving to clinical translation as there is a high probability of using peri-
renal ADSVF in the clinical settings. 
 
The gene expression analysis results from the ADSVF were as expected with the expression 
of factors related to repair and regeneration. 
 
Future research in this topic could focus on adipose tissue from patients with ESRF; as the 
transplant recipient is an attractive source of adipose tissue. We know different donor 
pathologies can alter properties of ADSVF. For example, Markus et al. found T-reg cells are 
significantly reduced in the ADSVF in the fat of obese rats compared to normal rats which 
had an effect of their ability to produce anti-inflammatory mediators (Feuerer et al. 2009). 
Further research could also be performed on peri-renal adipose tissue that has been stored 
on ice for 10 hours or so to better represent the peri-renal adipose tissue that comes with the 
donated kidney graft.   
 
In conclusion, this chapter has revealed that rat inguinal ADSVF varies slightly in its 
proportions of cell subsets compared to rat peri renal ADSVF and human peri renal ADSVF. 
But overall, the cell populations are similar between all sources. Rat inguinal ADSVF has 
proven its efficacy in ameliorating renal IRI therefore, the similar rat peri-renal and human 
peri renal ADSVF will likely have the same potential. Furthermore, a similar population is 
unlikely to have any additional risks associated with it. 
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Aim 3: The animal model 
 
To investigate the potential mechanism of action and biodistribution of the ADSVF, an 
animal model had to be chosen that could closely replicate the transplant patient. A new 
animal licence application was created specifically for this thesis with three severe animal 
protocols included in it. Over 200 microsurgical procedures were performed during this 
period of research. Samples in the form of tissue, RNA, serum, and histology from over 90 
rats have been studied and stored. A large proportion of which is not included in this thesis 
and is the subject of ongoing research. The animal licence created for this thesis has been 
adopted by other researchers studying renal IRI. 
 
Multiple rodent models exist which replicate acute kidney injury and renal IRI. The closest 
imitation would be to perform kidney transplants in rodents. However, despite being a 
powerful research tool, there are significant drawbacks to performing this model. Firstly, it 
is technically challenging, and experienced microsurgeons may find it difficult to 
anastomose the vessels repetitively and successfully. Consistent evolution of the technique 
has improved outcomes but the potential of complications, which would be terminal, remains 
high. (Plenter et al. 2015). Secondly, the surgery itself is lengthy with three anastomoses to 
be performed once adequate exposure is achieved. Finally, there is an additional procedure 
and animal sacrifice required to retrieve a kidney graft.  Overall, a time consuming, 
technically challenging, high-risk model with a long learning curve. Also, depending on the 
research, a contralateral nephrectomy is often performed a few days post-transplant. For 
those reasons, a transplant animal model as the foundations of this research would not be 
acceptable, especially when large numbers are planned. The unilateral IRI model, which was 
modified by Whalen et al. creates a significant permanent IRI with representative 
histological damage comparative to transplant related IRI. However, in a bid to better 
represent the transplant patients, reduce animal numbers and make it simpler, a further 
evolution of this model was created.  
 
Chapter four demonstrated that 2/3 nephrectomy of the contralateral untouched kidney is 
feasible with no increase in morbidity and mortality. The additional procedure, once 
experienced, takes the surgeon 15 minutes and the rat makes a full recovery. By performing 
this 2/3 nephrectomy of the right kidney, the left IRI kidney is now recovering in an 
environment of reduced renal function and associated metabolic imbalances – similar to the 
dialysis patient receiving a kidney transplant. As rodent dialysis does not exist this is 
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probably the furthest the animal model can be taken with regards to representing the 
transplant scenario.  
 
Non-invasive renal function monitoring further enhances the model as it allows for a 
longitudinal measurement of renal function. Also, it reduces the number of animals required, 
which is an important addition welcomed by the animal licence ethics boards.  
 
The minor technical improvements, described in chapter four, help streamline the surgical 
procedure without compromising animal welfare. In addition to being quicker, it also makes 
teaching the model easier to learn.  
 
As it stands, the model seems to have been optimised as much as possible. Future techniques 
and devices will no doubt allow it to continue to develop. It is an effective and acceptable 
means of testing therapies targeting renal transplant related IRI. The addition of 
immunosuppression would take the model one step closer to mimicking the renal transplant 
patient. 
 
Organoids may further reduce the need for animal testing. Kidney organoids have already 
been used to investigate some renal conditions such as polycystic kidney disease. Organoids 
that investigate IRI are however more challenging as the pathology of IRI is the result of a 
cessation of blood then restoration of blood. Complex kidney organoids with a representative 
vasculature to test IRI does not exist, but they may in the future have role to play in some 
specific aspects of IRI such as fibrosis formation. 
 
 
Aim 4: Biodistribution  
 
Few groups have used direct renal artery administration in their animal models to avoid non-
targeted biodistribution of the administered therapy. There have been no clinical studies in 
which stem cells or other types of cellular therapy have been injected into the renal artery. 
In most incidents of renal disease or injury the renal artery is not accessible. However, at the 
time of renal transplant the surgeon has easy access to the renal artery and veins. Therefore, 
administering therapy through this route could be considered a niche technique and only 
viable in the transplant setting. If renal artery administration of regenerative cells were found 
to be advantageous, the rapidly expanding field of interventional radiology would allow 
administration of regenerative cellular therapies for non-transplant related kidney injury 
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such as drug-induced, post heart transplant, post sepsis. Potentially even as a route for 
directed treatment for graft rejection.  
 
The aim of chapter five was to investigate if administration of ADSVF via the renal artery 
reduced off-target biodistribution. Through two modalities, DiR labelled cells, PKH26 
labelled cells, it was convincing that ADSVF remained in the kidney for at least 48 hours. 
Reducing the time for homing and ensuring maximum concentration possible of cells within 
the kidney for them to effectuate potential therapeutic paracrine action.  No significant 
increase in signal was seen in any other organ.  
 
The liver and lungs seem to be where most labelled regenerative cells collected after 
systemic administration in published studies. Also, in our work, the liver had increased 
signal in IVIS scanning and in sectioned fluorescent imaging, however, the diffuse quality 
of the fluorescence suggested degradation of the dyed ADSVF cellular membrane. For 
confirmation, studies through flow cytometry and immunohistochemistry of the liver and 
lungs, demonstrating minimal viable cells, would help further support the use of renal artery 
administration. 
 
Histological sections indicated that the majority of retained cells within the kidney resided 
within the cortex of the kidney. Interestingly research published this year found labelled 
ASC in both the cortex and the medulla (Zaw Thin et al. 2020). The experiments involved 
administering the cells via the renal artery under ultrasound guidance in healthy mice. One 
explanation could be that the injured vasculature in the kidneys in our model traps the cells, 
or the cells are attracted to the injured microvasculature and surrounding cells due to 
chemoattractants. To further investigate the micro localisation of labelled cells, the sections 
could be examined using immunohistochemistry and confocal microscopy. Imaging using 
higher magnification has since been performed by our group and confirms the presence of 
the ADSVF within the glomerulus. Recent studies using in vivo porcine renal artery 
administration and ex-vivo human kidney graft renal artery administration of labelled MSCs 
both confirmed the localisation of MSC within the cortex of the kidney (Sierra-Parraga et 
al. 2019; Thompson et al. 2020). Interestingly the porcine model was attempted again with 
deactivated MSC and biodistribution was unchanged so perhaps the chemoattractant effect 
of the injured kidney cells does not play such a significant role in biodistribution when 
administered via the renal artery (Sierra-Parraga et al. 2019). 
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Overall administration of ADSVF via the renal artery is an effective means of delivering the 
cells directly to an injured kidney. Unwanted non-target distribution appears to be reduced. 
Using the renal artery may allow for higher concentrations of ADSVF to be administered as 
there is less worry of systemic interference or conversely lower concentrations since more 
potentially therapeutic cells will be delivered locally. However, one major limitation of 
research from a clinical standpoint is the discrepancies of the rat microvasculature and 
human microvasculature and the concentration of ADSVF required. Encouraging as the 
results are as a means of administrating the cells, further research is required to address those 
points. One option would be to perform similar research on a porcine model. That way 
dosage titrations can be performed to find a therapeutic range and help determine the 
maximum dosage before deleterious clogging of the vessels occur. Another option, 
potentially more favourable, would be to administer the ADSVF in discarded organs 
(retrieved but rejected for implantation). Ex vivo kidney perfusion rigs would allow for 
functional analysis, and then once the observation period is finished, the kidneys could 
undergo analysis for thromboembolic events. This route would be more representative and 
would avoid a laborious large animal model. 
 
 
Aim 5: Mechanisms of action 
 
Chapter six set out to define potential mechanisms of ADSVF therapeutic action. We know 
from published research, MSC have an array of functions and to thoroughly investigate even 
several of these pathways would require extensive research. More specifically, this chapter 
aimed to confirm if uncultured ADSVF administered into a severe model of renal IRI 
implement some of the mechanisms described in existing research on MSC from adipose 
tissue and other origins. Through gene expression, protein detection and histology, we were 
able to highlight protective and anti-inflammatory properties along with reduced kidney 
fibrosis. These properties have all been revealed in other stem cell sources used to treat 
various diseases. As they act similarly, the risks of using ADSVF to treat renal IRI is unlikely 
to be hugely different from the clinical trial that has already taken place using ADSVF in 
various pathologies. Also, a lower concentration of ADSVF may be required compared to 
systemic administration as the full administered therapy is straight into the kidneys. Lower 
dosages will minimise the thrombotic risk of ADSVF.  
 
In summary, ADSVF has a repertoire of paracrine actions. The gene expression analysis 
results from this chapter were as expected with expression of factors related to repair and 
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regeneration. These results will not only add to the safety profile but may aid in discovery 
of optimal timing of administration. It seems likely that ADSVF provide a degree of 
protection from ischaemia reperfusion injury as kidney function, tubular injury score, sera 
microparticles levels are improved within 48 hours. The presence of ADSVF at the time of 
reperfusion dampens the harmful effects and aids in the maintenance of higher residual 
function and structure. It is unlikely these changes are due to regeneration so early on. 
Therefore, to ameliorate IRI, data indicate ADSVF should be administered peri- IRI. Pre IRI 
may provide even more benefits. 
 
Future studies could focus on and define some of these pathways in more details. Gene knock 
out techniques, single-cell sequencing and kidney organoids could all be considered.  As 
exciting and useful to other research groups as this would be, further knowledge of specific 
pathways may not be required to move forward to clinical trials. If a particular pathway was 
identified, it might be a potential target for future therapies, but in our envisaged point of 
care extraction and administration clinical model, the therapy (ADSVF) is relatively fixed.  
 
 
7.2 MOVING FORWARD WITH ADSVF IN RENAL TRANSPLANTATION 
 
Two routes can be embarked upon moving forward from the work presented. One takes the 
use of ADSVF a step closer to clinical translation. The other builds on the basic science of 
ADSVF to look at the therapeutic potentiators of ADSVF. 
 
Moving forward with the basic science could take multiple routes. Useful work would 
include delving further into mechanisms of actions of the ADSVF and, defining the role of 
the subpopulations of the ADSVF and the interactions between them. Creating a 3D 
environment (organoids) of the renal cortex and recreating IRI microenvironment would 
enable more focused, less diluted, analysis of gene expression and mechanistic studies. It 
would also reduce the need for animal use. Functional analysis may not be possible, but 
inflammation, fibrosis, angiogenesis pathways could be delineated in more detail. 
Identifying the most therapeutic subpopulations of the ADSVF would mean creating 
therapies which are more potent and could help avoid the thromboembolic risks of ADSVF 




There is enough basic science knowledge on MSC, ADSVF and ASC to move into 
translational research. This thesis builds on this knowledge specific to the clinical translation 
of ADSVF as a point-of-care intervention in the renal transplant setting. A few years ago, 
use of ADSVF in kidney grafts would have been an ambitious proposal, but two things have 
changed since. Firstly, more clinical studies have since been completed using stem cells for 
a various pathology which has led to feasibility and safety becoming more widely accepted. 
Secondly, the increased use of ex vivo perfusion rigs provide a means of administering 
ADSVF to the kidney before direct exposure to patients; a middle ground to injecting the 
ADSVF into a kidney graft in vivo. 
 
 
Progressing to a Clinical Trial 
 
For over ten years there have been many clinical trials of MSC in solid organ transplantation. 
Most of the research has been used as an induction therapy to prevent both delayed graft 
function and acute rejection. Safety, feasibility, and efficacy have been demonstrated, but 
these studies are highly variability and do not provide a blanket assurance of safety and 
efficacy of all cellular therapies. The condition being treated, the cell source, preparation 
technique, administration route and timing could all alter the outcome.  
 
The number of completed clinical studies specifically focusing on MSC used to combat renal 
transplant associated IRI is very low.  Of the few studies that are published, they have shown 
the safety and feasibility of MSCs in kidney transplant, but again none were uncultured 
ADSVF or via the renal artery. At least it is reassuring that systemic administration via a 
central vessel does not cause any first-pass organ injury (Pileggi et al. 2013). In theory, 
targeted administration via the renal artery will be even safer at reducing non-targeted 
engraftment. 
 
Currently 71 (10 recruiting, three not recruiting yet, and 32 completed) studies are registered 
on clinicaltrials.gov aimed at renal IRI specifically. Of those, three are using cellular 
therapies: Jarmi et al. from the Mayo Clinic in Florida are performing a feasibility and safety 
study of using ASC in DCD donors (Jarmi 2020). The 15 patients will be split into three 
groups of administrations: intraarterial, intravenous and intra-parenchymal. It is not known 
if these are uncultured ASC, and if the artery of administration will be the renal artery. The 
other two studies are looking at the intravenous administration of BM MSC after reperfusion.  
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Parraga et al. have administered MSC directly into the renal artery but this was in a porcine 
model of IRI (Sierra-Parraga et al. 2019). They report similar results to our biodistribution 
studies in which there is minimal off-target engraftment and retention was mainly seen 
within the renal cortex. This is reassuring as porcine kidneys better represent the size of 
human kidneys. With the cumulative knowledge, it does not seem unreasonable to establish 
a safety, feasibility clinical trial using ADSVF via the renal artery at the time of 
transplantation. There has been no research published of clinical trials looking at fresh 
uncultured ADSVF administered via the renal artery at the time of transplantation.  
 
When it comes to looking at the administration of cellular therapies on machine organ 
perfusion rigs, there has been much more progress compared to direct human studies. Again, 
no groups have used ADSVF as their cellular therapy of choice. Earlier this year a group 
from the United Kingdom published in the American Journal of Transplant their work 
administering cellular therapeutics directly into the renal artery of human kidneys in a 
normothermic machine perfusion rig (Thompson et al. 2020). They claim this was the first 
time multipotent adult progenitor cells have successfully been administered into human 
kidneys during normothermic machine perfusion (NMP). After 7 hours of NRP with MSC, 
they measured functional parameters, biodistribution, injury markers and cytokine profile. 
They concluded the MSC treated kidneys had improved urine output and microvasculature 
perfusion plus reduced markers of injury. Interestingly, they again found most of the labelled 
cells to be in the glomeruli, within the cortex, in keeping with our biodistribution studies. 
 
The significant difference in their study, compared to a study proposal building on the 
findings of this thesis, is the use of cultured BM MSC. The BM MSC NM P study was well 
designed and having a similar study design, to one that has been approved by a British ethics 
committee, would make obtaining approval to test ADSVF less arduous. Ethics approval 
will be one of the main hurdles to address when setting up a study using the ADSVF in ex 
vivo perfusion. Initially, it was presumed using ADSVF from the peri-renal adipose tissue 
of the donated kidney grafts would bypass some of the regulatory requirements. However, 
this is not going to be the case. The use of collagenases on adipose tissue to extract the 
ADSVF was considered a "significant manipulation" of the tissue and can no longer be 
considered homologous (Raposio & Ciliberti 2017).  
 
Another factor to consider is the concentration of cells to administer. The BM NMP study 
used 50 million cells which were proved safe and effective. Porcine studies have used around 
10 million cells. As thromboembolic events are the main concern, utilizing 50 million cells 
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makes sense as it has already proven safe and effective. Future studies could then look at 
titration dosage regimes and timings.  
 
The methods used within this thesis could be integrated into a clinical ex vivo perfusion 
study (Fig 7.1). Gene expression and biodistribution could be added to the outcomes as 
would functional analysis in the form of urine output, serum electrolytes, and injury markers 
such as NGAL. Applying to NHS Blood and Transplant regulatory body to receive paired 


























Figure 7.1 Two potential methods for delivering ADSVF in a clinical study using 
human kidneys. (1) The kidney is retrieved from donor as normal. The implanting centre 
removes the peri-renal adipose tissue, but instead of discarding it, the adipose tissue is 
processed on-site to extract the ADSVF using the Cytori therapeutics machine. The ADSVF 
is then either injected into the renal artery in a normothermic perfusion rig which recirculates 
1 2 
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any cells that pass out the renal vein and after a period of perfusion on the rig the kidney is 
then implanted in the recipient in the usual manner. Or the ADSVF is administered via the 
renal artery of the kidney at the time of transplantation surgery. (2) Kidney arrives at the 
implanting centre and is prepared for implantation as usual. Implantation surgery proceeds. 
Once skin incision is performed, subcutaneous adipose tissue is taken from the recipient and 
processed in theatre, using the Cytori machine, to extract ADSVF. The operation then 
continues as normal. When the ADSVF are ready they are administered via the renal artery 
of the kidney during the transplantation surgery. 
 
 
7.3 FUTURE OF CELLULAR THERAPIES IN KIDNEY TRANSPLANTATION 
 
The field of transplantation has come a long way since the first kidney transplant in 1954 by 
Joseph Murray in Boston. The transplant between identical twins was the first of hundreds 
of thousands of transplants which have since taken place. The most seismic shift in the 
practice of transplantation since then has been the advent of immunosuppression. 
Refinement of retrieval, preservation during transportation, surgery, immunosuppression, 
and post-transplant follow up ensured a steady improvement in transplant outcomes over the 
last 50 years. With demand for organs increasing and outstripping supply all around the 
world, we now more than ever need a solution to organ shortages.  
 
Increasing the number of organ donors will only take us so far, and in some societies, we are 
near fully maximising the donor pool. We need to make discarded kidneys useable; 
transplants that last longer and find a way to create more organs. For all these options, 
cellular medicine is the likely answer with both their regenerative cells subsets and 
immunoregulatory cell subsets playing a role.  
 












Cellular Therapies to Induce Immunotolerance 
 
For several years now, clinical trials have been investigating the use of cellular therapies in 
inducing immunotolerance. Last month in May of 2020 The ONE Study was published in 
the Lancet (Sawitzki et al. 2020). It analysed seven non-randomised phase 1 and 2A trails 
looking at the use of cell-based medical products in reducing immunosuppression in organ 
transplantation. Cells included T cell, dendritic cells and macrophages. There was also a 
reference control group. They concluded that the use of cellular therapy was safe and feasible 
and reported fewer infections in the early phase trials. The group have now moved onto the 
TWO Study which focusses on regulatory T cells. The door is open for more advanced 
clinical trials with dosages, timings, targeted, combination or altered cellular therapies. 
Successful regimes could be used in the general population soon, but whether 
immunotolerance lasts with reduced chronic rejection and more prolonged graft survival will 
take years to establish. 
 
Cellular Therapies to Ameliorate IRI 
 
The basis of this thesis was on cellular therapies used for their protective and regenerative 
potential against IRI. As previously discussed early in this chapter, the increasing popularity 
of perfusion rigs has allowed cellular therapies to be administered to organs with a safety 
net that avoids direct administration into transplant recipients. The vast combination of 
sources, preparations, additives, timing, and dosages means outcomes will undoubtedly 
improve.  Also, as discussed in chapter one, there are now techniques which can boost the 
regenerative capacity of cellular therapies. Unlike the immunomodulatory cellular therapies, 
the effectiveness of regenerative cellular therapies, such as ADSVF, to ameliorate IRI, will 
be known immediately after implementation. Therefore, there will be a higher chance that 
effective regimes will be discovered sooner – compared to waiting years to see if 
immunotolerance last. However longitudinal studies for both immunotolerance and 
regenerative cellular therapies will still be required. Regenerative cellular therapies will open 
the door to discarded kidneys and could also increase graft survival: as IRI and graft survival 
have a strong correlation. The use of regenerative cells is unlikely to solve the demand for 






Cellular Therapies in Xenotransplantation 
 
Xenotransplantation of a kidney was first performed over 100 years ago, and multiple 
attempts have been performed since. Nevertheless, even from non-human primates, the 
kidneys succumb to the hosts' immune defences. Nowadays, non-human primates are not 
the most likely source of xenotransplantation due to ethical reasons, high risk of infection 
transmission and organ size (Lu et al. 2019). Pig kidneys, however, address many of these 
issues and have a reduced size discrepancy. Also, porcine heart valves have been 
commercially available since the 1970s.  
 
The rejection faced by xenotransplantation is also much greater than unmatched human 
transplant due to the great genetic distances between primates and humans (Lu et al. 2019). 
Hyperacute rejection, acute humoral xenograft rejection, cellular rejection (NK, T cells, 
macrophages) then coagulation dysregulation all must be overcome for the xenograft to 
survive long-term. Gene modification of the pigs through techniques such as clustered 
regularly interspaced short palindromic repeats (CRISPR) to address the multiple antigens 
has been performed with varying degrees of success. Newer gene modifying techniques like 
CRISPR has speeded up the rate of progress. Gene modified pigs have been created, such as 
galactosyltransferase gene knockout pigs. Galactosyltransferase is the major hyperacute 
rejection xenoantigen of pigs (Kobayashi & Cooper 1999). In another study, pigs which 
express human complement regulatory proteins have reduced complement-mediated graft 
injury but fail to last long term (Burdorf et al. 2014). The longest graft survival to date, from 
pig to non-human primate,  is 499 days (S. C. Kim et al. 2019). It is inevitable in the not-so-
distant future a genetically modified pig will be the source of a kidney graft for humans. 
However, using the strategies described so far, human recipients will still require 
immunosuppression. 
 
Cellular therapies could role to play in the immunosuppressive regimes for 
xenotransplantation. Another central role in this field is the creation of human-animal 
chimaeras. With the discovery of induced pluripotent stem cells, there has been renewed 
interest in interspecies chimaeras and their potential in organ supply for transplantation. Two 
approaches include blastocyte complementation or targeted organ complementation. The 
latter being more favourable. Targeted organ complementation uses modified stem cells 
(modified by procedures such as gene editing) that are restricted to differentiating into the 
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organ of interest or by using lineage-committed progenitor cells. They are then implanted in 
zygotes, blastocysts or embryos of the host animal which has been genetically modified to 
be an organ-knockout. 
 
In 2017, there was the first proof of concept that an interspecies organ transplant can treat a 
medical condition (Yamaguchi et al. 2017). Then in the same year, a group from the Salk in 
San Diego were able to successfully inject pig embryos with human stem cells and maintain 
survival for almost one month (Jun Wu et al. 2017). To date, there has been no human 
chimerism that has developed long enough to create a functioning organ, but with growing 
understanding, it will undoubtedly happen in the near future. Using induced pluripotent stem 
cells or lineage-committed progenitor cells from the human requiring the organ could mean 
patient-specific and immune matched organs. Significant challenges will be the timing of 
the introduced stem cells to the embryo, especially before the immune system develops. In 
theory, it seems it will be a matter of when and not if human-pig chimerism for 
transplantation is achieved. However ethically this may be too much for society. Humanised 
pigs with human-like cognitive abilities or even looks will unlikely be an eventuality, 
especially with targeted organ approach, but it was enough for the United States of America 





Not a cellular therapy but worth mentioning are artificial. In 2011 surgeons in Iceland 
transplanted a completely synthetic lab-grown trachea, made from a non-composite polymer 
seeded with stem cells, in a young patient with cancer (Jungebluth et al. 2011). Since then, 
artificial organs have developed to perform more complex functions. SynCardia, a company 
from Arizona, USA have created an artificial heart which can provide in vivo cardiac 
function until a heart transplant becomes available (Morshuis et al. 2020). Creating more 
complex organs that can replace the need for liver or kidneys transplants have not been 
invented. It is unlikely that artificial organs will be able to perform all the functions of 
complex organs. The kidney for examples not only "filters" the blood but maintains water 
balance, blood pressure, acid-base balance, vitamin D homeostasis and the creation of red 
blood cells. However, they may be able to soon develop an artificial organ that perform 
essential functions such as the filtering and removal of excess fluids. The other functions 
could be managed pharmacologically. Such an organ is being developed by The Kidney 
Project, which is creating a bioartificial kidney at the University of California. They are 
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unlikely to be in widespread clinical use any time soon as it has never been implanted in 
humans. If successfully developed, they may prevent the need of a patient going on dialysis. 
However, whether they can be a long-term alternative to organ transplantation is unlikely as 
the outcomes of a transplant that performs all functions compared to an artificial organ that 
performs some essential functions is going to be preferred. Nevertheless, they could provide 
a valuable bridge for patients waiting for a transplant. If they are easier to implant, it could 
be used on patients not fit enough to undergo full transplant surgery or for those unable to 





Cellular Therapies in Bioengineering of Organs 
 
The holy grail for transplantation is the ability to create organs in the laboratory for 
implantation. Using recipient stem cells, the recipient will not require lifelong 
immunosuppression and will not suffer the failure of their graft due to chronic low-grade 
rejection. There are many methods currently being researched to overcome the challenges. 
Inducing stem cells to follow a particular organ differentiation has been achieved including 
the ability to create kidney tubular epithelial organoids. However, one of the more significant 
challenges is creating the complex structure of a functioning organ and in particular the 
vasculature. The kidney also requires a collecting system for urine which must be integrated 
with the functional tubules. Basic organs such as outer ear and oesophagus have been 
successfully created and implanted. In 2018 MacQueen et al. created a small heart beating 
ventricle complete with blood supply, but complex functioning structures suitable for 
implantation such as liver and kidneys are not likely to be bioengineered any time soon 
(MacQueen et al. 2018). 
 
There are multiple approaches taken to bioengineer organs. 3D scaffolds seeded with stem 
cells was the first tactic. Then 3D printing using a "bio-ink" of induced pluripotent cells 
allowed for more accurate structural design and has been successful in the simple organ 
structures. However, integrating the vasculature has not been possible with standard 3D 
printing. The induced pluripotent cells used in the bio-ink are reprogrammed into the 
functional cell required once they have been printed. Advances in 3D printing have resulted 
in the creation of functional tissues complexes with integrated vasculature but nowhere near 
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as complex as the vasculature required for each cell to be in close enough proximity to a 
blood vessel.  
 
Another technique involves taking an organ and removing all cellular material leaving the 
extracellular matrix. This process is called organ decellularisation. The extracellular matrix 
of the vasculature is remarkably mostly intact. In theory, the decellularised kidney can then 
be repopulated with stem cells to grow back into a functioning organ. Bombelli et al. 
demonstrated that renal stem/progenitor cells were able to populate the scaffold of a 
decellularised kidney slice and form proximal tubules, distal tubules and endothelium 
(Bombelli et al. 2018). Undeniably a massive feat but creating the right environment and 
developing a recellularisation technique to create a fully functioning kidney will be a 
significant challenge. 
 
To conclude, ADSVF from rat peri-renal and inguinal adipose depots share similar 
subpopulation but vary in the proportions of each subpopulation. These subpopulations are 
also found in human adipose depots. Administration of ADSVDF via the renal artery likely 
ameliorate IRI through similar mechanisms demonstrated when MSCs are administered via 
other routes. Renal artery administration of ADSVF is feasible and safe in animal models 
and reduces non-target distribution.  
 
The next step would be to study the use of ADSVF, via the renal artery in ex vivo organ 
perfusion, on kidneys rejected for transplantation. Cellular medicine is undoubtedly the 
future of solid organ transplantation and the transplant community has started to accept their 
role. Immune cellular therapies to induce immunotolerance and regenerative cellular 
therapies (stem cells and their associated stromal fraction) to ameliorate IRI has already 
started to see clinical translation. Organs from human-pig chimaeras will likely be available 
for human transplantation in the not-so-distant future but maybe deemed morally 
objectionable for many and therefore may not be adopted by all societies. Eventually, donor 
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ISOLATION OF ADIPOSE DERIVED STROMAL VASCULAR FRACTION 
 
A biological safety cabinet (BSC), scissors and forceps were cleaned with 70% ETOH before 
use. For extraction of the ADSVF, from the rat and human adipose tissue, the following 
steps were taken: 
1. Adipose tissue was transferred to a sterile 10cm Petri dish 
2. Scissors are used to mince the tissue down to small pieces of no more than 4mm 
in diameter. Initially, electronic homogenisation was attempted using the Gentle 
Macs (Miltenyi Biotec. Bergisch Gladbach, Germany) but final ADSVF 
quantities were inadequate.  
3. Homogenised tissue was then transferred to a 50ml conical tube, and 25ml of 
PBS was added - 5x the volume of adipose tissue. From our rats both inguinal 
regions would produce around 5ml of homogenised tissue 
4. 0.5ml Celase (Cytori Therapeutics Inc., San Diego, USA), which equates to 
3.5mg of Celase, was added to each conical tube containing 30ml of 
homogenised tissue and PBS. 
5. The tube was briefly vortexed and then put into an incubator with shaker for 
constant agitation for 30 minutes 
6. After the 30 minutes, the tube was shaken to break up any larger chunks and put 
back in the incubator for a further 15 minutes. 
7. The tube was then centrifuged for 5 minutes (600x g at room temperature with 
low brake speed) 
8. In the BSC, the supernatant was aspirated off, and 5ml of PBS was added using 
a new pipette to resuspend the cells.  At this point, up to 4 tubes can be combined 
if processing multiple samples at the same time. The volume was then adjusted 
up to 25ml with PBS 
9. Centrifuge a second time for 5 minutes (400x g at room temp with low brake 
speed) 
10. Supernatant aspirated without disturbing the cell pellet 
11. 25ml added to the tube and centrifuged a third time for 5 minutes (400x g at room 
temp with low brake speed) 
 231 
12. Supernatant aspirated without disturbing the cell pellet and the pellet 
resuspended with 25ml PBS 
13. 250ul of IntravaseTM (Cytori Therapeutics Inc., San Diego, USA) was added to 
the conical tube (250ul IntravaseTM for every 25ml of PBS) 
14. The tube was left to incubate at room temperature for 10 minutes on a shaker. 
15. Centrifuge a fourth time for 5 minutes (400x g at room temp with low brake 
speed) 
16. Supernatant aspirated and using a pipette and the pellet was resuspended with 
5ml PBS  
17. The cell suspension was passed through a 100um cell strainer and collected in a 
new sterile 50ml conical tube. The strainer was rinsed with 5ml of PBS to ensure 
maximum recovery of cells. 
18. The strained cell suspension was then passed through a 40ul cell strainer and 
collected in a new 50ml conical tube. Again, the strainer was rinsed with 5ml 
PBS to ensure maximum recovery of cells. This cell suspension is now 
considered the ADSVF 
Conical tubes containing cell suspension was put on ice while cell counting was 






















QUANTIFICATION, STORAGE AND PREPARATION OF ADSVF FOR 
ANALYSIS 
 
Cells were counted using the ChemoMetec NC-100 Mamillian NucleoCounter (Allerod, 
Denmark, Product number 900-0004) and its associated Reagent A100 (lysis buffer) & 
Reagent B (stabilizing buffer) and Nucleocounter cassettes. The cassettes are coated with 
immobilized propidium iodine, a fluorescent intercalating agent that binds to the DNA. 
Propidium iodine cannot pass an intact cell membrane; therefore attaches to the nucleus of 
dead cells and the Nucleocounter can then count the non-viable cells using fluorescent 
microscopy.  Then a new cell suspension sample is mixed with lysis buffer and then the 
stabilizing buffer to allow counting of the total concentration of cells. Through simple 
calculation, using the cell concentrations, the total viable cell population can be determined 




Once counted, the ADSCF was then prepared for storage if they were not going to be used 
or analysed immediately: 
1. The remaining cell suspension or ADSVF was centrifuged for 5 minutes (400x g at 
room temp with low brake speed). The supernatant was then aspirated. 
2. The cell pellet was resuspended with PBS. 0.5ml PBS is added for every 1 million 
cells in the cell pellet (as determined by the sample taken for cell counting). 
Therefore, if there were 3 million cells in the pellet 1.5ml of PBS would be added to 
resuspend the pellet. 
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3. A 1.5ml cryogenic tube was labelled and 700ul of Dulbecco's Modified Eagle 
Medium (DMEM) (Life Technologies Corporation. Paisley, UK) was added to each 
cryogenic tube. 
4. 1million cells (or 0.5ml) was taken from the cell suspension and put into the 
cryogenic tube containing the DMEM. 100ul of Dimethyl sulfoxide (Fisher 
Scientific UK Ltd. Loughborough, UK) and 200ul of rat serum is then added to the 
cryogenic tubes taking the total volume to 1.5ml. 
5. The Cryogenic tubes are then put into a cryogenic freezing container and placed in 
the –80oC freezer for 12 hours. Afterwards they are transferred to the liquid nitrogen 
for storage until required.  
 
Preparation for use 
When the ADSVF is required for analysis or use within the animal model the following steps 
were taken: 
1. Cryogenic tubes containing ADSVF are taken from the liquid nitrogen and allowed 
to thaw. 
2. The sample is then spun down using a mini centrifuge (Sprout. Heathrow Scientific, 
Illinois, USA) for at least 20 seconds and a visible pellet is formed 
3. The supernatant is decanted and 200micro litres of PBS added to re suspend the cells.  
4. Samples are spun again using the mini centrifuge for at least 20 seconds and a visible 
pellet is formed 
5. Steps 3 and 4 are repeated 
6. Once the wash is completed the pellet is resuspended with 200microliters of PBS 
using a pipette  
7. 20microliters of this solution was taken and added to another Eppendorf containing 
180microlitres of PBS. This 200microliters is used for calculating the viable cell 
population as described above using the NucleoCounter. 
8. If a specific number of cells are required, the volume is calculated, and excess cells 
are aspirated from the Eppendorf containing then thawed ADSVF 
9. 300micorliters of 10% rat serum is then added cell suspension. The total volume of 
cell suspension and rat serum is usually between 400 and 450 microliters depending 








RODENT MODEL OF RENAL TRANSPLANT ISCHAEMIA REPERFUSION 




• Wild Heerbrugg Ltd operating microscope – zoom 10-30x 60mm LED light ring 
(Microscope Systems Scotland) 
• Far infrared heating pad and infrared thermometer (Kent Scientific: DCT-15) 
• Operating board (30x30cm). Covered with disposable plastic sheeting, held in place 
with adhesive tape. 
• The following microsurgical instruments were obtained from Mercian® (Mercian 
Surgical Supply Co Ltd, Worcestershire, United Kingdom) 
o – Microsurgical vessel dilators with 0.1mm tips. (D-5a.1) 
o – Microsurgical vessel dilators with 0.2mm tips. (D-5a.2) 
o – Microsurgical vessel dilators with 0.3mm tips. (D-5a.3) 
o – Angulated forceps with 0.3mm tips. (JFA-5b) 
o – Dissecting microsurgical scissors with curved tips (SDC-15) 
o – Adventitia microsurgical scissors with sharp tips (SAS-15) 
o – Microsurgical needle holder without a lock, curved tips 0.4mm. (B-15-8) 
o – Tubing introducing forceps, tips 0.35mm. (TIF02) 
o – Clamp applying forceps. (CAF-4) 
o – Atraumatic vascular clamps. (B1-V and B2-V)) 
• Electric hair clippers 
• 15G Scalpel 
• Sterile Dressing packs (Nu-care Products Ltd, Bedfordshire, United Kingdom: 
DP10025) 
• Sterile Cautery (John Weiss & Son Ltd, Milton Keynes, United Kingdom: 0111122) 
• 30G Rycroft Cannula (0108003) 
• Blunt retractors (18200-12) and elastomers (18200-07) (Fine Science Tools, 
Heidelberg) 
• Sterile cotton tip applicators (Nu-care Products Ltd, Bedfordshire, United Kingdom: 
M982S) 
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• 10/0 nylon sutures. (Schuco Ltd, ZX-AK-0105, DR4 needle) or Ethilon® Suture, 
10/0 non absorbable, monofilament, 13cm, 3.8mm, 3/8 circle taper point needle 
(Ethicon, Inc. W2870) 
• Vicryl® Suture, 4/0 undyed, 19mm, 45cm, circle reverse cutting (Ethicon, Inc. 
W9925) 
• Prestige Latex Sterile Gloves (Nu-care Products Ltd, Bedfordshire, United Kingdom: 
GS33LE) 
• 365 Standard Sterile Gowns (Nu-care Products Ltd, Bedfordshire, United Kingdom: 
D20304) 
 
Stage 1 – 2/3 nephrectomy of right kidney 
 
Young adult male Fisher 344 rats were anaesthetised with isoflurane. Abdominal hair is 
shaved, and the rat is placed on a heating mat. The skin is prepped with chlorhexidine and 
draped to obtain a sterile field. A two-centimetre upper midline incision is made using a fully 
aseptic technique. Using scissors, the peritoneum is opened. Bowel contents are gently 
retracted to the left to reveal the right kidney. The fascia surrounding the renal hilum are 
opened and the renal artery identified. Due to varying anatomy, non-traumatic micro-forceps 
are used to briefly (3 seconds) clamp branches of the renal artery in order to determine blood 
distribution form that particular artery. Using 10-0 Nylon one or two or three branches of 
the renal artery are ligated to leave only 1/3 of the kidney perfused with arterial blood. Bowel 
retraction was then removed to return the normal positioning of the bowel. Peritoneum and 
skin are closed individually using a continuous 4-0 polyglactin suture (Vicryl®). Total 
surgical time ranged from 15-30minutes. Post-surgical care:  The animal is injected with 4ml 
of subcutaneous 0.9% saline postoperatively and placed alone in the warmed recovery cage 
with free access to food and water. Buprenorphine analgesia was injected subcutaneously, 
at 0.005mg per 100g of body weight. The animal is returned to its home cage once fully 
recovered from the anaesthesia. 
 
 
Stage 2 – ischaemia reperfusion injury of left kidney and cannulation of renal 
artery  
 
Once recovered from the right partial nephrectomy procedure for at least two weeks the rat 
is anaesthetised with isoflurane. Abdominal hair is shaved, and the rat is placed on a heating 
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mat. The temperature is adjusted to maintain the core temperature of 36.5-37oC. The skin is 
prepped with chlorhexidine and draped to obtain a sterile field. Using a fully aseptic 
technique, the previous midline incision is reopened and extended to around five 
centimetres. Bowels are gently retracted to expose the left kidney. The fascia surrounding 
the renal hilum is opened, and the left renal artery is identified. A segment of the renal artery 
is carefully cleared of fascia and its attachment to the renal vein with blunt dissection using 
cotton tips and forceps. Two non-traumatic vascular micro clamps are placed on the renal 
artery to induce renal ischaemia and the time noted. The kidney is inspected to make sure 
the clamps have entirely occluded perfusion. If the animal is to receive an intervention via 
the renal artery then 20 minutes before the end of the ischaemia (minute 100) an incision 
large enough to fit a 30-gauge catheter is made to the anterior wall of the renal artery between 
the clamps. 7x105 ADSVF cells in 0.3ml PBS is administered with a 1ml syringe and a 30-
gauge catheter through the incision. The distal clamp is momentarily released to allow the 
infusion to travel through the renal artery and into the kidney. Perfusion of the kidney with 
the ADSVF/PBS is confirmed by the visualisation of the kidney changing colour. The distal 
clamp is re-applied to prevent back bleeding from the kidney. The renal artery incision is 
repaired longitudinally with interrupted 10-0 Nylon.  Clamps are removed after 120 minutes 
of warm ischaemia. Bowel retraction is removed to allow the normal positioning of the 
bowel. Peritoneum and skin are closed individually using a continuous 4-0 polyglactin suture 
(Vicryl®). Total surgical time ranges from 140-160minutes. Post-surgical care: The animal 
is injected with 2.5ml of subcutaneous 0.9% saline postoperatively and placed alone in the 
warmed recovery cage with free access to food and water. Buprenorphine analgesia is 
injected subcutaneously, at 0.005mg per 100g of body weight. The animal is returned to its 





When learning either the 2/3 nephrectomy procedure or the IRI with renal artery cannulation 
procedure, there is initially a period of training on humanely killed rats. The number varies 
as per trainee but is approximately five. Then, under supervision, the trainee will commence 
a period of training on several live animals which will be humanely killed before recovery 
(5 to 10 depending on trainee progress).  The trainee will commence to operate, supervised, 
on experimental rats that will be recovered. Once a success rate of >80% is achieved, then 
they are approved for independent practice. 
 
 237 
To reduce animal numbers during training, the 2/3 nephrectomy procedure can be performed 
on both the left and right kidneys of the cadaveric and non-recovered rats. Similarly, the IR 
with renal artery cannulation training can be performed on both the right and left kidney of 
the cadaveric and non-recovered rats. 
 
 
Developed surgical guidelines 
 
After performing over 200 microsurgical procedures, we have found the following tips to be 
helpful: 
• 10-0 monofilament suture is expensive and was not always straightforward to source. 
After using it use the remaining suture was soaked in chlorhexidine, rinsed and 
stored. Before the next operation, the suture was then autoclaved in autoclave 
approved box. The same suture could be used to perform multiple procedures. We 
had no issue with infection or suture fracture, causing the breakdown of the 
anastomosis. 
• Closing peritoneum with a continuous suture (3-0 Vicryl®), locking it then running 
the stitch back to close the skin allows for a two-layer closure with one stitch. We 
had no hernia postoperatively using this method. 
• Having two sets of microsurgical instruments makes it possible to perform multiple 
2/3 nephrectomy surgeries in a morning session. One set can be sterilised as the other 
is in use. 
• Precise, sharp and undamaged microsurgical scissors are essential to make a small 
clean hole in the renal artery. We had our scissors refurbished and realigned if they 
were dropped or not cutting cleanly. 
• Surgery should be stopped, and rat terminated if any bowel injury occurs. Suture 
repair of the bowel, washout of abdomen and antibiotics postoperatively is unlikely 
to be successful and can lead to unnecessary distress to the rat postoperatively. 
• When performing IR surgery, a 1cm x 1cm cutting of a sterile swab rolled up can be 
placed in the abdomen to gently wedge the spleen up into the left upper quadrant out 
of the operating field. Good surgical exposure is essential for efficient and safe 
operation. Make sure to remove at the end of the operation. 
• Opening the avascular tissue between the kidney hilum and peri-renal fat and then 
following this plane up the medial edge of the kidney is a quick route to get behind 
the fat covering the renal artery. Once making this incision, the fat medial to the 
kidney can be lifted, and the renal artery can be easily identified and traced back to 
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the aorta.  Not only is this route quick and causes minimal bleeding it also avoids the 
need to tie off the suprarenal vein. 
• During IRI surgery locating the renal artery should be the priority after creating 
adequate exposure. Once the artery has been located, it should be clamped. This will 
start the 120 minutes of ischaemia. Then skeletonising the rest of the renal artery can 
begin, so it is ready for cannulation. Skeletonising the artery may take up to 30 
minutes, and if this is done before clamping it is essentially adding 30 minutes on to 
the operation. From knife to skin to clamping the renal artery takes around 15 
minutes. After the 120 minutes ischaemia, it takes around 10 minutes for a final 
inspection to ensure no bleeding, placement of organs back into their anatomical 
position and closure of peritoneum and skin. Total operative time can, therefore, be 
as little as 2hour 30minutes. Two per day is feasible. 
• Cannulating the renal artery with the 30G Rycroft cannula in the right hand and using 
not traumatic forceps in the left hand to gently clamp around the artery cannulated 
by the catheter allows administration of therapy in a more controlled manner with 
minimal spillage and minimal damage to the artery. 
• Opening the proximal renal artery clamp but leaving the distal clamp can allow 
testing of renal artery suture repair without reperfusion of the kidneys. Patency and 
haemostasis of the repair are assessed. Once the repair is proven to be adequate, the 
distal clamp remains on until the desired 120minutes of ischaemia has been achieved 
then the distal clamp can be removed at exactly 120minutes. 
• Some bleeding after suture closure of the renal artery defect does not necessarily 
mean a further suture is required. Some very light pressure with a cotton tip 
applicator (just enough pressure to stop bleeding but not occlude the vessel - often 
the weight of the applicator alone is enough) for one full minute can often be enough 
to stop the bleeding. If it is still bleeding, another suture can be added. 
 
